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ABSTRACT

CD147, also known as basigin, extracellular matrix metalloproteinase inducer,
neurothelin, tumour cell-derived collagenase stimulatory factor, M6, HT7, OX47 or
gp42, is a transmembrane glycoprotein of the immunoglobulin super-family. It is
expressed in many neuronal and non-neuronal tissues with high expression in the
hippocampus, pre-frontal cortex, thyroid, heart, early erythroid, amygdala and placenta.
This protein is involved in various cellular and biological functions such as lymphocyte
migration and maturation, tissue repair, cancer progression, T and B lymphocyte
activation and induction of extracellular matrix metalloproteinase. The CD147 protein
interacts with with cyclophilin A, cyclophilin B, sterol carrier protein, caveolin-1 and
integrins, and can influence beta amyloid peptide levels, a protein that is central to
Alzheimer’s disease pathology.

Mechanisms through which CD147 regulates bata amyloid levels still remain unclear,
thus the current study investigated the impact of high cholesterol and beta amyloid 42
loading on CD147 expression in rat primary cortical neuronal cultures. Its expression in
human brain tissue from Alzheimer’s disease and non-Alzheimer’s disease dementias
and APPswe transgenic mice fed on a high fat/high cholesterol diet were also
determined. CD147 over expression experiments in rat primary cortical neuronal and
SH-SY5Y cultures using recombinant adenoviruses (AdRSV-CD147 and AdRSVEmpty) in the presence and/or absence of cyclophilin A were employed to determine
level of proection against oxidative stress and toxicity. Finally sequencing of the CD147
promoter region (-392 to -242 nucleotides) was perfomed to identify possible single
neucrotide polymorphysims that may be linked to Alzheimer’s disease pathology.

iii

The in vitro experiments conducted in this study have shown that cholesterol and beta
amyloid loading and oxidative stress result in increased CD147 expression in rat
primary cortical neuronal cultures and that CD147 protects neuronal cultures from beta
amyloid toxicity only in the presence of cylophilin A. However in vivo experiments in
animal model have shown that a high fat/high cholesterol diet does not affect brain
CD147 levels as evidenced by unchanged expression levels in APPswe mice.

Human studies have revealed a correlation between CD147 and γ-secretase complex
components (nicastrin and presenilin 1) in the hippocampus. However, there is no
difference in CD147 protein expression between hippocampus and frontal cortex from
Alzheimer’s disease patients. Sequencing of the CD147 promoter region, where sterol
carrier protein binds to initiate CD147 transcription, has identified two novel single
neucrotide polymorphysims (-61A>G and 37C>G). However, single neucrotide
polymorphysims within this region are not associated with Alzheimer’s disease
pathology.
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ABBREVIATIONS
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CHAPTER 1
Introduction

1.1: Alzheimer’s disease (AD)

In November 1901, a woman called Auguste Deter was admitted to a mental hospital by
a German neuropathologist/psychiatrist Alois Alzheimer because of impaired memory,
paranoia and disorientation complaints. Her condition deteriorated after a few years
leading to language deficits, hallucinations and aggressive behaviour. Her physical and
mental condition deteriorated considerably, consequently resulting in her death in 1906.
After Auguste’s death, Alzheimer performed an autopsy on her brain and identified
unusual formations which are now known as the characteristic hallmarks of Alzheimer’s
disease, namely neurofibrillary tangles and amyloid plaques.

Currently, dementia, of which Alzheimer’s disease (AD) is the most common form, is
posing escalating social and financial burdens especially with the ageing population.
Globally, it is estimated that there are about 26.6 million dementia cases with
approximately 245,000 cases being in Australia, and of these, 50 – 70 % are AD cases.
This is expected to rise to approximately 1.1 million by 2050 with an annual financial
impact on the Australian community already exceeding $6.6 billion annually (Access
Economic Report, 2003).

The disease is a progressive neurodegenerative disorder

resulting in atrophy of the brain due to neuronal loss (Fig. 1.1B) and clinically, is
characterised by memory impairment and behavioural changes. To date, post-mortem
examination is still the most affirmative determination of AD, based on the presence of
the pathological hallmarks. With advances in brain imaging technology such as
magnetic resonance imaging (MRI), computed tomography (CT) and positron emission
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tomography (PET), there is now an opportunity to diagnose and differentiate AD antemortem from various other dementias. Over the past several years there has also been
intensive research to identify biomarkers that can be used to diagnose AD with high
sensitivity and specificity, prior to onset of symptoms.

Although pathological hallmarks of AD (Fig.1.2 and 1.3) have been known for over a
century, there is still no consensus on the chain of events that result in the onset and
progression of AD. A number of hypotheses have been postulated to account for
neuronal dysfunction/loss in the AD brain. Of these, the most widely studied and
accepted is the “amyloid hypothesis” which postulates that the aggregation and
accumulation of a small peptide, termed amyloid-β (Aβ), triggers a cascade of events
that include the generation of free radicals, oxidative damage and inflammatory
processes, resulting in neurodegeneration. The Aβ protein is a small 4-kDa peptide that
is generated from the proteolytic processing of its parent molecule, the amyloid
precursor protein (APP) (see below and Fig.1.5) (Yu et al., 2000, Jankowsky et al.,
2004, Krishnaswamy et al., 2009, Ionov and Pushinskaya, 2010, Perez et al., 2010, Guo
et al., 2011, Kim et al., 2011).

Dysregulated proteolytic processing of APP or impaired Aβ clearance are primary
events that lead to the accumulation of Aβ within the AD brain. In familial cases, where
genetic mutations are inherited in an autosomal dominant manner, the dysregulated
proteolytic processing of APP is thought to lead to the accumulation of Aβ, whereas in
the more common sporadic cases, the impaired clearance of Aβ from the CNS is
thought to be a major contributor to AD pathogenesis. One protein that has been
implicated in both the production and clearance/degradation of Aβ is CD147. The
CD147 protein is a transmembrane glycoprotein originally described for its ability to
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activate metalloproteases and amongst its many functions has been recently thought to
modulate Aβ levels. Discussed below is a general overview of AD pathogenesis and the
implications for CD147 in modulating Aβ accumulation and neuronal functions that
may be compromised in AD.

1.2: Neuropathological Characteristics of Alzheimer’s disease (AD)

As AD progresses, gross morphological changes occur, such as the widening of the
sulci, narrowing of the gyri and enlargement of the ventricles of the brain, in the
frontotemporal areas (Fig.1.1) (Wu et al., 2003, Wu et al., 2010). During the early
stages of AD there is atrophy of the medial temporal lobe, hippocampus, and the
amygdala (Cahill and McGaugh, 1998). Loss in brain mass due to degeneration is
generalised. The progression of brain atrophy starts from the temporal lobe and spreads
to the frontal lobe and cerebral cortices (Baum et al., 1995). Measurement of the medial
temporal lobe has been used in diagnosis and in the monitoring of disease progression
(Denihan et al., 2000).
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A

B

Figure 1.1: Representative schematic diagram of post-mortem brain cross-sections.
Differential characteristics of health control brain (A) and Alzheimer’s disease patient
(B). The AD brain is featured by severely enlarged ventricles and shrinkage of the
cerebral cortical and hippocampal regions, which are responsible for memory and
cognitive functions.
(Image courtesy:http://knol.google.com/k/lara/alzheimer-s-disease/Ing3X-E/g1JpHQ).
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The histopathological hallmarks of AD are senile plaques (SP), neurofibrillary tangles
(NFTs) and congophillic amyloid angiopathy (CAA) (Vinters and Gilbert, 1983). The
early NFT and SP deposits are concentrated in regions of the brain mostly associated
with memory and learning such as the hippocampus (Masters and Beyreuther, 1995,
Gilman, 1997).

1.2.1: Neurofibrillary tangles (NFT)

A key characteristic of AD is the pattern of NFT lesions in the brain that is symmetrical
in both hemispheres (Braak and Braak, 1997). In healthy neurons, microtubules are
parallel structures involved in cell motility, transport, shape and mitosis that are
supported by tau proteins (Goedert, 1993, Avila et al., 2004). The equilibrium between
phosphorylation and de-phosphorylation of tau modulates the cytoskeleton influencing
the morphology of the axon (Maccioni et al., 2001). The hyper-phosphorylation of tau
protein reduces the binding of tau to microtubules resulting in the formation of
filamentous structures called paired helical filaments (PHF) which are the basic
constituents of NFT (Fig. 3) (Goedert, 1993, Gilman, 1997).

1.2.2: Senile plaques (SP)

Senile plaques consist of a central core of radiating amyloid fibrils surrounded by
dystrophic neurites and activated glial cells. Plaques may also appear as a diffuse
amorphous deposition of Aβ (Eikelenboom et al., 2010, Hurtado et al., 2010, Perl,
2010). Silver staining reveals a central core of Aβ surrounded by swollen abnormal
neurites (Fig. 1.2) (Anderton, 2002, Mathis et al., 2004). Congo red staining reveals a
characteristic birefringence seen under polarised light indicating the anti-parallel beta26

sheet conformation of Aβ; this is the characteristic that makes it “amyloid”.
Transmission electron microscopy reveals the fibrillary nature of the plaque cores that
reflects the distinguishing pattern of Aβ aggregation (Morris, 1997). The number of SP
are greatly increased in AD (Mathis et al., 2004), compared to what can be found in an
apparently normal person – it is thought that the presence of significant numbers of SP
and NFT indicate pre-clinical AD, since by the time AD symptoms arise,
neurodegeneration has been occurring for years.
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B

A
Figure 1.2: Neurofibrillary tangles (NFT) and senile plaque (SP)

Comparison of a normal brain (A) and pathological hallmarks of AD (B) showing NFT
described as filamentous structures arranged in bundles within affected neurons and SP
with the characteristic dense core of beta amyloid. (Image courtesy: http://ww.spice-oflife.com).
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1.2.3: Cerebral amyloid angiopathy (CAA)

Congophillic amyloid angiopathy (CAA) is due to Aβ peptide accumulation in blood
vessel walls within the brain (Fig.1.3) (Weller et al., 2000).

CAA increases the

frequency of intracerebral haemorrhage as a result of vessel wall weakness. Smooth
muscle tissue is replaced by Aβ in the blood vessels. This results in hindrance of
arterial elasticity which plays a significant role in the clinical pathology of AD (Weller
et al., 2000).

Figure 1.3: Congophillic amyloid angiopathy
Concentric cellular, eosinophilic thickening of penetrating cortical vessels with severe
luminal narrowing, typical of advanced amyloid angiopathy (haematoxylin and eosin)
(Weller et al., 2000)
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1.3: Risk factors of AD

Alzheimer’s disease can be classified broadly into two groups, late-onset AD (LOAD,
occurring >65 yrs) and early onset AD (EOAD, occurring < 65 yrs). The more common
sporadic late-onset cases are associated with many risk factors. Of these age and
possession of the ε4 allele of the APOLIPOPROTEIN gene (APOE ε4) are the major
risk factors for most populations globally (Roses, 1994, Martins et al., 1995, Roses,
1997, Martins et al., 2006).

Many other potential risk factors for AD have been

described which include, low levels of sex steroids (Pericak-Vance et al., 1991, Poirier
et al., 1993, Strittmatter et al., 1993, Haskell et al., 1997, Lambert et al., 1998, Short et
al., 2001), increased levels of gonadotropins (Smith et al., 1998, Bowen et al., 2000,
Short et al., 2001), head injury, physical inactivity, stroke, diabetes, hypertension, and
hypercholesterolemia. In addition to APOE ε4, recent genome-wide association studies
in humans have identified a number of possible additional loci associated with increased
risk for LOAD (Caselli et al., 2009). These have revealed associations of specific genes
such as TOMM40, APOC1, CLU, CRI, PI-CALM, EXOC3L2, BIN1and APOC2 with
LOAD (Bertram et al., 2007, Harold et al., 2009, Lambert et al., 2009, Seshadri et al.,
2010). Although these genes have had various, significant associations with LOAD,
APOEε4 is still by far the strongest genetic risk factor of AD.

The human APOE gene is located on the long arm of chromosome 19 (19q13.2)
(Olaisen et al., 1982, Das et al., 1985). It is 3.7 kb in length containing three exons and
introns and encodes a 34kDa protein. There are three major polymorphisms of APOE
(ε2, ε3, and ε4), which result from a single amino acid substitution at residues 112
and/or 158 (Utermann et al., 1980, Rall et al., 1982, Weisgraber et al., 1982). Of these
APOE alleles, the ε4 form is associated with an increased risk of developing AD with
approximately 40-60% of sporadic cases carrying this allele. The APOE ε4 allele is
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associated with a rapid decline in memory in individuals without dementia and in
individuals considered to have mild cognitive impairment (Boyle et al., 2010). Further,
the risk of developing AD markedly increases in individuals with increasing copy
number of the ε4 allele. Risk increases from 3.5 times when carrying one copy of ε4
(heterozygous) to almost 15 times when carrying two copies of ε4 (homozygous)
compared to those lacking ε4 (Breitner et al., 1998, Davidson et al., 2006). Individuals
who have AD and have two copies of the ε4 gene develop the disease earlier compared
to those that do not possess this gene or have only one copy of this gene. Similarly,
individuals with two copies of APOE ε4 also appear to have a more severe pathology.
The APOE ε2 allele, on the other hand, associated with a reduced frequency in the AD
population, is associated with a delayed age of onset of AD and is associated with a less
severe pathology than that observed with AD patients harbouring APOE ε4. Thus the
presence of the APOE ε2 allele is thought to exert a protective effect.

The combination of APOE ε4 and other environmental or dietary risk factors for AD
can increase the risk of developing the disease further. The presence of the APOE ε4
allele in western society also increases the risk of other disorders associated with high
fat/ high cholesterol intake, including type-2 diabetes, hypertension (high blood
pressure), hypercholesterolemia (high cholesterol levels) and cardiovascular disease, all
of which are also AD risk factors (Simons et al., 1998a). Research reports have also
shown evidence that a higher intake of calories and saturated fat may be associated with
increased risk of AD in individuals with the APOE ε4 allele (Kalmijn et al., 1997,
Refolo et al., 2000a, Mihovilovic et al., 2007, Torreggiani et al., 2009). Furthermore,
individuals with type-2 diabetes possessing the APOE ε4 allele are at twice the risk of
developing AD compared to ε4 carriers who do not have diabetes (Martins et al., 2006).
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These studies provide evidence in support of an interaction between APOE ε4 and
dietary factors enhancing the risk of AD.
The major function of apoE is to mediate the clearance of lipoproteins by interacting
with the low-density lipoprotein (LDL) family on receptors in liver cells (Beisiegel et
al., 1989). ApoE-containing lipoproteins initially bind to cell surface heparin-sulphate
proteoglycans, and are subsequently transferred to the LDL receptor-like protein (LRP)
or LDL receptor for endocytosis via clathrin coated vesicles (Ji et al., 1993, Havel,
1998). Studies also suggest an important role for apoE in the uptake and redistribution
of cholesterol within the CNS (Roheim et al., 1979, Pitas et al., 1987, Holtzman et al.,
1995).

Several mechanisms of action of apoE have been proposed that may account for its
association with AD. These include modulating the metabolism of Aβ by influencing
its clearance and aggregation rates (Bales et al., 2002). In animal models, apoE has been
associated with brain cholesterol such that high cholesterol levels increase Aβ
accumulation within the brain (Refolo et al., 2000a). A study by Naslund et. al.,
(Naslund et al., 2000) showed that ApoE co-localised with Aβ in SP within brain tissue
from AD cases. ApoE has also been shown to enhance the aggregation of Aβ1-40
(Sanan et al., 1994). Conflicting results from various studies exist on the influence of
the apoE ε4 isoform on cellular uptake of Aβ1-40 with some studies showing this
isoform to be correlated with increased Aβ40 uptake. Conversely other groups have
shown that Aβ uptake is reduced in the presence of the apoE ε4 isoform compared to
the other apoE isoforms (Yang et al., 1995, Cole et al., 1999). These discrepancies have
been explained by the fact that earlier studies showing enhanced aggregation of Aβ1-40
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with apoE ε4 isoform used poorly lapidated apoE which compromised its function
(Yang et al., 1995).

Recent studies have shown that apoE binds to Aβ and may modify its biological
activities. Wilhelmus and colleagues (Wilhelmus et al., 2005) evaluated the effect of
apoE on Aβ-mediated toxicity of cerebrovascular cells.

Their results showed that

cultured cells with ε4/ε4 genotype were more vulnerable to Aβ toxicity than those with
ε3/ε3 or έ3/ε4 genotype (Wilhelmus et al., 2005). Taken together, these outcomes
suggest that apoE plays a direct isoform specific role in Aβ deposition. This notion is
supported by the findings in mouse models where differences in isoform specific action
on Aβ aggregation and clearance by apoE ε4 and apoE ε2 respectively were identified
(Smith et al., 1998).

Increased levels of apoE have a detrimental influence on the neuronal cell system
promoting cytotoxicity or neurite degeneration (Hashimoto et al., 2000). However, low
levels of plasma apoE are found in AD subjects (Veer et al., 2011). Current data suggest
that one mechanism by which apoE may alter the risk for AD is isoform-dependent
regulation of Aβ cytotoxicity. It is thought that extracellular apoE binds to Aβ and
thereby modifying Aβ -mediated cell toxicity (Wilhelmus et al., 2005). This however
changes with each apoE isoform where apoE ε2 is most protective and apoEε4 is least
protective due to isoform specific differences in binding to Aβ (Mahley et al., 1996).
ApoE is also thought to have isoform specific effects on microglia activation in AD
brains (Egensperger et al., 1998) or an inhibitory effect on activation of cultured glial
cells by Aβ peptides (Hu et al., 1998).
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A role for apoE in the clearance of Aβ has also received attention. There are two major
Aβ clearance mechanisms in the brain – firstly there is receptor mediated clearance by
cells in brain parenchyma (microglia, astrocytes, neurons), along the interstitial fluid
(ISF) drainage pathway, or through the blood brain barrier (BBB). Secondly Aβ can be
cleaved by endopeptidases such as insulin degrading enzyme (IDE) and neprilysin
which are both expressed in neurons and vascular cells, as well as other enzymes such
as endothelin converting enzymes (Bu, 2009). Aβ peptide clearance in the periphery has
been shown to be mediated by apoE. For example, Hone et al. demonstrated that Aβ is
rapidly removed from plasma by murine peripheral tissues and that the rate of clearance
is affected by apoE (Hone et al., 2003). In this study, C57 BL/6J and APOE knockout
mice were intravenously injected with Aβ40 peptide and blood was taken from the
retro-orbital sinus at various time-points. In the C57 BL/6J mice, it was observed that
the liver had removed a large proportion (40.8%) of the injected Aβ followed by the
kidney (4.4%) by 90 minutes, whereas these tissues had undetectable levels of Aβ in the
APOE knockout animals (Hone et al., 2003). Recent findings have extended this work
and have shown that the presence of apoE ε4 led to a reduced plasma clearance of Aβ
and reduced uptake by two major peripheral organs that clear Aβ from the periphery,
the liver and kidney (Sharman et al., 2010). It was also found that levels of the Aβ
degradation enzyme, insulin degradation enzyme (IDE) were reduced in brain and
kidney from mice harbouring the APOE ε4 allele. The decreased capacity of apoE ε4 to
clear/degrade Aβ from the periphery and the associated lower levels of IDE, particularly
in the brain, suggest an explanation for the greater brain Aβ accumulation and higher
risk of AD in APOE ε4 carriers. Individuals carrying the APOE ε4 allele also bear some
risk of developing the early-onset form of AD. However there are also some familial
AD subjects that are not associated with either APP, PS1 or PS2 mutations or APOEε4
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inheritance that suggests that other underlying factors may be responsible for such
familial forms of AD.

Overall, EOAD accounts for only a small percentage of AD cases but is the most severe
form of the disease. The majority of EOAD cases are familial forms of AD showing
autosomal dominant inheritance. Familial AD (FAD) is typically associated with an
early age of onset (reviewed by (Martins et al., 2009). Most of our knowledge of the
molecular events underlying the development of AD comes from FAD since we can use
genetic analysis to identify the genes and proteins involved. Mutations at only three
loci are known to cause FAD although other loci may yet be found (Caselli et al., 2009).
One locus hosts the gene for the Amyloid Precursor Protein (APP) from which Aβ is
cleaved by the action of two “secretases”; β-secretase and γ-secretase (see section1.5.1).
Mutations in APP alter these cleavages so that Aβ production is increased or more
aggregation-prone forms of Aβ are formed (reviewed by (Martins et al., 2009). The
remaining two loci host the presenilin genes PSEN1 and PSEN2 with mutations in these
genes accounting for 50-70% of EOFAD cases (Zhang et al., 2010a, Stevens et al.,
2011). The presenilin proteins form the catalytic core of protein complexes with γsecretase activity (see section1.6). Mutations in the presenilins also appear to alter the
rate of Aβ production (see section1.6.1). The role of Aβ in AD pathogenesis and its
production are described in detail below.

1.4: Beta Amyloid protein (Aβ)
As described before in section 1.2.2.2 SPs containing amyloid deposits are
neuropathological hallmarks of the AD brain. The accumulation and aggregation of Aβ
is central to the amyloid hypothesis and has a major role in AD pathogenesis (Maccioni
et al., 2001). The Aβ protein is a proteolytic fragment of the amyloid precursor protein
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(APP) (Fig.1.6) (Hartmann et al., 1996). There are two major forms of Aβ, Aβ40 which
terminates at Val40 of the Aβ sequence and the longer and more pathogenic form Aβ42,
which terminates at Ala42 of the Aβ sequence. Aβ42 forms aggregates more quickly
resulting in the formation of senile plaques (SP) (Iwatsubo et al., 1994)
Immunochemical studies suggest that the deposition of Aβ42 precedes Aβ40 (Iwatsubo et
al., 1994, Lippa et al., 1998). It is estimated that approximately 90% of Aβ found in the
sporadic AD brain is Aβ40, with the remaining 10 % Aβ42 (Chapman et al., 2001). Aβ
in cerebrospinal fluid (CSF) and blood is secreted by neuronal/glial cells and
accumulates in cerebral capillaries, arterioles and venules. Furthermore, blood platelets
are key contributors of secreted Aβ in the periphery (Maccioni et al., 2001, Borroni et
al., 2002). Increased levels of soluble form of Aβ40 are more strongly correlated with
AD than amyloid plaque load (Fonte et al., 2001, Hemar and Mulle, 2011, Lewczuk et
al., 2011). Furthermore, recent evidence has shown that small aggregates of Aβ, termed
oligomers or protofibrils are the major neurotoxic species rather than the amyloid fibrils
or the senile plaques themselves (Goedert and Spillantini, 2006a, b, Spillantini et al.,
2006). These aggregated forms of Aβ in the brain parenchyma trigger a cascade of
pathological events that lead to AD pathology, neuronal loss and the associated
cognitive decline (Hardy and Higgins, 1992, Small et al., 2001). Several factors are
involved in the process of Aβ aggregation and toxicity that contribute to AD pathology
some of which are discussed below.

1.4.1: Aβ mediated toxicity
The soluble forms of Aβ aggregates have been implicated in disruption of several
cellular functions including mitochondrial activity (Dyrks et al., 1992, Butterfield et al.,
2001 , Palmblad et al., 2002, Lustbader et al., 2004a), oxidative stress (Martins et al.,
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1986, Butterfield et al., 2001 ), receptor mediated functions (Yaar et al., 1997, Wei et
al., 2002 , Fuentealba et al., 2004, Pereira et al., 2004, Bhaskar et al., 2009), disruption
of Ca2+ homeostasis (Mattson et al., 1993, Hartmann et al., 1994), membrane
depolarization and disorder (Muller et al., 2001, Verdier et al., 2004) and microglia
activation (Giulian et al., 1996). Most studied mechanisms of Aβ induced toxicity are
described below.

1.4.2: Mitochondrial dysfunction

Neurons are highly differentiated cells that need large amounts of Adenosine triphosphate (ATP) and depend on mitochondrial function and oxygen supply to survive
(Ames, 2000, Erecinska et al., 2004). As a result neuronal function and survival are very
sensitive to mitochondrial dysfunction (Fiskum et al., 1999, Nicholls and Budd, 2000).
Neuronal death and loss in AD may be attributed to an intracellular interaction between
Aβ and Aβ binding alcohol dehydrogenase (ABAD) which in turn alters the enzyme’s
active site and prevents native dehydrogenase activity (Lustbader et al., 2004b,
Caspersen et al., 2005). This is evidence of the presence of a mitochondrial pool of Aβ
within the AD brain that disrupts normal mitochondrial function. This is supported by
the finding of Aβ accumulation within mitochondria from brains of AD patients, rodent
models, and neuronal cells over expressing APP (Caspersen et al., 2005, Crouch et al.,
2005, Manczak et al., 2006). Since APP and γ-secretase components are present in
mitochondria, Aβ could be generated within mitochondria (Anandatheerthavarada et al.,
2003, Hansson et al., 2004, Devi et al., 2006) which may in turn significantly impact the
functions of the mitochondrial electron transport chain which is essential for the cell’s
energy requirement (Casley et al., 2002, Crouch et al., 2005) leading to neuronal death
due to oxidative stress.
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1.4.3: Oxidative stress

Oxidative stress is a major contributor to neuronal cell loss in a number of
neurodegenerative disorders including AD, and there is strong evidence linking
oxidative stress to Aβ. Oxidative stress occurs due to over and/or under production of
reactive oxygen species (ROS) via oxidative phosphorylation within the mitochondria
that exceeds antioxidant defence systems, leading to oxidative damage of cellular
components. ROS are by-products of ATP generation as the CNS consumes 20% of the
total oxygen supply. This notion is supported by the findings of Martins et al (Martins et
al., 1986) who reported an increase in activity of enzymes from the hexose
monophosphate pathways in post-mortem AD brain samples compared to age-matched
controls. This increased activity of the hexose monophosphate enzymes reflected the
increased oxidative stress in the AD brain. Several subsequent reports have also
confirmed the original finding and have shown extensive oxidative damage in AD,
including lipid peroxidation (Sayre et al., 1997, Butterfield et al., 2002), oxidized
proteins (Bissette et al., 1991, Smith et al., 1991) nucleic acid damage (Gabbita et al.,
1998, Lovell et al., 1999) and advanced glycation end-products (AGE) (Markesbery and
Lovell, 1998, Perry et al., 2003). Oxidative damage in AD may be a direct result of Aβ
peptide accumulation which cause neurotoxicity by production of ROS (Behl et al.,
1994) through interaction with metals, mainly copper (Cu) (Curtain et al., 2001, Dong et
al., 2003). Aβ-Cu combination generates hydrogen peroxide (H2O2) that has been shown
to cause oxidative damage of lipids and intracellular proteins. These findings clearly
show that Aβ mediated generation of ROS contributes to neuronal cell death in AD.
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1.4.4: Synaptic toxicity

Cognitive impairment in AD is often attributed to synaptic dysfunction and neuronal
cell loss in the hippocampus which is one region of the brain crucial for memory
(Hyman et al., 1984, Davies et al., 1987 ). Depleted neurotransmitters and synaptic
connections are indicators of synaptic loss ((Whitehouse et al., 1982, Small et al.,
2001) and impact learning and memory skills by affecting signal transmission between
neurons. There is now evidence that naturally secreted low molecular weight Aβ
oligomers and synthetically derived oligomeric Aβ42 disrupt signal transmission in the
hippocampus leading to loss of hippocampal plasticity (Nagerl et al., 2004, Zhou et al.,
2004). The biochemical mechanism by which soluble oligomers bind to synaptic plasma
membranes and interfere with signalling molecules that are required for synaptic
plasticity is unclear. Studies show that Aβ oligomers can interact with membranes to
induce a cascade of structural changes such as opening of ion pores, enhancing
membrane permeability or ion conductance by modulating a wide array of ion channels
and affecting osmotic flux (Mattson and Chan, 2003, Demuro et al., 2010). Disrupted
cellular homeostasis affects neuritic dystrophia and blockage of intra-neuronal
signalling essential for cognitive functions that may consequently lead to synaptic
dysfunction (De Fusco et al., 2003, Lingrel et al., 2007, Moseley et al., 2007). There is
also data that has shown that intracellular Aβ accumulation and soluble Aβ oligomers
can induce synaptic dysfunction and dendrite loss. However, the molecular mechanisms
that underline the loss of synapses and ensuing decline in memory related functions
caused by Aβ are complex. Neurodegeneration in AD is specific to particular regions of
the brain, but it is still not clear what makes the particular subset of neurons and their
processes more vulnerable to the effects Aβ toxicity.
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1.5: The Amyloid Precursor Protein (APP) and its proteolytic processing
The amyloid precursor protein (APP) is highly expressed primarily in the brain but is
also found in non-neural cells from many different tissues such as liver, kidney and
muscle though the level of expression in most peripheral tissues is markedly lower
(Turner et al., 2003). The function(s) of APP is still not fully understood but there is
evidence to indicate that it plays an important role in an intricate protein signalling
network and associated with the regulation of non-neuronal cell mitosis (Nishimoto et
al., 1993, Popp et al., 1996). APP is thought to maintain nerve cell growth, morphology
and functional plasticity and plays a role in learning and memory (Janus et al., 2000,
Morgan et al., 2000, Bayer et al., 2001). The localisation of APP within synapses
suggests that APP plays a role in neuronal communication (Chapman et al., 2001). The
non-neuronal isoform of APP which contains the Kunitz protease inhibitor domain
(KPI) may be involved in cellular adhesion and inhibition of serine proteases (Festoff
et al., 2001). The major neuronal form of APP is a glycoprotein comprised of 695
amino acids, characterized by a large ectodomain, a transmembrane domain and a small
endodomain (reviewed in (Sisodia and Price, 1995). The APP gene is encoded on
chromosome 21. Six different APP isoforms have been identified and are generated
from the alternative splicing of exons 7, 8 and 12. These APP isoforms are broadly
divided into two groups, either containing KPI (KPI-APP) or lacking KPI (non KPIAPP) (Hook et al., 1999). The KPI-APP group include APP563, APP751, and APP770.
The non KPI-APP includes APP695, APP365, and APP714 and dominates in neuronal
cells. The latter group lacks the KPI domain due to splicing out of exon 7 during
transcription (Ponte et al., 1988).
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Figure 1.4: Amyloid Precursor Protein.
Schematic diagram of APP showing the three main sections: ectodomain,
transmembrane and cytoplasmic domain.
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1.5.1: Amyloid precursor protein (APP) processing

The APP protein undergoes proteolytic cleavage by enzymes termed BACE, α, and γsecretases which act via two competing pathways (reviewed in Krishnaswamy et al.,
2009). The non-amyloidogenic pathway involves the cleavage of APP by α- secretase
which precludes Aβ formation whereas the alternative amyloidogenic pathway involves
APP cleavage by β and γ-secretase resulting in the Aβ production. These two competing
pathways are discussed below.
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Figure 1.5: Proteolytic Processing of Amyloid Precursor Protein (APP).
The two competing APP pathways and the enzymes involved in each pathway.
Non-amyloidogenic and Amyloidogenic pathways (adapted from(Barron et al.,
2006)).
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1.5.1.1: α-secretase cleavage of APP

The non-amyloidogenic pathway involves the cleavage of APP by α- secretase between
residues 16 and 17 of the Aβ sequence thus precluding Aβ formation. Cleavage by αsecretase results in the liberation of a secreted form of APP (α-APPs) and a membrane
bound C-terminal fragment of APP which contain residues 18-42 of the Aβ domain
(Sisodia and Price, 1995). The membrane bound C-terminal fragment is further cleaved
by γ-secretase, at the C-terminal end of Aβ, to liberate non-amyloidogenic fragments.
Cleavage of APP by α-secretase is regulated by protein kinase C or other factors such as
hormones (Buxbaum et al., 1993, Bayer et al., 2001).

Tumour necrosis factor-α converting enzyme (TACE), a disintegrin and a
metalloproteinase, which belong to The ADAM family of type-1 transmembrane
glycoproteins, (ADAM9, ADAM 17 and ADAM 10) have all been shown to have αsecretase activity. These metallo-proteases are involved in cellular activities such as
cellular adhesion and membrane protein shedding (Black et al., 1997). These metalloproteases have been shown to process APP in a number of in vitro and in vivo studies.
In vitro co-expression of ADAM9 with APP resulted in increased production of αAPPs
(Koike et al., 1999). Its activity has also been demonstrated in the plasma membranes
and the protein secretory pathway (Kuentzel et al., 1993, Refolo et al., 1995, De
Strooper, 2007). Over-expression of ADAM10 has been shown to facilitate α-cleavage
of APP whereas knock down precludes endogenous α-cleavage activity in cell lines
including primary neurons (Lammich et al., 1999, Lopez-Perez et al., 2001, Kuhn et al.,
2010). There is data that suggest that ADAM10 is the constitutive α-secretase that is
active at the cell surface as evidenced by reduced ADM10 protein levels in platelets of
sporadic AD patients which correlate with reduced sAPPα levels (Colciaghi et al.,
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2002). This has also been confirmed in neurons from mice with neural ADAM10
knock-out which resulted in significant reduction of sAPPα production to negligible
levels (Jorissen et al., 2010).

1.5.1.2: βeta-site APP cleaving enzyme
Beta site APP cleaving enzyme (BACE), formerly known as β-secretase, is a 501
amino acid trans-membrane protein consisting of signal, trans-membrane, luminal and
cytosolic domains (Vassar et al., 1999). Two isoforms of β-secretase (BACE 1 and 2)
which belong to the aspartyl-protease family have been identified (Vassar, 2004). In the
amyloidogenic pathway BACE cleaves APP at the N- terminus of the Aβ domain to
release a β-APPs product and a membrane bound C-terminal fragment (β-CTF).
Subsequent cleavage by γ-secretase releases Aβ40 or Aβ42 and the APP intracellular
domain (AICD). (Naslund et al., 2000). The BACE gene is located on chromosome
11q23.3, near a region recently identified as having increased lode scores for AD
(Hussain et al., 1999, Vassar et al., 1999).

The biological functional and genetic

association studies indicate that polymorphisms in the BACE1 gene might be a genetic
risk factor for late-onset AD (Kan et al., 2005).

Unlike BACE2, which is highly expressed in heart, kidney and placenta tissue (Yang et
al., 1995), BACE1 is highly expressed in the brain with relatively low amounts in most
peripheral tissues with the exception of the pancreas (Vassar et al., 1999). Overexpression of BACE correlates with increased cleavage of APP and its activity increases
with age (Li et al., 2000b). Furthermore BACE1 levels are elevated in AD brain
especially in regions vulnerable to neurodegeneration (Li et al., 2000b, Holsinger et al.,
2002). In addition BACE1 knockout mice crossed with APP transgenic mice have low
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cerebral Aβ levels (Luo et al., 2001), providing further evidence that BACE1 accounts
for the majority of β-secretase activity in the brain.

1.5.1.3: γ-Secretase cleavage of APP
Following APP cleavage by BACE, the last step in Aβ generation is the cleavage of the
β-CTF by γ-secretase at the C-terminal end of the Aβ region. This final cleavage by γsecretase releases Aβ40 or Aβ42 (Naslund et al., 2000). The complete structure of the γsecretase enzyme has not yet been fully identified but it is well established that the
presenilins together with anterior pharynx defective (APH-1), nicastrin, and presenilin
enhancer (PEN-2) are the core members of the enzyme complex. (Xia et al., 1997, Zhou
et al., 2005). It has been originally proposed that two different γ-secretases termed γ40secretase and γ42-secretase exist which are responsible for the generation of Aβ40 and
Aβ42 respectively (Citron et al., 1996). However, more recently a model has been

proposed to suggest a single γ-secretase enzyme with a broad range of activity,
performing multiple cleavages sequentially along the APP-C99 fragment. The

“successive cleavage” model, originally proposed by Ihara and colleagues (Qi-Takahara

et al., 2005, Takami et al., 2009) provides a sequence of cleavage events by γ-secretase
that occurs within the C-terminal fragment of APP (C99) to generate Aβ40 and Aβ42.
In this model, after BACE cleavage of APP (to form the N-terminal of Aβ) the
remaining C-terminal part of APP-C99 is first cleaved within the transmembrane
domain at the epsilon (ε)-site nearest the cytosol to release the AICD. Cleavage
proceeds progressively in increments towards the N-terminal of Aβ at zeta (ζ) and γ
sites respectively. This model also proposes that Aβ40 and Aβ42 are generated from a
different cleavage process and depends on the initial position of ε-cleavage
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The γ-secretase enzyme is a high molecular weight aspartyl protease that cleaves type I
transmembrane proteins within the hydrophobic environment of the lipid bi-layer. In
addition to cleaving APP to release Aβ, γ-secretase also cleaves other substrates such as
Notch to release the notch intracellular domain (NICD) fragment (Esler and Wolfe,
2001, Lee et al., 2002). Notch is a type I transmembrane protein which is first acted
upon by a distintegrin and metalloprotease within the extra-cellular region, followed by
γ-secretase mediated cleavage within the trans-membrane domain to liberate NICD.
This fragment translocates to the nucleus where it co-activates the transcription of the
genes involved in many developmental pathways (Ray et al., 1999). Th e γ-secretase
enzyme also cleaves sterol regulatory element binding protein (SREBP), an integral
membrane protein located in the endoplasmic reticulum consisting of N- and C-terminal
domains after being acted upon by sterol sensitive protease in the luminal loop (Sakai et
al., 1996). SREBP plays a significant role in cholesterol homeostasis by stimulating
transcription of sterol-regulated genes and plays a role in the activation of proteins
involved in cholesterol biosynthesis (Leonard et al., 1986, Wang et al., 1994, Brown
and Goldstein, 1997). There are several other γ-secretase substrates. Examples include
epithelial (E) and neural (N) cadherins, involved in cell adhesion, CD44 that acts as a
signal transduction molecule and activates transcription in the nucleus, and Erb-B4,
which plays a significant role in neuronal development by regulating cell proliferation
and differentiation (Okamoto et al., 2001, Yarden and Sliwkowski, 2001, Marambaud et
al., 2003). Due to the large number of substrates γ-secretase has been a difficult target to
develop inhibitors and/or modulators of its activity.

1.6: The γ-secretase complex components
The γ-secretase complex is a multimeric protein complex composed of Presenilin 1
(PS1), Nicastrin (NCT), anterior pharynx defective-1a (APH-1a), and Presenilin
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enhancer-2 (PEN-2) (Kimberly et al., 2003) (Fig.1.6). Its molecular weight has been
reported to be different in some studies. One study reported it to be ~2MDa, whereas
others reported it to be ~250KDa and ~500KDa (Li et al., 2000a, Edbauer et al., 2002,
Farmery et al., 2003, Kimberly et al., 2003, Li et al., 2003b). PS1/2 which is the
catalytic components of the γ-secretase share 67% of the overall protein sequence
(reviewed in (Krishnaswamy et al., 2009). There is also evidence of the existence of
distinct PS1 and PS2 complexes where PS1 containing complexes produce both Aβ40
and Aβ42 whereas PS2 containing complexes only produce Aβ42 (Lai et al., 2003,
Mastrangelo et al., 2005). Other proteins that are involved in modulating Aβ levels such
as CD147 (Fig.1.6) but do not appear to be core components of the complex have also
been identified (Winkler et al., 2009).

1.6.1: Presenilins

The Presenilins (PS1 and PS2) are transmembrane proteins consisting of 8-10
hydrophobic domains (Sherrington et al., 1995, Lehmann et al., 1997). The gene spans
more than 50 to 75kb and is organized into 12 exons, the first two corresponding to 5’
untranslated regions (Alzheimer’s Disease Collaborative Group, 1995; (Mitsuda et al.,
1997). Two presenilin genes have been identified; presenilin 1 (PS1) located on the
short and long arms of chromosome 14 and presenilin 2 (PS2) found on the long arm of
chromosome 1. The PS1-holoprotein is composed of 467 amino acids with a molecular
weight of 45 kDa (Sherrington et al., 1996, Lehmann et al., 1997). PSI is similar in
structure to sperm integral membrane proteins (SPE) which play a role in membrane
trafficking in the organelles within the Golgi (L'Hernault and Arduengo, 1992, Levitan
and Petersen, 1995). The similarity to SPE may suggest that PS1 is also involved in
protein trafficking. Other roles for PS1 include signal transduction during development,
apoptosis and cellular calcium ion homeostasis (Marjaux et al., 2004). However, its role
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in APP metabolism and processing has received the most attention. Initial evidence
comes from many in vivo and in vitro studies which have shown that mutations in PS1
increase the production of the longer more pathological Aβ species (Martins et al.,
1995, Guo et al., 1997, Xia et al., 1997, Jankowsky et al., 2004). A subsequent study
provided evidence that presenilins may have γ-secretase activity and represents the core
catalytic subunit of the enzyme. Many reports have shown that presenilin ablation or
mutagenesis of two highly conserved aspartate residues within transmembrane domains
6 and 7 result in a reduction in Aβ levels in vitro and in vivo (De Strooper et al., 1999,
Steiner et al., 1999, Wolfe et al., 1999, Esler et al., 2000). Furthermore, aspartyl
protease inhibitors and transition state analogue inhibitors designed to target the active
site of the protease, all reduce Aβ40 and Aβ42 levels and have been shown to have
affinity label and bind to PS1 (Esler et al., 2000, Li et al., 2000a, Seiffert et al., 2000).
In addition, physical interactions between presenilins and γ-secretase substrates have
been identified (reviewed in (Verdile et al., 2004)). Although initial evidence strongly
implicated presenilins in γ-secretase catalytic activity they do not exhibit typical
aspartyl protease structural characteristics, in particular they lack the typical D(T/S)G
motif required for the active site of an aspartyl protease. However, presenilins do
contain the two aspartyl residues (e.g.: D257 and D385 for PS1) which are either critical
for the active site on the γ-secretase complex or constitute the active site. The formation
of this aspartyl catalytic site could result from one or multiple presenilin molecules. The
full length PS1 protein is rapidly endoproteolytically cleaved within its characteristic
large hydrophilic loop into amino- and carboxyl-terminal fragments (NTF/CTF) of ~27
and ~17 kDa, respectively (Borchelt et al., 1996, Thinakaran et al., 1996, Podlisny et al.,
1997). These fragments are thought to interact with each other to form the catalytic
component of γ-secretase (Levitan et al., 2001, Laudon et al., 2004a, Laudon et al.,
2004b). The stoichiometry and the nature of the interaction between these fragments
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remain unclear. It has also been shown by many studies that the NTF:CTF form a
heterodimer in mammalian cells (Seeger et al., 1997, Grunberg et al., 1998, Yu et al.,
1998, Beher et al., 1999) leading to suggestions that this heterodimer is the active γsecretase. However, Cervantes and colleagues 2001 (Cervantes et al., 2001) provided
evidence that the presenilin fragments can form a tetramer by identifying heterodimers
as well as NTF and CTF homodimers in yeast. Evidence for heterodimer and NTF
homodimer (but not CTF homodimer) formation has been provided by photo affinity
labelled cross linking studies (Schroeter et al., 2003). This formation provides a core of
aspartyl residues required for aspartyl protease activity. However, it has yet to be
established whether the hypothetical “core” is formed between fragments from one PS1
molecule or multiple molecules within the complex.

The PS proteins (PS1 and PS2) share 62% amino acid identity and several lines of
evidence suggest that these proteins have quite distinct functions. Mice lacking PS1 die
before birth and the embryos display severe skeletal and brain deformities, whilst mice
lacking PS2 develop mild pulmonary fibrosis and haemorrhages with age (Shen et al.,
1997, Steiner et al.,1999, Rozmahel et al., 2002). Neuronal cultures isolated from PS1
ablated mice, when compared to those isolated from PS2 knockout mice, exhibit higher
Aβ production and are less sensitive to γ-secretase inhibitors (Lai et al., 2003). Lai and
colleagues also provided evidence suggesting the existence of distinct PS1 and PS2
containing complexes (Lai et al., 2003). Evidence exists that these complexes may have
a differential capacity to generate Aβ, whereby PS1 containing complexes produce both
Aβ40 and Aβ42, and PS2 containing complexes are involved in Aβ42 (but not Aβ40)
generation (Mastrangelo et al., 2005). Placanica et al., (Placanica et al., 2009) provided
further evidence for distinct PS1 and PS2 γ-secretase complexes in the generation of Aβ
where they are in dynamic equilibrium, possibly under control of pen-2 expression. It
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has also been suggested that PS2 is less efficient at generating Aβ peptide than PS1
(Bentahir et al., 2006, Placanica et al., 2009).

Evidence for different capacities for PS1 and PS2 to process other γ-secretase substrates
comes from a study that has shown that notch defects in PS1 null mice can be rescued
with wild-type PS2, but fails to rescue APP processing (Mastroangelo et al., 2005).
These findings suggest that PS2 is capable of facilitating Notch processing but is
associated with only very low levels of Aβ production. Although the presenilins share
some sequence identity (67%), there are domains within these proteins that show
sequence divergence, where transmembrane (TM) 3 and 4 and the large cytoplasmic
domains show 38% and 68% sequence divergence. This information could be used to
identify critical areas between these two proteins responsible for their activities.

A very large number of missence mutations have been isolated in the human presenilin
genes from families with EOAD (>190 mutations in PS1, and 23 in PS2,
http://www.molgen.ua.ac.be/ADMutations). A large number of these mutations are
missense mutations involving substitution of a single amino acid. Others include small
deletions, insertions or splice mutations (De Strooper, 2007).

The I4Sev5 and

Glu318GLY mutations are exceptions because they exhibit incomplete penetrance
(Rossor et al., 1996, Helisalmi et al., 2000). Mutations in the presenilins are known to
be scattered throughout these proteins and it has been proposed that these mutations
may all be hypomorphic – i.e. they decrease γ-secretase activity (Wolfe, 2007). The
decreased presenilin/γ-secretase activity as a result of mutations might shift the ratio of
Aβ production from shorter forms (e.g. Aβ40) that are less toxic (or possibly even
protective) towards production of longer forms (predominantly Aβ42) that have a
greater tendency to form toxic oligomers .
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1.6.2: Nicastrin (NCT)
Nicastrin is a type 1 transmembrane glycoprotein which was identified as a component
of the γ-secretase enzyme complex when it was found to co-immunoprecipitate with
PS1 and APP (Yu et al., 2000). It is comprised of a 670 amino acid long hydrophilic Nterminal domain, a trans-membrane domain, and a relatively short cytoplasmic Cterminus of 20 amino acid residues (Yu et al., 2000). The protein is synthesized as an
endoglycosidase-H-sensitive glycosylated precursor protein which is an immature form.
It is then modified by complex glycosylation in the Golgi apparatus and by sialylation
in the trans-Golgi network to generate the mature nicastrin molecule (Yu et al., 2000).
NCT is physically associated with presenilin and has a major role in stabilization and
proper localization of presenilin to the membrane-bound γ-secretase complex (Kopan
and Goate, 2002). NCT plays a role as a scaffold for the assembly of the γ-secretase
enzyme complex that binds APH-1 to form the first sub-complex (Morais et al., 2003,
Periz and Fortini, 2004). It is also thought that NCT plays a role in the assembly of the
γ-secretase complex within the endoplasmic reticulum and intracellular trafficking of
the complex to the cell surface (Shah et al., 2005, Zhang et al., 2005). Evidence has
also been provided to suggest that NCT is essential for the interaction between the γsecretase complex and APP-C99 (Shah et al., 2005).

1.6.3: Anterior Pharynx defective homolog-1 (APH-1)
The Aph-1 molecule is a 30 kDa transmembrane protein comprising 308 amino acids
(Goutte et al., 2002). Two human homologues of APH-1 genes exist, APH-1a and
APH-1b located on chromosome 1 and 15 respectively. APH-1a exhibits isoforms,
APH-1aS and APH-1aL, generated through alternative splicing of a single transcript
52

(Lee et al., 2002, Gu et al., 2003, Saito and Araki, 2005). APH-1a and APH-1b are
expressed in certain human and mice tissues such as hippocampus, cortex, medulla,
testes, lung and the large intestines (Saito and Araki, 2005, Coolen et al., 2006),
whereas APH-1aS is expressed more than APH-1aL (Saito and Araki, 2005). Both
APH-1a and APH-1b are multi-pass membrane proteins with seven transmembrane
domains (Fortna et al., 2004) whereas APH-1aS and APH-1aL have different Cterminal sequences (Lee et al., 2002, Gu et al., 2003). In vitro evidence has shown that
down-regulation of APH-1a and APH-1b alters the formation of the multimeric
complex and strongly reduces the production of Aβ (Luo et al., 2003). Knock down
experiments of APH-1a result in impaired maturation of NCT and decreased expression
of PS1, PS2, and PEN-2 proteins (Saito and Araki, 2005). In vivo experiments have
provided evidence that complexes containing different isoforms of aph-1 may also have
different functionality. Mice lacking APH-1a are embryonic lethal whilst those lacking
APH-1b appear to be normal phenotypically (Ma et al., 2005, Serneels et al., 2005,
Serneels et al., 2009), suggesting that aph1a complexes are essential for Notch
signalling during embryogenesis. In the absence of APH-1a an active γ-secretase
complex formation is disrupted (Ma et al., 2010). Collectively these data suggest that
complexes containing aph-1a are active and those containing aph-1b maybe redundant.

However, aph-1b complexes have been shown to have a role in neuregulin-1 (Nrg-1)
signalling.

Aph-1b

knockout

mice

show

signs

of

schizophrenia

including

hypersensitivity to psychiatric drugs, sensory motor gating abnormalities and working
memory deficits (Dejaegere et al., 2008). In addition, subsequent findings show that
inactivation of aph-1b γ-secretase complexes led to a reduction in AD pathology
without altering Notch related signalling (Serneels et al., 2009), suggesting the
existence of different complexes that selectively process certain substrates.
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Apart from the scaffolding function it shares with nicastrin, aph1 also interacts with the
mature forms of PS1, nicastrin and pen-2 (Lee et al., 2002, Hansson et al., 2004,
Hansson et al., 2005) on the cell surface where it binds the γ-secretase substrates and
facilitates cleavage (Hansson et al., 2005). Structural and functional similarities between
aph-1 and other proteases that possess the ability for intra-membranous cleavage such as
rhomboid, (Urban et al., 2001, Lee et al., 2003a) suggests that it may also have catalytic
activity, though there is yet no direct evidence for this.

1.6.4: Presenilin Enhancer 2 (PEN-2)
The Presenilin Enhancer 2 (PEN-2) is a ~12 kDa protein with 101 amino acids and
consists of two trans-membrane domains with its N- and C- termine facing the lumen of
the endoplasmic reticulum (Crystal et al., 2003). Interaction of PEN-2 with other
proteins aids the stability of the γ-secretase complex which is otherwise degraded by the
proteasome in the absence of this interaction (Crystal et al., 2003, Prokop et al., 2004).
PEN-2 is required for stabilization of the presenilin N- and C-terminal fragments within
the γ-secretase complex and also contributes to the maturation of nicastrin. Further,
PEN-2 is thought to contribute to the endo-proteolysis of the presenilin holoproteins
into N- and C-terminal fragments (Prokop et al., 2004). Interaction of PEN-2 with
APH-1 and NCT in drosophila increases the formation of presenilin fragments and
promotes γ-secretase activity (Takasugi et al., 2003).

Knockout and knockdown

experiments of PEN-2 expression have shown a marked decrease in PS1 endoproteolysis and Aβ production, suggesting

that PEN-2 is essential for both PS1

fragment formation and γ-secretase activity, (Steiner et al., 2002, Takasugi et al., 2003).
PEN-2 has been shown to bind to PS1 and the “DYLSF” domain of PEN-2 and a “NF”
motif on trans-membrane 4 of PS1 have been shown to be critical for this interaction
54

(Hasegawa et al., 2004, Kim and Sisodia, 2005). The C-terminal fragment of PEN-2 has
been shown to be critical for γ-secretase activity, where altering the length of the PEN-2
CTF (Naruhashi et al., 1997) or introducing loss of function mutations into the CTF
(Hasegawa et al., 2004, Prokop et al., 2004) reduces Aβ40 and Aβ42 levels.

Although PS, NCT, aph1 and Pen2 are known to be the core-components of γ-secretase
there are a number of other proteins that interact with components of the γ-secretase
enzyme or APP to modulate Aβ production (Zhou et al., 2005, Chen et al., 2006). One
such protein is CD147. As a major focus in this study the sections below will describe
the structure, function and roles in neuronal homeostasis and in regulating Aβ levels
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Figure 1.6: Assembly of γ-secretase enzyme complex to form the active enzyme.
NCT and APH-1 binds to form NCT: APH -1 sub complex, presenilin binds to this sub
complex forming a trimeric complex that is transported to the cell surface after the posttranslational modification of NCT, wherein PEN-2 attaches to the complex. Following
the BACE cleavage of APP molecule, γ-secretase cleaves APP-C99 releasing Aβ1-40 or
Aβ1-42 (adapted from (Verdile et al., 2007)).
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1.7:CD147 is a multifunctional protein that modulates Aβ levels

The CD147 protein has been identified in various species and assigned different names
(Table 1.1). Initially termed tumour cell-derived collagenase stimulatory factor (TCSF)
because of its ability to induce matrix metalloproteinase (MMP) expression in
fibroblasts, the CD147 cell membrane receptor protein is now classified as a transmembrane glycoprotein belonging to the immunoglobulin super-family (IgSF) (Biswas
and Vonderhaar, 1987, Fossum et al., 1991, Miyauchi et al., 1991, Kasinrerk et al.,
1992, Biswas et al., 1995), that has been shown to induce the production of several
MMPs (Kataoka et al., 1993, Biswas et al., 1995, Guo et al., 1997). It has been
classified as a member of a small family of related proteins, including the
teratocarcinoma antigen GP70 and the synaptic glycoprotein SDR1, that share the
features of two Ig-like extracellular domains, a short cytoplasmic tail, and a single transmembrane domain (Fossum et al., 1991, Shirozu et al., 1996). In addition to playing a
vital role in foetal development, CD147 is critical to the development of the nervous
system, spatial learning and memory, sensory inputs and retinal functions (Naruhashi et
al., 1997, Muramatsu and Miyauchi, 2003, Zhou et al., 2005). The CD147 protein has
been linked to cancer, tumour progression and arthritis. More recently this protein has
been implicated in AD pathogenesis (Nabeshima et al., 2006a, Winkler, 2008,
Nahalkova et al., 2010), in particular regulating Aβ levels (Zhou et al., 2005, Vetrivel et
al., 2008b). The following sections provides a detailed discussion on CD147 protein
structure, expression and function with particular focus on neuronal functions and its
role in neurodegenerative diseases such as AD.
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Table 1.1: CD147 nomenclature

Designated name
Extracellular

Species

Reference

Matrix Human

(Kasinrerk et al., 1992)

Metalloproteinase-Inducer
(EMMPRIN) and M6
Neurothelin, 5A11 and HT7

Chicken

(Seulberger et al., 1990, Fadool and
Linser, 1993, Schlosshauer et al., 1995)

OX47 and CE9

Rat

(Fossum et al., 1991, Nehme et al., 1995)

CD147, gp42

Human

(Altruda et al., 1989, Miyauchi et al.,

and Mouse 1991, Miyauchi et al., 1995)
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1.7.1: Protein structure and expression.
CD147 is composed of an extracellular domain of 187 residues, a 24-residue transmembrane domain and a 40 amino acid cytoplasmic region (Biswas et al., 1995). Its
extracellular region has two Ig domains (Domain1 and Domain 2) and an N-terminal
domain with several enzyme catalytic sites. The trans-membrane (TM) domain contains
a glutamic acid residue thought to be important in protein-protein association (Fig.1.7)
(Miyauchi et al., 1990, Fossum et al., 1991).
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Extra-cellular

Intra-cellular
N

N

SP

Domain 0

Domain 1

N

Domain 2

TM Cyto-domain

Figure 1.7: Human CD147 protein.
Structure showing the signal peptide sequence (SP), consensus asparagines-linked
glycosylation sites (N), extracellular domains (0, 1 and 2), transmembrane domain
(TM), and cytoplasmic domain (Cyto-domain) (adapted from (Belton et al., 2008)).
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Although, the CD147 protein is expressed in most tissues, it is relatively highly
expressed in tumours where it has been demonstrated to participate in tumour invasion
and metastasis (Reimers et al., 2004, Tang et al., 2004, Tang et al., 2005, Nabeshima et
al., 2006b). It is also highly expressed on activated T and B lymphocytes, dendritic
cells, monocytes, macrophages, heart, early erythroid, thyroid, pre-frontal cortex and
placenta (Kasinrerk et al., 1992, Kochi and Ushio, 1999, Liang et al., 2005). Patients
with systemic lupus erythematous (SLE) exhibit elevated CD147 levels in activated
CD3+ T Cells compared to healthy donor, suggesting its involvement in the progression
of SLE (Pistol et al., 2007). In the brain CD147 is highly expressed in neurons within
the cornu ammonis (CA) region and dentate of the hippocampus (Fan et al., 1998).
Other brain areas that express CD147 include the upper layers of the cortex, with the
CA region of the hippocampus and neuronal processes showing weak expression
(Vetrivel et al., 2008b).

CD147 can also be detected in conditioned media from tumour cell cultures (Biswas,
1984, Tang et al., 2004, Hanata et al., 2007), in supernatant of lipid loaded macrophages
(Yue et al., 2009) and more recently detected in human serum (Moonsom et al., 2010)
indicating that CD147 can be secreted and is present in a soluble form. The function(s)
of soluble CD147 remain unclear, however, it has been shown to stimulate stromal
fibroblast cells to express metalloproteases (MMPs), facilitating matrix degradation,
tumour invasion and metastasis (Tang et al., 2004). Similar functions have been
suggested for soluble CD147 in atherosclerotic plaque destabilization (Yue et al., 2009).

1.7.2: Functions of CD147
In non-diseased tissue CD147, has been shown to interact/associate with several
proteins. Its trans-membrane and cytoplasmic domains play a critical role in protein61

protein interactions associated with the plasma membrane (Kirk et al., 2000). In
pathology, CD147 is implicated in some diseases such as cancer where it facilitates its
metastasis through MMPs induction and systemic lupus erythematous (SLE) (Biswas,
1984) that is characterized by activated T Lymphocytes. The CD147 protein also has
important roles in the central nervous system and more recently has been implicated in
neurodegenerative diseases such as AD (Nahalkova et al., 2010). The following sections
will discuss some of the more established neuronal and non-neuronal roles for CD147.

1.7.3: Non neuronal functions of CD147
A number of functions for CD147 appear to be due to its ability to regulate metalloproteinases (MMPs), a family of proteolytic enzymes which are capable of degrading
molecules of the extracellular matrix (Sanderson et al., 2005). In reproduction,
degradation of the endometrium after embryo implantation is facilitated by MMPs,
which is influenced by CD147 expression in fibroblasts (Li et al., 2001, Chen et al.,
2007). Induction of MMPs by CD147 in human placenta promotes parturition by
inducing foetal membrane rupture and detachment from the uterus. Roles for CD147 in
reproduction also appear to extend to fertilization where CD147 knock-out mice are
infertile, due to deficiencies in spermatogenesis (Igakura et al., 1998) and roles in
sperm-egg interaction (Sexena et al., 2001).

CD147 facilitated induction of MMPs also appears to have a role in stromal cells of
cancer tumours where it maintains extracellular matrix integrity and cell communication
through association with intergrins (Curtin et al., 2005). Integrins are cell surface
receptors composed of alpha and beta chain heterocomplexes that serve as bi-directional
transducers of extracellular and intracellular signals during cell adhesion, proliferation,
differentiation and tumour progression. The structural and functional properties of both
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intergrins and CD147 provide a conducive environment for the interaction of the two
proteins.

Tumorigenic cells expressing CD147 induce MPP expression by neighbouring
fibroblasts facilitating cancer cell migration (Biswas, 1982, Kataoka et al., 1993, Biswas
et al., 1995, Heppner et al., 1996). Further evidence that CD147 regulates MMP
expression during cancer metastasis is provided by studies in human breast cancer and
glioblastoma cell lines where suppression of CD147 by antisense RNA decreased MPP2, MPP-9 and also down-regulated vascular endothelial growth factor (VEGF) (Liang et
al., 2005, Tang et al., 2005). The consequences of CD147 induction of MMP extends to
tissue repair where diseased eye corneas have elevated levels of CD147 localized to
those areas of greatest MMP expression (Gabison et al., 2005). The mechanism by
which CD147 regulates MMP production is largely unclear, although its glycosylation
is necessary for its action as de-glycosylated CD147 induces MMP secretion from a
breast cancer cell line (Sun and Hemler, 2001, Tang et al., 2004).

One possible

mechanism is through the mitogen-activated protein kinase (MAPK) signalling pathway
which is known to regulate MMP production. Knock-down of CD147 by siRNA has
been shown to inhibit phosphorylation of the MAPK signalling molecules SAPK/JNK,
suggesting a possible mechanism by which CD147 regulates MMP levels (Qian et al.,
2008).

Evidence also exists that CD147 has a role in transport of products from the glycolytic
pathway. The monocarboxylate transporter (MCT) protein catalyses the protein linked
monocarboxylates including lactate and pyruvate, glucose metabolites necessary for the
maintenance of metabolic homeostasis within most cells (Halestrap and Price, 1999,
Kirk et al., 2000). Of the four isoforms, only MCT1 and MCT4 interact with CD147
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and this association facilitates the expression of both MCTs and CD147 (Kirk et al.,
2000). These two isoforms require direct interaction with CD147 for their transport to
the plasma membrane (Kirk et al., 2000) in order to mediate lactate transport across the
plasma membrane (Wilson et al., 2002). Deficiency in MCT 1 and MCT 4 in the retina
affects the photoreceptor cells due to reduced lactate transport resulting in blindness.
Similarly CD147 absence or depletion leads to impaired surface expression of MCT1,
which results in the death of photoreceptor cells due to lack of lactate transport (Philips
et al., 2003). Taken together these findings indicate that CD147 acts as a chaperone for
MCT1 and MCT4 translocation to the plasma membrane.

The identification that CD147 is a signalling receptor for cyclophilin A (CyPA)
provided a novel function for this transmembrane glycoprotein (Yurchenko et al.,
2002). CyPA is an ubiquitously expressed intracellular protein belonging to the
immunophillin family, and is known to function as a ligand for the immunosuppressive
drug, cyclosporine (Liu et al., 1991, Colgan et al., 2005) and shown to also regulate
protein trafficking in cells (Brown et al., 2001, Chklovskaia et al., 2001, Ansari et al.,
2002, Huang et al., 2002). Elevated cyclophilins levels have been reported in several
inflammatory conditions including severe sepsis (Tegeder et al., 1997), vascular smooth
muscle cell disease (Jin et al., 2000), and rheumatoid arthritis (Billich et al., 1997).
These inflammatory effects may be mediated by cyclophilins-CD147 interactions which
initiate/progress the recruitment of leucocytes, which express CD147 receptor,
(Yurchenko et al., 2001, Yurchenko et al., 2005) into inflamed tissues (Sherry et al.,
1992, Xu et al., 1992, Allain et al., 2002).

The roles of CD147 in cell development, tumour progression, cell metabolism and
signalling have been well studied. However, its role in the CNS has received less
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attention. Cell signalling and its ability to interact with a number of proteins, including
cyclophilins, has suggested roles for CD147 in neuroprotection and in the pathogenesis
of neurodegenerative diseases such as AD. These roles are discussed further below.

1.7.4: Neuronal functions of CD147
Expression of CD147 (Basigin) has been shown to be extensively expressed in a
number of regions of the mouse CNS (Fan et al., 1998). The regions include: mitral
cells in the olfactory bulb; limbic system including the amygdala and piriform cortex;
hypothalamus including the paraventricular nucleus and the ventromedial nucleus, the
Purkinje cells in the cerebellum; the pontine nucleus in the pons; thalamus; retina
including the outer and inner granular layers and ganglion cells (Fan et al., 1998). Such
extensive expression in many regions of the CNS suggests a number of functions and
particularly the relatively high expression in the limbic system (Fan et al., 1998), would
suggest functions in memory and behaviour. This was addressed by Naruhashi and
colleagues (Naruhashi et al., 1997) where a number of behavioural tasks were carried
out in mice lacking CD147. Compared to wild-type and heterogeneous (Basigin +/-)
mice, the CD147 null mice (Basigin -/-) performed worse in memory and learning tasks
(e.g. Y-maze and water finding tasks). In addition CD147 null mice were less sensitive
to light, pain, and induced electric shock, reflecting the importance of CD147 in sensory
functions.

Through its interaction, the CD147 receptor has been proposed to mediate neuroprotection mediated by CyPA (Boulos et al., 2007) which is abundantly expressed in the
brain, primarily localized to neurons (Goldner and Patrick, 1996) and co-localises with
neuronal CD147 receptor in the hippocampus and cortex of rodents (Lad et al., 1991,
Goldner and Patrick, 1996, Fan et al., 1998). Although its role in the CNS is undefined,
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CyPA has been implicated in neuronal differentiation (Hovland et al., 1999, Chiu et al.,
2003, Song et al., 2004), cortical plasticity (Arckens et al., 2003) and embryonic
neuronal growth and development (Nahreini et al., 2001). CyPA is also up-regulated in
neuronal cultures following pre-conditioning treatments (Meloni et al., 2005). Overexpression of CyPA in primary cortical neuronal culture has been shown to attenuate
neuronal death induced by oxidative stress or ischemic insults (Boulos et al., 2007).
Similar protection was also achieved with the addition of exogenous human CyPA
protein to neuronal cultures. Activation of the CD147 receptor by CyPA was shown to
stimulate the phosphorylation of ERK1/2, which activates the anti-apoptotic proteins
Bcl-2 (Riccio et al., 1999) and Bag-1 (Perkins et al., 2003) and phosphorylationmediated inactivation of pro-apoptotic proteins such as Bim (Biswas and Greene, 2002)
and Bad (Bonni et al., 1999, Zhu et al., 2002).

These downstream pro-survival

signalling events may be one mechanism through which CyPA/CD147 interaction
protects neurons from toxic insults. Although a role for CD147 in neuronal protection
has been reported, its involvement in neurodegenerative diseases has been directed at
AD, where it appears to control levels of Aβ.

1.7.5: CD147 interactions with γ-secretase and modulating beta
amyloid levels.

A role for CD147 in modulating Aβ levels came about following the observation that
knock-down of CD147 resulted in increased levels of secreted Aβ40 and Aβ42 from
cells (Zhou et al., 2005, Vetrivel et al., 2008b) (Fig.1.8B). The mechanism by which
CD147 modulates Aβ accumulation is unclear, with two studies proposing different
mechanisms of action. Zhou and colleagues (Zhou et al., 2005) showed that CD147 is
possibly a regulatory component of the γ-secretase complex. In their study it was
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observed that CD147 depletion using RNAi resulted in elevated Aβ40/42 production,
without affecting expression levels of NCT, pen-2, aph-1 and PS1(Zhou et al., 2005).
However, Vetrivel and colleagues (Vetrivel et al., 2008b) showed that CD147 did not
interact with the other γ-secretase complex components and concluded that it was not an
integral part of the complex. Instead, the authors showed that CD147 mediates the
degradation of Aβ possibly via stimulating the production of the MMPs, which have
previously been shown to degrade Aβ (Backstrom et al., 1996, Nalivaeva et al., 2008,
Kong et al., 2010). The discrepancies between these two studies could be due to
methodological differences and it is possible that CD147 may have varying functions in
different cell lines. Vetrivel and colleagues used HEK-293 (compared to CHO cells
used in the Zhou et al study) in over-expressing CD147. Nahalkova and colleagues
(Nahalkova et al., 2010) recently provided further evidence that CD147 interacts with γsecretase components and may influence Aβ production. The authors showed that the
sub-cellular distribution of CD147 was altered from a cell surface localisation in PSwt
and PS1-/- cells, to a peri-nuclear localisation in PS2-/- cells. This study not only
indicated that specific components of γ-secretase interact with CD147, but also implied
that CD147–γ-secretase interaction may occur in mitochondria-associated membranes
(MAM), the cellular fraction where the majority of γ-secretase activity is proposed to be
localized (Area-Gomez et al., 2009, Schon and Area-Gomez, 2010).

Purification and biochemical characterization of interactors of endogenous γ-secretase
in HEK-293 cells showed that CD147, together with TMP21 a member of the p24
cargo-protein family, which functions in quality control and protein transport in the ER
and Golgi (Li et al., 2000a), co-purified in a high molecular complex with γ-secretase
(Winkler et al., 2009). However, these proteins could not be affinity captured with γsecretase inhibitors, indicating that they are not part of the active γ-secretase complex.
67

These findings support the notion that both CD147 and TMP21 may act to control Aβ
levels (Fig.1.8A) within the cell but they most likely are not part of the core
components of the γ-secretase complex, thereby affecting Aβ levels indirectly.
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Figure 1.8: The γ-secretase complex proteins.
Proteins of the γ-secretase complex (Psn, Nct, APH-1 and PEN-2) with CD147 as a
regulatory subunit of the γ-secretase complex showing reduced generation of Aβ
peptides (A) and without CD147 showing increased generation of Aβ peptides (B).
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1.7.6: CD147 expression in AD.

Considering the roles of CD147 in neuro-protection and modulating Aβ levels, it would
be conceivable that modulating CD147 transcription or its expression would impact on
its activity. Apart from in vitro over-expression and knock-down studies in proof-ofconcept studies, the effects of modulating CD147 transcription/expression on AD
pathology have not been explored. Indeed, whether CD147 transcription or protein
expression is altered in AD has not been fully examined.

Only one study has

investigated CD147 protein expression levels in different brain regions in a small
number of control and AD brain samples (Nahalkova et al., 2010). The numbers used
(n=3/group) were too small to show significant differences in CD147 levels, however
qualitative analysis of immunostained tissue sections revealed that CD147 staining was
more intensive in the neurons and capillaries in both frontal cortex and thalamus of AD
compared to control brain. More detailed, quantitative analysis in a larger number of
tissue samples is required to determine if CD147 protein expression is significantly
altered in AD. In addition, correlations with plaques and NFTs would be required to
determine if CD147 expression is significantly associated with AD pathology.

Evidence also exists that CD147 may be modulated at the transcription level. One study
investigated the presence of natural anti-sense transcripts (NATs) in AD associated
genes including PRESNILINS, BACE1/2, APP, APOE, TAU, NICASTRIN, PEN2,
APH1A/B as well as CD147 (Guo et al., 2006). The exact function of NATs remain
unclear, however they are thought to play a role in suppressing gene expression (Yelin
et al., 2003, Alfano and Poli, 2005). The authors showed that NATs were present in
CD147 and 3 other genes, namely APP, BACE2, and APH1A critical for Aβ
production. These results suggest that NATs may have a role in modulating Aβ
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production, by controlling expression of genes important in APP metabolism including
APP itself, components of Aβ generating enzymes and CD147. Polymorphisms or other
genetic variations in the CD147 gene and associations with AD have yet to be
investigated; however if such variations exist, particularly in the promoter, they may
impact on Aβ accumulation. Such variations may alter binding of transcription factors
such as sterol carrier protein 2 (SCP-2), which is known to control CD147 expression
by binding its promoter region, in turn altering γ-secretase activity (Ko and Puglielli,
2007). Accumulated evidence presented above, indicates a role for the multifunctional
CD147 receptor in AD pathogenesis, possibly by modulating Aβ levels through altering
production or clearance. However, its involvement in AD pathogenesis may not be
limited to Aβ.

Many pathological conditions involving inflammation are associated with increased
CD147 expression in tissues and cells. These include lung inflammatory diseases (Foda
et al., 2001, Hasaneen et al., 2005), rheumatoid arthritis (Konttinen et al., 2000, Tomita
et al., 2002, Zhu et al., 2006, Yang et al., 2008, Damsker et al., 2009), systemic lupus
erythematosus (SLE) (Pistol et al., 2007), chronic liver diseases induced by hepatitis C
virus (HCV) (Shackel et al., 2002), atherosclerosis (Spinale et al., 2000, Choi et al.,
2002, Yoon et al., 2005, Siwik et al., 2008) and ischemia (Boulos et al., 2007, Waldow
et al., 2009). Inflammatory mediated increases in CD147 levels are thought to be a
mechanism by which MMPs are activated and potentiate tissue repair and or
remodelling, for example in instances of myocardial infarction (Spinale et al., 2000,
Siwik et al., 2008, Nie et al., 2009) or destabilization of atherosclerotic plaques (Yoon
et al., 2005).

CyPA- CD147 interactions also appear to play important roles in

inflammation. The up-regulation of CD147 expression observed in most inflammatory
diseases, overlap with an up-regulation of CyPA. This is thought to contribute to the
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recruitment of immune cells to sites of inflammation via a chemokine-like activity
(Yurchenko et al., 2005). Pro-inflammatory leucocytes have been reported to have
increased expression of CD147, compared to non-inflammatory cells (Zhu et al., 2005).
This may facilitate the interaction between leucocytes and thereby further promoting
leukocyte recruitment. Recent evidence for this was shown by Damsker and colleagues
(Damsker et al., 2009), where activated CD4+ T cells showed enhanced CD147
expression. The CyPA- CD147 interaction may also contribute to MMP production. In
an apoE deficient mouse model of atherosclerosis, knock-down of CD147 and the
presence of cyclophillin inhibitor during cell differentiation, hindered up-regulation of
MMPs. Whereas the presence of CyPA up-regulated MMPs and both CD147 and CyPA
were found in atherosclerotic plaques in these mice. The results suggested that
CyPA/CD147 pathway may have a role in atherosclerotic plaque pathology.

The presence of CD147 mRNA transcripts in microglia (Inoue et al., 1999) and
astrocytes (Meeuwsen et al., 2003) suggests a potential role for this protein in
inflammatory processes mediated by these cells. Indeed, it may have a similar role as it
has in the periphery where it could facilitate chemokine-mediated recruitment of
inflammatory cells. However, at present there is no evidence that CD147 can mediate
release of cytokines from astrocytes or microglia. The presence of CD147 in astrocytes
may also mediate other functions. Since CD147 is up-regulated in astrocytes in a mouse
model of permanent focal cerebral ischemia and co-localises with MMP-9 suggests its
participation in neurovascular remodelling (Kleene et al., 2007) through ATPase in
astrocytes which bound to CD147 and facilitated lactate transport via the astroglial
monocarboxylate transporter 1 (MCT1) (Maekawa et al., 2008). Astrocytic lactic
transport facilitated by MCT and activated by CD147 has important implications in
maintaining glucose metabolism “glycolytic flux” in the brain (Gandhi et al., 2009).
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This has implications in AD, as brain glucose metabolism is impaired in AD individuals
with mild cognitive decline (MCI) and transgenic mouse models of AD (Bigi et al.,
2003, Hooijmans et al., 2007).

1.8: Regulating CD147 expression.

1.8.1 Control of CD147 expression by Sterol carrier protein (SCP)

The expression of CD147 is controlled by sterol carrier protein 2 (SCP-2), a protein that
is involved in trafficking and intracellular utilization of cholesterol and other lipids. The
SCP protein plays a key role in cholesterol metabolism as it facilitates in cholesterol
uptake (Hirai et al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al., 1996,
Schroeder et al., 1998, Atshaves et al., 1999), intracellular transport (Puglielli et al.,
1995), esterification (Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al.,
1986, Yamamoto et al., 1991).

In addition it has been shown to remodel lipid

composition, structure and function of lipid rafts (Schroeder et al., 2007). The levels of
SCP are altered in a number of diseases where lipid metabolism is abnormal, including
diabetes and zellweger syndrome, where patients lack SCP-2 and are deficient in fatty
acid oxidation and normal lipid metabolism (reviewed in (van Heusden et al., 1990,
Wirtz, 1997)). In the neurodegenerative disease, Niemann-Pick Type C disease, where
there is failure of cholesterol trafficking within the endosomal-lysomal pathway caused
by mutation in the NPC protein (Nixon, 2004, Lo et al., 2010, Gallala et al., 2011), there
is a marked reduction in levels of the 13KDa SCP-2 protein and accumulation of lipids
in the lysosomes and Golgi (Roff et al., 1992). Interestingly, some intriguing parallels
exist with NPC and AD, such as NFT formation, lysosomes dysfunction and
accumulation of Aβ (reviewed in (Nixon, 2004).
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The SCP-2 gene is part of a fusion gene that contains two initiation sites encoding a
15.4 kDa (pro-SCP-2) and a 58.9 kDa (SCP-x) protein (Ohba et al., 1994, Ohba et al.,
1995). The 58.9 kDa SCP-x protein undergoes a post-translational cleavage process to
yield a mature 12.9 kDa SCP-2 where it has been shown to translocates to the nucleus
and activate CD147 transcription (Ko and Puglielli, 2007). In contrast, expression of
pro-SCP-2 has been shown to abolish activity of 12.9 kDa SCP-2 and inhibit CD147
transcription, resulting in an increase in Aβ production. SCPx/SCP-2 expression and
synthesis has been shown to be regulated by hormones (McLean et al., 1989, MendisHandagama et al., 1998), hypolipidemic drugs, lipid rich conditions (Kraemer et al.,
1995) and during development. (Trzeciak et al., 1987, Baun, 1993, Mori et al., 2009).
Although over-expression and knockdown studies have revealed that SCP-2 can
regulate CD147 levels, impacting on Aβ production, whether regulating SCP-2 levels
impacts on CD147 expression has yet to be determined.

1.8.2: Regulation of SCP and γ-secretase activity by cholesterol

The largest pool and concentration of cholesterol in the body exists in the brain where it
is a constituent of cell membranes and myelin. Cholesterol is important for normal brain
function and defects in cholesterol metabolism are associated with serious neurological
and mental dysfunctions (Tint et al., 1994). Brain cholesterol is efficiently protected
from exchange with circulating lipoproteins by the blood-brain barrier (BBB) and thus
most of the cholesterol found in the brain is synthesized locally, although at a low rate.
Alterations in cholesterol metabolism occur with age and have been implicated in both
increased AD risk and progression of this disease (Jarvik et al., 1995, Igbavboa et al.,
1996). Cardiovascular risk factors such as hypercholesterolemia, increased LDL and
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reduced HDL levels, hypertension, obesity and type II diabetes make important
contributions to the risk of developing AD. These risk factors also impact on disease
pathogenesis and are known to modulate the levels of key AD associated proteins
including Aβ. In neurons and other cell lines cholesterol levels modulate APP
metabolism modulating secretase activity (Racchi et al., 1997, Simons et al., 1998b,
Galbete et al., 2000a, Kojro et al., 2001, Runz et al., 2002). Evidence exists that cellular
sites that are rich in cholesterol and siphingolipid-rich membranes microdomains (so
called lipid rafts; (Lee et al., 1998, Wahrle et al., 2002), contain BACE1 and the γsecretase complex, promoting Aβ production at these sites (reviewed in (Cheng et al.,
2007)). Knowing that SCP has a role in nearly all aspects of cholesterol metabolism and
also facilitates CD147 transcription, it is conceivable that changes in cholesterol
homeostasis (i.e. under cholesterol loading) will alter levels of SCP, thereby impacting
on CD147 levels. Indeed cholesterol enrichment in rat aortic smooth muscle cells
resulted in an increased SCP mRNA and protein levels of SCPx and SCP-2 protein
(Kraemer et al., 1995), providing evidence that cholesterol and its derivatives can
regulate SCP expression. Whether this results in changes in CD147 levels, thereby
impacting on Aβ levels remains to be determined. Given the apparent relationship
between cholesterol and Aβ it is important to investigate factors involved in cholesterol
transport and metabolism such as sterol carrier protein (SCP).

1.12: Hypothesis

Alzheimer’s disease is a very heterogeneous and a multifactorial ageing disorder of the
nervous system. Accumulation and toxicity of the Aβ protein are key mediators of
neurodegeneration in AD and its levels can be modulated through altering its production
and clearance. A number of factors and cellular pathways (and proteins within these
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pathways) are known to influence the production and or clearance of Aβ. The CD147
protein has recently been implicated in AD pathogenesis, in particular regulating Aβ
levels. The roles of CD147 in cell development, tumour progression, cell metabolism
and signalling have been well studied. However, its role in the CNS has received less
attention. Cell signalling and its ability to interact with a number of proteins, including
cyclophilins, has suggested roles for CD147 in neuroprotection and in pathology of
neurodegenerative diseases such as AD. Considering the roles of CD147 in neuroprotection and modulating Aβ levels, it would be conceivable that modulating CD147
transcription or its expression would impact on its activity. Apart from in vitro overexpression and knock-down experiments in proof-of-concept studies, the effects of
modulating CD147 transcription/expression on AD pathology have not been explored.
Indeed, whether CD147 transcription or protein expression is altered in AD or in the
presence of risk factors has not been fully examined. One such factor is cholesterol
metabolism, which could impact on CD147 expression through regulating one of its
major transcription regulators, Sterol Carrier Protein (SCP-2).

1.13: Aims
This thesis explores the effects of modulating CD147 expression on neurodegeneration
and AD pathogenesis and addresses the following specific aims:

1. To determine if cholesterol and Aβ accumulation alters CD147 protein levels in
vitro and alter neuronal toxicity.
2. To determine if cholesterol alters CD147 levels in a mouse model of AD.
3. To determine if CD147 protein levels are altered in AD brain.
4. To determine if polymorphisms within the promoter region of CD147 are
associated with AD and correlate with Aβ accumulation.
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CHAPTER 2

Materials and Methods

2.1: Materials

Table 2.1: Commonly used chemicals
CHEMICAL

SUPPLIER

Ammonium persulphate (APS

Bio-Rad Irvine, CA.- USA

Acrylamide

Bio-Rad Irvine, CA.- USA

Aprotonin

Sigma Saint Lous, MO - USA

Ammonium chloride (NH4CL)

Sigma Saint Lous, MO - USA

Adenosine triphosphate (ATP)

Sigma

Agarose (Biotechnology grade)

Ameresco

Ampicillin (sodium salt)

Sigma

Agar

Amresco

Bacto-tryptone

Difco

Bacto-Yeast extract

Difco

Bis-tris

Bio-Rad Irvine, CA.- USA

Bicine

Bio-Rad Irvine, CA.- USA

Bradford reagent

Bio-Rad

Calcium chloride

BDH

Dithiotreitol (DTT)

Sigma Saint Lous, MO - USA

D-(+)-Glucose

BDH
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Dimethylsulphoxide (DMSO)

Sigma

Di-sodium hydrogen orthophosphate

Sigma

DNA molecular weight marker standard

Promega

(1.0 kb ladder)
DNA molecular weight marker standard

Promega

(Lambda HindIII digest)
Deoxynucleotide triphosphates (dNTPs)

Promega

Ethylenediaminetetra acetic acid (EDTA)

BDH chemicals Pty. Ltd., Vic. - Australia

Ethylphenyl-polyethylene glycol (NP40)

ICN Biomedicals, Inc. Aurora, Ohio USA

Ethanol

BDH chemicals Pty. Ltd., Vic. - Australia

Ethidium bromide

Sigma

Glacial acetic acid

BDH

Glycine

Bio-Rad Irvine, CA.- USA

Glycerol

Sigma

Human recombinant cyclophilin A

Biomol

(hrCyPA)
Hydrochloric acid

BDH

Isopropyl alcohol

BDH

Isopropylthio-β-D-galactoside (IPTG)

Boehringer Mannheim

Kanamycin sulphate

Sigma

Leupeptin

Sigma Saint Lous, MO - USA

Methanol

BDH chemicals Pty. Ltd., Vic. - Australia

Magnesium chloride

BDH
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M-MLV Reverse transcriptase, RNase H

Promega

minus Point mutant

N,N,N,N,N’-Tetra-methyl thylenediamine

Bio-Rad Irvine, CA.- USA

(TEMED)
N1N-dimethylformamide

BDH

Phenylmethyl-sulfonyl fluoride (PMSF)

Sigma Saint Lous, MO - USA

Phosphate buffered saline (PBS)

Fisher Biotech International Ltd., Perth Australia

Potassium chloride

BDH

Protein molecular weight marker

Invitrogen

Protease inhibitors

Roche

Pfu DNA polymerase

Promega

RNasin ribonuclease Inhibitor

Promega

Sodium dodecylsulfate (SDS)

Bio-Rad Irvine, CA.- USA

Restriction enzymes

Promega, New England (NEB) Biolabs

Sodium acetate

BDH

Sodium dihydrogen orthophosphate

Sigma

Sodium dodecyl sulphate (SDS)

Sigma

Sodium hydroxide

BDH

Trizol reagent

Invitrogen

Trizma base

Sigma

Tween20

Sigma

T4 DNA ligase

Promega
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Table 2.2: Preparation of buffers/solutions and reagents
SOLUTION
PREPARATION
Acrylamide/bis (49.5%/3%)

A stock solution was made by dissolving 96g of
acrylamide and 6g of bis-acrylamide in double
distilled water (DDW) making up to 2 litres and the
stock solution stored at 4 oC.

Ammonium persulfate (10% w/v A stock solution was made by dissolving 1g APS
APS)

powder in DDW making the final volume to 10 ml,
Aliquoted (1ml) and stored at -20oC

Anode

Buffer

(10x

stock A stock solution was made by dissolving 242.2g

solution)

Tris-chloride in DDW making up to 1 litre

Ampicillin

A stock solution was made by dissolving 50 mg/ml
stock in WFI, sterilised by microfiltration (0.2 µm)
and stored at -20°C

Aβ42

Aβ42 was prepared by dissolving 1mg in 180μl
20mM NaoH, 630μl Baxter water and 90μl 10x
PBS pH7.4 and sonicate for 5 minutes. Centrifuge
and transfer supernatant into a new tube. Measure
absorbance

on

a

Shimadzu

UV/VIS

Spectrophotometer at 214nm (1:24 dil.). Calculate
concentration by multiplying OD by the correction
(15.45) and dilution (25) factors.
Cholesterol (5mg/ml)

Cholesterol working solution was prepared by
dissolving 40mg/ml cholesterol stock in 6 ml sterile
Baxter water
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Cathode Buffer (10x

stock A stock solution was made by dissolving 121.1g of

solution)

Tris, 179.2g tricine and 10g SDS in DDW, making
the final volume to 1 litre.

Carbonate/Bicarbonate

Buffer 50mM carbonate/bicarbonate buffer consisted of

(50mM)

0.26g of Na2CO3, 0.21g of NaHCO3, with addition
of DDW made up to 50ml and adjusted to pH 9.6
using HCl.

DNA loading dye

6x stock prepared in 1 x TAE buffer and containing
bromophenol blue (0.25%), xylene cyanol ff
(0.25%) and 30% glycerol

dNTPs (10 mM stock solution)

A stock solution was made by mixing 100 µl of
each constituent (dATP, dTTP, dCTP and dGTP
each at 100 mM) with 600 µl of WFI, dispensing
100 µl aliquots and stored at -20°C

Ethidium bromide

Prepared as 10 mg/ml stock with WFI. Stored in
the dark, at 4°C

ELISA Blocking Buffer

Blocking Buffer was prepared by dissolving 0.25g
of bovine serum albumin (BSA: Sigma Chemical
Co., USA) into 25ml of PBST.

ELISA Standards (Aβ40)

Standards were prepared by diluting 1mg/ml Aβ40
stock with PBST to concentrations ranging from
15.625 pg/ml to 1μg/ml

ELISA

Detection antibody solution were prepared by
diluting 0.125g BSA in 12.5ml of PBST and 12.5µl
of secondary antibodies (R208) (1:1000) for each
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plate. The Neutravidin HRP solution was prepared
by the addition of 1.25µl of nHRP and 12.5ml of
PBST (1:10000).
MgCl2 (1M)

MgCl2 (1M) was prepared by dissolving in WFI
and sterilised by microfiltration/0.2 µm

MgSO4 (1M)

MgSO4 (1M) was prepared by dissolving in WFI
and sterilised by microfiltration/0.2 µm

MOPS SDS running buffer

Supplied as 20x stock (Invitrogen) and composed
of MOPS (1 M); Tris Base (1 M); SDS (69.3 mM);
EDTA (20.5 mM) made up in ultrapure water.
Unadjusted 1x buffer is pH 7.7

NuPAGE lauryl dodecyl sulphate

Supplied as 4x stock (Invitrogen) and composed of

(LDS) sample buffer

glycerol (4 g); Tris-Base (0.682 g); Tris HCl (0.666
g); LDS (0.8 g); EDTA (0.006 g); Serva Blue G250
(0.75 ml of 1% solution); phenol red (0.25 ml of
1% solution) made up in 10ml of ultrapure water.
Unadjusted 1x buffer is pH 8.5

NuPAGE transfer buffer

Supplied as 20x stock (Invitrogen) and composed
of bicine (500 mM); Bis-Tris (500 mM); EDTA
(20.5 mM); chlorobutanol (1 mM) made up in
ultrapure water. Unadjusted1x buffer is pH 7.2

Oligonucleotides (Custom)

Synthetic oligonucleotides were ordered as
250ng/ml solutions from Proligo (USA) and stored
at -20°C

Phosphate buffered saline (PBS)

10x stock was prepared by dissolving 11.5 g of di-
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pH7.5

sodium hydrogen orthophosphate anhydrous (80
mM), 2.96 g sodium dihydrogen orthophosphate
(20 mM), 5.84 g sodium chloride (100 mM) in
Milli-Q water to1000 ml

Sodium acetate

Prepared as 3 M solution (pH 5.2) in Milli-Q,
adjusted with glacial acetic acid and autoclaved

TAE

A one litre, 50x stock solution was prepared by
combining Trizma base (242 g), 57.1 ml of glacial
acetic acid and 100 ml of 0.5 M EDTA (pH 8.0)
with Milli-Q water

TB Buffer

HEPES (10 mM), CaCl2 (15 mM), KCl (250 mM)
were dissolved in WFI and the pH adjusted to 6.7
with KOH, prior to adding MnCl2 (55 mM). The
solution was sterilised by microfiltration/0.2 µm
and stored at -4°C
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Table 2.3: Special equipment list
EQUIPMENT

COMPANY

Dry Block Heater

Ratek Instruments Australia

Electrophoresis Power Supply

Amersham Pharmacia Biotech

FLUOstar Optima Spectrophotometer

BMG Labtech

Florescent Microscope

Olympus

Gene Pulser Xcell

Bio-Rad

IBlot

Invitrogen

Mastercycler Gradient

Eppindorf

Qp RT-PCR (BioRad)

Bio Rad – South Africa

Scanner, UMAX 1220S

UMAX Technologies Inc., CA.- USA

Sonifier 450

Branson

UVmini-12 Spectrophotometer

Shimadzu – Japan

VI-CellTM XR Cell Viability Analyser

Beckam Coulter- USA
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Table 2.4: Reagents for mammalian cell culture
REAGENT
SUPPLIER
B27 supplement

Invitrogen Carlsbad, CA - USA

β-mercaptoethanol

Sigma

D-Glucose

Sigma

Dulbecco’s

modified

Eagles

medium ICN Biomedical, Costa Mesa, CA - USA

(DMEM)
Foetal calf serum (FCS)

JRH Biosciences Lexan, KS - USA

Gentamycin

Invitrogen

Glutamax

Invitrogen

Hanks balanced salt solution (HBSS

Invitrogen

Hibernate E media

Brain Bits, Springfield IL - USA

L-glutamine

Sigma

Neurobasal medium without L-glutamate

Invitrogen

OPTI-MEM and DMEM

ICN Biomedical,

Poly-D-Lysine

Sigma

Penicillin

Sigma-Aldrich

Pty.

Ltd.,

Sydney-

Australia
Streptomycin

Sigma

Trypsin, 0.25% (1X) with EDTA 4Na

Trace

Biosciences

Australia
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Pty

Ltd.,

Vic.-

Table 2.5: Bacterial culture media
MEDIA
PREPARATION
F-12 Medium

Dissolve 1 packet of media in a litter of dH2O, add 2.4g sodium
bicarbonate and 2g D-glucose and adjust pH to 7.2. Filter
sterilized and add 5%FCS.

2x YT Medium

Dissolve 16g bacto-tryptone, 10g bacto-yeast extract and 5g
sodium chloride in 900 ml deionised H2O, make up to 1000ml
and sterilize at 15 lb.sq.in on liquid cycle

SOB++

Bacto-tryptone (20 g), Bacto-yeast (5 g), NaCl (0.5 g) and KCl
(0.186 g) dissolved in WFI to a final one litre volume and
sterilised. Prior to use, 20 ml of MgCl2 (1 M stock) and MgSO4
(1 M stock) was added to a final concentration of 10 mM

Terrific Broth

Dissolve 12g bacto-tryptone, 24g bacto-yeast extract and 4ml
glycerol in 900ml-deionised water. Add 0.17M KH2PO4 and
0.72M K2HPO4 solution prepared by dissolving 2.31g KH2PO4
and 12.54g K2HPO4 in 90ml dH2O adjusted to 100ml.
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Table 2.6: PCR Reagents
REAGENT

SUPPLIER

DNA and Gel purification systems

Promega Corporation, Madison, WI - USA

DNA loading dye

Promega

dNTPs

Qaigen ,Victoria – Australia

KAPA SYBR FAST RT-PCR master mix

BioRad, Cape Town - South Africa

KpnI

Promega

Xhol

Promega

1kb DNA ladder

Promega

T4 ligase

Bio-Labs, - New England

T4 ligase buffer

Bio-Labs, - New England

Table 2.7: Test Kits
KIT

SUPPLIER

Amyloid Beta Assay Kit

Covance- USA

Cholesterol Assay Kit

Cayman Chemical company, MI- USA

LDH Cytotoxicity Assay Kit

Cayman Chemical company, MI – USA

Micro BCA Pierce Protein Assay Kit

Pierce, Rockford, IL., USA

Light Shift Chemiluminescent EMSA Kit

Pierce, Rockford, IL., USA

7-Deaza-2’-Deoxy-Guanosine Kit

Jena Bioscience, Jena - Germany
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Table 2.8: List of antibodies
ANTIBODY

USE

DILUTIO

SOURCE

SUPPLIER

Mouse

Chemicon, California –

monoclonal

USA

Rabbit

Millipore,

polyclonal

Wales – Australia

Mouse

DAKO,

monoclonal

Denmark

Mouse

Abcam,

monoclonal

Australia

Mouse

Kindly provided by Dr

polyclonal

Paul Mathews, NYU

Donkey

Amersham,

N

Anti-EMMPRIN

Immunohis

(Allain et al.)

tochemistry

1:200

MAB2623
Anti-Human βeta

Immunohis

amyloid 1-40/42

tochemistry

1:200

New

South

polyclonal
antibody (AB5076)
Biotinylated Rabbit Immunohis
Anti-Mouse

tochemistry

β-Actin (AB8229)

Western

1:200

1:5000

blot
C1/1.6

Western

1:5000

blot
Donkey anti-

Western

Rabbit HRP

blot

Donkey anti-Goat Western
(HRP)
Donkey

1:10000

Glostrup

–

Waterloo

–

Buckinghamshire – UK.
1:20000

Goat

Santa Cruz – USA

1:5000

Mouse

Chemicon – USA

1:1000

Mouse

kindly provided by Pankaj

blot
anti- Western

Mouse (HRP)

blot

M42 – Aβ42

ELISA

Mehta, NY- USA
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M40–Aβ40

ELISA

1:1000

Rat

kindly provided by Pankaj
Mehta, NY- USA

Nicastrin

Western

1:500

Rabbit

blot
Presenilin

Western

polyclonal
1:2000

blot
PEN 2

Western

1:2000

blot
SC-9754 (Human)

Western

Western

1:5000

1:5000

blot
Sheep anti- Mouse Western
HRP
SCP-2

Mouse

Kindly provided by Dr

monoclonal

Paul Mathews, NYU

Rabbit

Sigma

polyclonal

blot
SC-9757 (Rat)

1:10000

Goat

Santa Cruz biotechnology

polyclonal

Inc – USA

Goat

Santa Cruz biotechnology

polyclonal

Inc – USA

Mouse

Amersham,

blot
(NB100- Western

93459)

blot

WO2

Western

Sigma

Buckinghamshire – UK.
1:5000

1:2500

blot

Goat

Novus Biologicals, CO -

monoclonal

USA

Mouse

Kindly provided by Dr

polyclonal

Colin Masters, University
of Melbourne

4G8 Rodent Aβ

6E10

ELISA

Human/pig ELISA

1:1000

1:400

Aβ

Mouse

Sigma,

monoclonal

Australia

Mouse

Covance- USA

monoclonal
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Sydney

–

2.2: Methods
2.2.1: Cell Cultures
2.2.1.1: Culturing Primary Rat Neurons

All animal experiments were approved by the University of Western Australia (UWA)
and Edith Cowan University (ECU) Animal ethics committees. Establishment of
cortical cultures was as previously described (Meloni et al., 2005). Briefly, cortical
tissue from E18 to E19 Sprague-Dawley rats were dissociated in Dulbecco’s modified
Eagle medium (DMEM; Invitrogen supplemented with 1.3mM L-cysteine, 0.9mM
NaHCO3, 10U/ml papain (Sigma , USA) and 50U/ml DNase (Sigma) and washed in
cold DMEM/10% horse serum. Culture plates (6-well) were coated with poly-D-Lysine
(50μg/ml; 70-150K; Sigma) and incubated overnight at room temperature. The poly-DLysine was removed and replaced with Neurobasal Media (containing 2% B27; 4%
FCS; 1% horse serum; 62.5μM glutamate; 25μM 2-mercaptoethanol and 30μg/ml
penicillin). Neurons were plated at a density of 3 x 106 cells per well and cultures were
maintained in a CO2 incubator (5% CO2; 95% air balance and 98% humidity) at 37oC.
On DIV 4 half the media was removed and replaced with fresh NB/2% B27 containing
the mitotic inhibitor cytosine arabinofuranoside (Cara), one third of the culture media
was removed and replaced with fresh NB2° on day in vitro (DIV) 9, and the cultures
were maintained at 37oC in 5% CO2.

2.2.2: Cell viability assessment

Cell viability was assessed by measuring lactate dehydrogenase (LDH) release using the
Cayman Chemicals test kit (Cayman Chemical Company, MI – USA) according to
manufacturer’s instructions. Differences between groups were determined by ANOVA
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with p < 0.05 considered statistically significant. Unless otherwise stated, all
experiments were conducted at least three times.

2.2.3: Cholesterol Treatment of Rat Primary Cortical Neuronal Cultures

Rat primary cortical neuronal cultures were seeded in 6-well plates in NB2 media
(4ml/well). Prior to treatment, 2ml media was removed and treatment prepared in the
equal volume and added back to the respective wells. Cholesterol concentration of 0, 5,
10, 15, 20 and 30µg/ml water soluble-cholesterol (5mg/ml stock) were used to treat the
neurons at DIV12 and used at DIV14 and DIV14 for western blot and LDH analysis
(see section 2.6.3., below)

2.2.4: Aβ Treatment of Rat Primary Cortical Neuronal Cultures

Freshly prepared Aβ42 peptide (10μM) was added to appropriate wells in neuronal
cultures at DIV 7 for the CD147 over expression experiments. Neuronal cultures were
treated with 0, 1, 2.5, 10 and 15 μM Aβ42 at DIV14 at 37oC for 48 hours.

2.3: In vivo Experiments
2.3.1: APPswe mice

The APPswe mice were purchased from Animal Resources Centre (ARC) (WA,
Australia). Two groups of APPswe mice were fed on normal or high fat/high cholesterol
diet for 60 days. Animals were weighed once a week. The experiment group (18
animals) comprising 9 males and 9 females were fed on a high fat/high cholesterol diet
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SF08-033 (comprised of 10% fat, 0.75% cholesterol, 0.3% cholate and additional
vitamins). The control group (18 animals, 9 males and 9 females) were maintained on
normal chow. Animals were sacrificed at 90 days and tissue samples (liver, kidney and
half of the brain) were collected and snap frozen in liquid nitrogen and stored at – 80oC.
The other half of the brain was fixed in 10% formal-saline and kept at RT whereas the
plasma was kept at -80oC until further processing. Tissues were homogenized in PBS
cocktail containing protease inhibitor (Roche) prior to protein determination and
western blot analysis. The levels of CD147, FL-APP, and APP-CTF were measured in
all tissue homogenates whereas Aβ40/42 levels were only measured in plasma and brain
samples.

2.3.2: Human Subjects

Brain samples (frozen and 10% formal-saline fixed) of AD, Lewy body disease,
frontotempral dementia and controls were obtained from the West Australian Brain
Bank Network (WABBN). Frozen tissues were homogenized as described in section
3.3.3 and used for protein determination and western blot analysis. Paraffin-embedded
tissue

section

(0.5μ)

were

prepared

from

fixed

tissues

and

used

for

immunohistochemistry analysis.

2.3.3: Homogenisation of Tissues

Frozen human hippocampal and frontal cortex tissues and rat brain, kidney and liver
tissue were kept on dry ice prior to being homogenized. Tissue fragments (approx. 100
mg) were homogenised in 300µl of tissue homogenising buffer containing protease
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inhibitor (Roche) using a hand-held Kinematica polytron homogeniser (KPH). Samples
were aliquoted (25 µl) and stored at -80°C for further analysis.

2.4: Protein Procedures
2.4.1: Protein Extraction from Cultures

Culture media was removed from 6-well plates and 150µl of RIPA lysis buffer (1M
Tris-HCl pH7.5, 5M NaCl, 0.5M EDTA, 0.5ml of 10% SDS and 125ul Igepal)
containing protease inhibitor (20ul of protease inhibitor in 1ml of lysis buffer) was
added to each well and the resulting lysate transferred to a new eppindorf tube,
vortexed, and centrifuged at 14000 rpm at 4oC for 30 minutes. The supernatant was
collected, aliquoted and stored at -80oC until further analysis.

2.4.2: SCP-2 Protein Generation

SCP-2 protein was generated using KRX E.coli cell line. The cells were transformed
with pro-SCP and SCP-x DNA (1ul) and subcultured on Kanamycin agar plates over
night. Following the transformation of chemically competent KRX cells with expression
vectors, colonies were inoculated into 2ml tubes containing 2x YT media; fitted with
Eppendorf LidBac membrane filters and incubated overnight at 37°C with shaking
(1400rpm). Two hundred millilitres of Terrific Broth (containing 50µg/ml kanamycin)
was inoculated with 2ml of the overnight culture. The flask of KRX cells containing the
required plasmid vector was incubated at 37°C in a conical flask (2L) with shaking
(275rpm), until OD600 reached 0.8-1.0. The flask was transferred to room temperature
with shaking (275rpm) until the OD600 reached approximately 1.3 (1.2 - 1.5). Protein
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expression was induced by the addition of 1mM IPTG and 0.1% Rhamnose. The
cultures were incubated at room temperature with shaking (275rpm) for approximately
18 hours.

Cultures were transferred to a 250ml pre-cooled centrifuge bucket and centrifuged at
10000g for 10 minutes at 4°C. The supernatant was discarded and the pellet was stored
at -20°C. Pellets were re-suspended in 25ml Lysis buffer. The cell suspension was
subjected to three passages of homogenization using a French press, followed by
centrifugation at 10000g for 10 minutes. Inclusion bodies containing the desired protein
were recovered from the homogenate as a pellet. The lysate was retained and further
processed to recover recombinant proteins localized to the cytoplasm.

2.4.3: Cytoplasmic Protein Purification

The purification of pro-SCP and SCP-x cytoplasmic protein was achieved through
Immobilized Metal Ion Affinity Chromatography (IMAC). The lysate was treated with
1ml of Ni-NTA agarose beads (Qiagen) and gently mixed at 4°C for 1 hour. The
combined solution was centrifuged at 2000g for 5 minutes, and the supernatant
removed. Four millilitres of wash solution was then mixed with the remaining beads,
followed by centrifugation at 2000g for 5 minutes. This step was repeated 4 times. To
elute the protein, 1ml of elution buffer was added to the beads, centrifuged for 5
minutes at 2000g and the supernatant collected. This step was repeated using 1ml,
followed by 0.5ml of elution buffer. In total approximately 2.5ml of protein solution
was collected using this method.
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The protein solution was transferred to dialysis tubing and dialysed against three 2 litre
volumes of dialysis buffer solution at 4°C, over a 24 hour period. The protein solution
was then removed from the cellulose tubing, combined with glycerol (10%), filter
sterilised (0.2µM) and stored at -80oC.

2.4.4: Determination of Protein Concentration

The Micro BCA Pierce protein assay kit (Pierce) was used to determine the protein
concentration in each sample. Sample blanks (PBS), samples and standards (100µl)
were transferred to a 96-microplate wells and 100µl of detection reagent (prepared
according to the manufacturer’s instructions) was added and incubated at 56°C for 15
minutes. Absorbance was measured at 595nm using a microplate reader (Bio-Rad
Model 3550) and protein concentration (μg/ml) were extrapolated from a standard
curve.

2.5: Immunobloting

Protein (25µg/ml) was separated by SDS-PAGE, transferred to nitrocellulose
membranes and analysed by immunobloting (Peano et al., 2011). Membranes were
incubated in blocking buffer (TBS containing skim milk 5% w/v) at RT for 1 hour then
incubated with primary antibody in TBST (containing skim milk 0.5% w/v) (SC-9753
and SC-9754 for mouse and human EMMPRIN respectively, C1/1.6 for FL-APP and
CTF, NT1 for PS1, ant-PEN2, β-actin and ant-nicastrin) RT for a further 2 hours.
Membranes were washed three times for 10 minutes in TBST and incubated with
secondary antibodies at RT for a further one hour. Membranes were washed three times
for 10 minutes in TBST with a final wash with TBS to remove the Tween 20. Following
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treatment with luminal enhancer solution diluted 1:1 with stable peroxidase solution
(Pierce, Rockford, IL., USA) at RT for 2 minutes; membranes were exposed on
Amersham Hyperfilm-ECL film at RT for up to 10 minutes until the desired signal
intensity was attained.

Films of western immunoblots were scanned and optical density determined through the
Bio-rad, Quantity-One software (GS-800 Calibrated Densitometer – BioRad).
Specifically film backgrounds were subtracted from optical density of individual protein
bands. An internal control was run on each gel for inter-gel normalisation. Levels for
the proteins of interest were represented as a ratio of to the β-actin, to control for inter
sample loading differences and presented in scatter plots. Western blots for all
individual data points are presented in next to their corresponding scatter plots.

2.6: Enzyme Linked Immunosorbent Assay (ELISA)
2.6.1: Aβ1-40/1-42 ELISA

Brain homogenates were prepared in Paul Mathew’s homogenisation buffer (250mM
sucrose, 20mM Tris-HCL, 1mM EDTA, and 1mM EGTA pH 7.4). In brief
homogenized brain tissues were centrifuged at 4oC (100,000g) for one hour and the
supernatants were again centrifuged at 4oC (30,000g) for one hour and stored at -80oC.
Aβ levels were measured in supernatants using ELISA method. In brief, primary
antibody (6E10; 1:400; Covance- USA) was incubated in 96-well plate at 4°C overnight
and washed with phosphate buffered saline with PBST. Plates were incubated in
blocking buffer at RT for 1 hour and washed with PBST. Samples and standards
(250µl/well in duplicates) were loaded and incubated at RT for 2 hours followed by an
overnight incubation at 4°C. Plates were washed with 100µl/well PBST and 100µl/well
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of detection antibody solution (containing antibody R306; 1:1000; Covance- USA) was
added and incubated at RT for 1.5 hours and unbound detection antibody was removed
by washing with PBST. Thereafter 100µl/well neutravidin-HRP solution (nHRP;
1:10,000 in PBST) was added and incubated at RT for 1 hour before washing with
PBST followed by addition of 100µl TMB/KGP reagent to each well and incubated at
RT in the dark for 10 – 15 minutes. The reaction was stopped by addition of 100µl stop
solution 1M (H3PO4) to each well and the absorbance read at 450nm on a Bio-Rad
Model 3550 Microplate reader.

2.6.2: Plasma Cholesterol ELISA

Total plasma cholesterol was measured using the cholesterol assay kit (Cayman
Chemical Company, MI- USA) according to the manufacturer’s instructions. In brief,
50ul of plasma and standards were added to appropriate wells in a 96-well plate
followed by the addition of 50 μl assay cocktail (containing 4.745ml assay buffer, 150μl
cholesterol detector, 50μl HRP, 50μl cholesterol oxidase and 5μl cholesterol esterase)
incubated for 30 minutes at RT and the fluorescence measured at excitation 580nm and
emission 595nm wavelengths using a FLUOstar Optima spectrophotometer (BMG
Labtech). Cholesterol concentration (mM) was calculated using the formula below:

[ Sample adjusted fluorescence – (y – intercept) ]
slope
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X sample dilution X 0.001

2.6.3: CytoTox 96® Non-Radioactive Cytotoxic Assay (LDH Assay)

Lactate dehydrogenase (LDH) is a stable cytosolic enzyme released from dead cells
following plasma membrane degradation. The CytoTox 96® Non-Radioactive
Cytotoxic Assay (Promega) is a colorimetric assay which quantitatively measures LDH.
In brief, lactate dehydrogenase released by cells is measured following the enzymatic
LDH mediated conversion of the tetrazolium salt (INT) substrate into its red formazan
product, which is detected spectrophotometrically at 490nm. The amount of formazan
produced is proportional to the number of lysed cells in culture. Differences between
groups were determined by ANOVA where p< 0.05 was considered statistically
significant. Unless otherwise stated, all experiments were conducted at least three times.

2.7: Maintenance of bacterial cells

For long-term storage, both recombinant and non-recombinant bacterial cells were
resuspended in 2xYT medium containing 15% glycerol, aliquoted out into sterile 2 ml
cryotubes (Nunc), snap frozen in liquid nitrogen and stored at -70°C. Cells were
recovered from slightly thawed frozen aliquots using sterile loops or micropipette tips
and used to inoculate agar or liquid culture media.

2.8: Competent Cells
2.8.1: Preparation of Chemically Competent KRX Cells

KRX cells were thawed slowly on ice, and 5µl was inoculated into 1 ml of 2x YT
media, and incubated on Thermo mixer Comfort (Eppendorf) incubator at 37°C for 1
hour with shaking (300rpm). A 100µl aliquot of the broth mixture was plated onto a
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pre-dried 2x YT agar plate, and incubated at 37°C overnight. Two colonies were
inoculated into two 2ml tubes containing 2x YT media; fitted with Eppendorf LidBac
membrane filters and incubated overnight at 37°C with shaking (1400rpm).

Three millilitres of overnight KRX broth was inoculated into 500ml of fresh SOB
medium, and incubated at 28°C with shaking at 225rpm. Once the OD600 of KRX
broth reached 0.4, the culture was transferred to nice slurry for 10 minutes, and then
centrifuged at 3,000g in a pre-cooled bucket rotor for 10 minutes. The cell pellet was
gently resuspended in 100ml of ice cold TB, incubated on ice a further 10 minutes, and
re-pelleted by centrifugation at 3,000g for 10 minutes. The cell pellet was gently
resuspended in 18.6ml of TB, mixed with 1.4ml of DMSO, and incubated on ice a
further 10 minutes. Aliquots of the cell mixture (0.6ml) were transferred to 1.5ml
microfuge tubes, snap frozen in liquid nitrogen and stored at -80°C.

2.8.2: Assessment of Chemically Competent KRX Cells

Freshly prepared competent cells were assessed for their competency in the following
manner. Two microlitres of freshly thawed competent cells were transformed with
0.1ng of pGEM 3Z plasmid DNA. A 100µl aliquot of the transformation mix was plated
onto agar plates (containing ampicilin; 50µg/ml) and incubated at 37°C overnight. The
colonies were then counted and the transformation efficiency was calculated according
to the following formulation.
90cfu

× 103 = 9 × 106 colony forming units (CFUs)/µg of plasmid DNA

0.01ng
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2.8.3: Transformation of Chemically Competent KRX Cells

An aliquot of KRX cells was thawed on ice. Eight microlitres of DNA was added to
1.5ml microfuge tubes containing 50µl of competent cells, gently mixed and incubated
on ice slurry for 10-30 minutes. The transformation mix was heat shocked at 42°C for
30-45 seconds; returned to ice for 2 minutes, and 900µl of pre-warmed 2x YT was
added, followed by incubation at 37°C for 1 hour with gentle shaking (300rpm).
Transformation mixes were plated on 2x YT agar plates (containing the appropriate
antibiotic) and incubated at 37°C overnight.

2.9: Preparation of Recombinant Adenovirus

Recombinant RSV-Empty and RSV-CD147 viruses were prepared according to the
method of (He et al., 1998), with some modifications. Briefly pShuttle plasmid DNA
was linearized by Pmel digestion and introduced into E.coli strain BJ5183 carrying
pAdeasy (Zeng et al., 2001) by electroporation (Gene Pulser II, Biorad). Recombinants
were selected on media containing 50μg/ml kanamycin, and their plasmid DNA
checked by PacI digestion. HEK-293 cells grown to 90% confluence in 25cm2 flasks
were transfected with 3μg of PacI linearized recombinant plasmid DNA using
Lipofectamine2000 (Invitrogen, USA) Viral plaques appeared within 5 – 10 days and
viral material used to for subsequent amplification of the virus in HEK-293 before
purification and concentration using the Adeno-X virus purification kit (BD
Biosciences, USA). Viral titres were determined by end-point dilution assay, as
indicated by EGFP reporter expression
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2.10: RNA/DNA methods
2.10.1: General handling

All plastic ware, solutions and buffers used in conjunction with DNA or RNA were
either certified free of DNases or RNases as supplied by the manufacturer or prepared
in-house and sterilised appropriately. In general, preparations of oligonucleotides, DNA
and RNA were reconstituted in sterile WFI and stored at -20°C. For analytical or
preparative work, oligonucleotides, DNA or RNA samples were handled aseptically,
and were thawed and maintained on ice when in use.
2.10.2: RNA extraction

Total RNA was extracted from tissue cultures or animal tissue samples using TRIZOL
Reagent, a mono-phasic solution of phenol and isothiocyanate and used according to the
manufacturer’s instructions. Total RNA was resuspended in sterile water for injection
(WFI) at 0.2 to 1.0 µg/ml and stored at -80°C

2.10.3: Genomic DNA extraction

Total genomic DNA was extracted from cells grown in culture using the MasterPure
Complete DNA and RNA Purification Kit from Epicentre Technologies. Total genomic
DNA was resuspended in sterile WFI and stored at -20°C.

2.10.4: Plasmid extractions

Small-scale isolation of purified plasmid DNA from E.coli was performed with the
Wizard Plus SV Minipreps DNA Purification System Kit (Promega). Single colonies
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were inoculated into 1.8 ml of 2xYT medium (containing an appropriate antibiotic) in
microfuge tubes fitted with a PTFE membrane lid (LidBacEppendorf) and grown 16-18
hours at 37°C with shaking at 1400 rpm. Cells were pelleted by centrifugation and
plasmid DNA was recovered by following the manufacturer’s instructions. Plasmid
DNA was eluted from the mini-column in 80-100 µl sterile WFI.

2.11: Cloning of the PCR Products and Cell Transformation

Cloning was performed by adding 0.5 - 4μl PCR product, 1μl salt solution, 1μl sterile
water and 1μl TOPO vector in a final volume of 6μl. The mixture was then incubated at
room temperature for 5 minutes and placed on ice ready for transformation.
KRX cells were thawed on ice for 5 minutes or till completely thawed and 200μl of
cells transferred to chilled tubes on ice. DNA (8μl) was added to the cells and incubated
for 15 minutes. The cells were heat shocked on Thermo mixer Comfort (Eppendorf) for
45-50 seconds at 42oC and immediately placed on ice for 2 minutes. 2YT medium
(900μl) was added to each tube and incubated on Thermo mixer Comfort (Eppendorf) at
37oC for 60 minutes with shaking at 225rpm. Tubes were centrifuged for 1 minute at
14000rpm and pellet suspended in 100µl media. Cells were cultured on Kanamycin agar
plates and incubated at 37oC overnight. The following day colonies (one colony per
tube) were suspended in 1.800ml 2YT medium with Kanamycin and incubated
overnight on Thermo mixer Comfort (Eppendorf) incubator with shaking speed set at
14000rpm.
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2.12: Restriction enzyme digestion

Restriction enzyme reactions were performed on plasmid DNA for both preparative and
analytical purposes. In general, restriction digests comprised DNA (0.2-3.0 µg) in
sterile WFI and combined in a 20-80 µl reaction volume with 1x restriction enzyme
buffer (supplied as a 10x stock by the enzyme manufacturer) and at least 4 Units of
enzyme per µg of DNA. Reactions were allowed to proceed for at least 2 hours at the
temperature specified by the manufacturer. For double or triple digests, reactions were
either conducted separately followed by purification (as described in section 2.3.2.6) or
simultaneously if enzyme buffer conditions were compatible. Linearization of plasmid
vector DNA by restriction digestion was performed for 12-18 hours using excess
restriction enzyme. For directional cloning into expression vectors, whereby the use of
two different restriction enzymes was necessary, digests were always performed
sequentially.

2.13: Ligations

For ligation reactions, insert DNA (100-250 ng) was combined with sterile WFI in a
volume of 25 µl with: 1x T4 DNA ligase ligation buffer (supplied as a 10x stock by the
enzyme manufacturer, Promega); linearised plasmid vector DNA (25-50 ng) and T4

DNA ligase 4.5 Units. Ligation mixtures were incubated at room temperature for 12-18
hours and stored at -20°C. Insert to plasmid DNA ratios were kept at a minimum of 3:1.

2.14: Quantitation of DNA

Where necessary, DNA and RNA samples were quantified spectrophotometrically by
measuring absorbance at two wavelengths, 260 nm and 280 nm. The instrument used
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for this purpose was the NanoDrop (Analytical Technologies) and the protocols
followed were described by the manufacturer. The concentration and purity of nucleic
acid in the sample is automatically calculated by the instrument, and whilst
concentrations were dependent on the quantity of starting material, pure preparations of
RNA and DNA routinely gave OD260/OD280 ratios of approximately 1.8.

2.15: Agarose gel electrophoresis

Plasmid DNA, RNA, restriction enzyme fragments and PCR products were mixed with
DNA loading dye and electrophoresed in agarose gels (0.7-2.5% w/v) using a TAE
buffer system. Gels were pre-stained with ethidium bromide (0.5 µg/ml) and bands
were visualised by UV transillumination (Foto/UV21, Fotodyne transilluminator), sized
against DNA molecular weight markers and imaged/digitised following capture with a
digital camera (brand, Kodak).

2.16: DNA sequencing

The ABI PrismBig Dye Terminator version 3.1 reaction ready fluorescent labelling
sequencing mix, employing Ampli Taq DNA polymerase, was used to sequence
double-stranded DNA. Briefly, 2.0 µl of stock reaction mixture was combined with: 25
ng of DNA oligonucleotide sequencing primer; 500-750 ng of purified double-stranded
plasmid DNA template and made up to 10 µl with WFI. Cycling conditions used were:
initial denaturation at 96°C for 1 minute, followed by 25 amplification cycles (96°C for
30 seconds, 50°C for 30 seconds and 60°C for 4 minutes) and a final 11°C hold. To
precipitate the resulting DNA product, samples were mixed with 20 µl of WFI, 3 µl of
sodium acetate (pH 5.2) and 75 µl of ice-cold 100% ethanol. The samples were held at
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room temperature (protected from light) for 20 minutes, and centrifuged at 14000 rpm
for 30 minutes. The entire supernatant was carefully aspirated and discarded. Two
hundred and fifty microlitres of 75% ethanol were added to the tube containing the
DNA pellet. The tube was gently inverted several times and centrifuged at 14 000 rpm
for 10 minutes. The entire supernatant was carefully aspirated and the DNA pellet dried
at 65°C for 2 minutes. Dried samples were submitted to the Department of Clinical
Immunology (Royal Perth Hospital) or the Australian Neuromuscular Research Institute
(Queen Elizabeth II Medical Centre) sequencing facilities.

2.17: Human CD147 promoter amplification and sequencing
2.17.1: Slowdown PCR for amplifying GC-rich sequences

Slowdown PCR was performed as described by Frey et al (Frey et al., 2008). In brief
the reaction contained 2μl each primer (forward 5’ CCAGAAAGGTAACCGCCAGC
and reverse 5’ GCCATGATTCCTATTCCTCGC; Gene Works, AU), 1.6μl MgCl2, 2 μl
DNA, 0.2 μl Taq polymerase, 4 μl 10x PCR buffer (Phusion), 1.5 μl 7-Deaza-dGTP, 2
μl dNTPS and 9.7 μl dH2O. The thermal cycle conditions are as follows:
1 cycle of 95oC for 5min., setting heating ramp to 2.5oC-1 and the cooling ramp rate for
reaching anneaniling temperature to 1.5oCs-1
48 cycles of 95oC x 30 sec denaturation. 30secannealing with a progressively lowered
temperature from 70-53oC at a rate of 1oC every third cycle and a primer extension of
40 sec at 72oC. 15 cycles of 58oC, 4oC hold. The 360bp product (which covers the
region of interest -392 to -242 nucleotides) was verified by agarose electrophoresis and
viewed under UV on Biorad Gel doc.
2.17.2: Amplification of the CD147 promoter

Human genomic DNA samples (health controls; n=100 and AD cases, n=100) were
sourced from the Australian Biomarker and Lifestyle (ABIL) study (Perth and
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Melbourne – Australia). Sequencing of the CD147 promoter region was done at Applied
Genetic Diagnostics (APG), Department of Pathology-University of Melbourne. The
~30-50ηg genomic DNA was amplified by PCR in a reaction containing 400nM each
primer

(forward

5’

AGGCTCTGGGAGTACAGACG

and

reverse

5’

CCGGGAGGAACCTCTAGTC), 1mM MgCl2, 200uM dNTPs, 8% DMSO and 2U of
AmpliTaq Gold (Applied Biosystems). The thermal cycle conditions are as follows:
1 cycle of 94oC for 5min
35 cycles of 94oC x 45sec, 60oC x 45sec, 72oC x 45sec
1 cycle of 72oC x 10min, 4oC hold.

2.17.3: Sequencing of the CD147 promoter

The 709bp product (which covers the region of interest -392 to -242 nucleotides) was
verified by agarose electrophoresis before pre-sequencing cleanup using EXOSAP-IT
(GE Healthcare) and a sequencing reaction with 5uM forward primer and Big Dye V3.1
terminators (Applied Biosystems). The Qiagen DyeEx kit was used to clean up the
product before capillary electrophoresis on an ABI3130xl Genetic Analyser with POP7
polymer. The product was amplified by PCR and sequenced by capillary electrophoresis
on an ABI 3130xl Genetic Analyser and compared to the reference sequence
NG_007468.1 using Mutation Surveyor Software. Results were confirmed by repeat
PCR and sequencing.
Analysis and visualization of LD and haplotype maps was undertaken using the
Haploview V4.2 software (Barrett et al., 2005). Generated data files were then analyzed
in SPSS using student T-test and One Way Anova.
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2.18: Immunohistochemistry of Human Brain Tissue – Paraffin Embedded
Sections

Frozen and formalin fixed frontal cortex and hippocampal tissues were sourced from
the Western Australian Brain Bank Network (WABBN) in conjunction with the
National Neural Tissue Resource Centre (NNTRC) and the Australian Brain Bank
Network (ABBN). Paraffin sections were prepared in our laboratory. Paraffin sections
were de-parafinized in 3 changes of xylene for 15 minutes followed by hydration in 3
changes of alcohol and distilled water for 2 minutes then rinsed in water. Antigen
retrieval (EDTA pH8) was achieved by boiling sections for 20 minutes. This was
followed by peroxidise blocking (3% Hydrogen Peroxide) for 30 minutes. Non-specific
binding was blocked by 10% normal goat serum for 10 minutes, and exposed to antiCD147 (Santa Cruz; 1:400) diluted in PBS for 90 minutes at room temperature.
Preparations were washed three times in PBS prior to the addition of the secondary
antibody and incubated for 20 minutes. Tissues were washed three times followed by
the addition of Streptavidin for 20 minutes at room temperature. This was followed by
counterstaining with Haematoxylin for 5 minutes, dehydrated and cleared then mounted
with DPX.

Slides were viewed and pictures taken using fluorescence microscopy

(Olympus IX70) with Olympus DP70 digital camera.

2.19: Statistical Methods
2.19.1: Linkage, allelic and haplotypic analysis

Linkage Dysequilibrium was estimated by D’ and r2 as implemented in Haploview V4.2
software (Barrett et al., 2005). Allelic and haplotypic associations with clinical
classification were undertaken using chi-squared (χ2) tests as implemented in
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Haploview. Corrections for multiple testing were considered if mandatory, 1000
permutations as implemented in Haploview. Genotype associations were then analyzed
using IBM SPSS® Statistics version 19.

Analysis of association with categorical

variables (i.e. clinical classification) was undertaken using χ2 analysis, whilst continuous
variables were analyzed using either the Student’s T-test or One Way ANOVA, where
appropriate.

2.19.2: Additional statistical analysis

The resulting data was analysed using the statistical analysis system software ‘SPSS
V17.0 for windows using One-Way ANOVA, Independent Sample T-test, and
correlation analysis. The mean and standard deviation were used to report the data
distribution and independent group ANOVA was used to compare differences among
groups. All p-values reported are two-tailed and the significant level is 0.05.
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CHAPTER 3

Cholesterol modulates CD147 expression in vitro.

3.1: Introduction

Factors associated with an increased risk of developing Alzheimer’s disease (AD),
which is related to toxic Aβ peptide accumulation in the brain include diet, obesity, old
age, genetic profile (e.g. ApoE allele- isoform ε4), age-dependent reproductive hormone
changes and head trauma (Sparks et al., 1990, Sparks, 1997).

In addition, high

circulating plasma cholesterol levels and pre-existing cardiovascular diseases can also
increase the risk of AD (reviewed in (Martins et al., 2006)). Furthermore,
epidemiological findings linking diet and AD in humans are supported by animal
dietary experiments. For example, high fat/high cholesterol diets in rabbits, cynomolgus
monkeys and APPswe transgenic mice leads to increased Aβ brain deposition (Sparks et
al., 1994b, Sparks et al., 2002, Wu et al., 2003, Schmechel et al., 2004). Taken together,
these studies link high fat/high cholesterol diets with increased Aβ accumulation.

Aβ peptides are generated by the sequential cleavage of amyloid precursor protein
(APP) by the beta amyloid cleaving enzyme (BACE) followed by the γ-secretase
enzyme (Li et al., 2000a, Naslund et al., 2000). The γ-secretase enzyme occurs in a
complex with presinilin-1 (PS1), APH-1, presinilin-2, PEN-2 and Nicastrin. Recently,
the CD147 receptor was found to co-fractionate with members of the γ-secretase
complex, and proposed to modulate Aβ formation, via an as yet undescribed regulatory
mechanism (Biswas et al., 1995, Zhou et al., 2005, 2007). However, follow-up studies
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have indicated that instead of regulating Aβ production, CD147 has a role in its
degradation and clearance (Vetrivel et al., 2008b). Regardless of the mechanism, both
studies support a role for CD147 negatively modulating Aβ peptide levels (Zhou et al.,
2005, Vetrivel et al., 2008b), where reductions result in Aβ accumulation (Zhu et al.,
2005).

The CD147 cell membrane receptor protein is a transmembrane glycoprotein belonging
to the immunoglobulin super-family (IgSF) (Biswas and Vonderhaar, 1987, Fossum et
al., 1991, Miyauchi et al., 1991, Kasinrerk et al., 1992, Biswas et al., 1995), which can
induce the production of several MMPs, inducing MMP9 which is up-regulated in AD
Brain (Kataoka et al., 1993, Biswas et al., 1995, Guo et al., 1997). CD147 is also a
member of the small family of related proteins that includes the teratocarcinoma antigen
GP70 and the synaptic glycoprotein SDR1 (Fossum et al., 1991, Shirozu et al., 1996).
Cell signalling and its ability to interact with a number of proteins, including
cyclophilins, has suggested roles for CD147 in neuroprotection and in pathology of
neurodegenerative diseases such as AD. (Kirk et al., 2000, Yurchenko et al., 2002,
Wilson et al., 2005, Ko and Puglielli, 2007).

The sterol carrier protein 2 (SCP-2) has a major role in cholesterol metabolism and
trafficking (Baum et al., 1997, Zanlungo et al., 2000), where it facilitates the rapid
translocation of lipids such as cholesterol between membranous organelles, into cells
and tissues such as liver and blood (Baum et al., 1997, Zanlungo et al., 2000).
Importantly, SCP 2 regulates CD147 transcription (Ko and Puglielli, 2007), suggesting
that CD147 expression is influenced by cholesterol metabolism. Knowing that SCP has
a role in nearly all aspects of cholesterol metabolism and also facilitates CD147
transcription, it is conceivable that changes in cholesterol homeostasis (i.e. under
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cholesterol loading) will alter levels of SCP, thereby impacting on CD147 levels. This
chapter determines whether CD147 expression in primary rat neurons is altered under
conditions of cholesterol loading or accumulated Aβ.

3.2: Aims
Specific aims:
Determine if addition of exogenous cholesterol or Aβ alters the expression of CD147
and full length APP protein in rat primary cortical neuronal cultures
1) Determine if cholesterol affects the viability of rat primary cortical neurons in
cultures.
2) Determine if cholesterol affects CD147 levels in rat primary cortical neuronal
cultures.
3) Determine if Aβ treatment affects CD147 protein and FL-APP levels in rat
primary cortical neuronal cultures.
4) Determine if adenoviral mediated CD147 protein over expression with or
without CyPA can protect rat primary cortical neurons and SH-SY5Y cells
against Aβ42 mediated toxicity.

3.3: Material and methods
3.3.1: Neuronal cultures

Primary cortical rat neuronal cultures were established in 6 well plates from E18
embryos as described in section 2.2.1.1. Neurons were plated at a density of 3 x 106
cells per well and cultures were maintained in a CO2 incubator (5% CO2; 95% air
balance and 98% humidity) at 37oC. On day in vitro four (DIV4) half the media was
removed and replaced with fresh NB/2% B27 containing the mitotic inhibitor cytosine
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arabinofuranoside (Cara), one third of the culture media was removed and replaced with
fresh NB2° on DIV9, and the cultures were maintained at 37oC in 5% CO2.

3.3.2 Cholesterol and Aβ treatment of primary cultures

Cultures were treated on DIV12 with water soluble cholesterol (Sigma) for 48 hours.
Prior to treatment, 2ml media was removed and replaced with an equal volume media
containing cholesterol. Cholesterol concentration consisted of 0, 5, 10, 15, 20, and
30µg/ml prepared from a stock of water soluble cholesterol (5µg/ml).

Rat primary cortical neuronal cultures were exposed to increasing levels of Aβ42 for 48
hours and/or hydrogen peroxide (H2O2) (3µM). Freshly prepared Aβ42 peptide (10μM
oligomeric Aβ) was added to neuronal cultures at DIV 7 to determine CD147
expression induction levels. Neuronal cultures were treated with 0, 1, 2.5, 10 and 15 μM
Aβ42 at DIV14 at 37oC for 48 hours. CyPA protein was prepared in house.

3.3.3: Preparation of pRSV-shuttle vectors encoding human CD147

Total RNA was isolated from the human glioma cell line U251, reverse transcribed and
amplified by PCR using gene specific primer pairs containing unique restriction sites
(bold) and a Kozak sequence (underlined) as follows: - forward (Kpn1)
5’ggtaccgccaccatggcggctgcgctgttc3’ and reverse (Xho1) 5’ctcgagtcaggaagagttcctc3’.
The resulting PCR products were gel purified, ligated into pGEM-Teasy (Promega,
USA) and sequence verified. For sub cloning, the CD147 cDNA fragment was released
by restriction enzyme digestion and ligated into the modified shuttle plasmid
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pRSV/WPRE/CMV: EGFP (Boulos et al., 2006) to generate the pShuttle vector pRSV:
CD147.

3.3.4: Adenoviral vector construction

Recombinant adenoviruses were prepared according to the method of He et al. (1998),
with some modifications (Boulos, Meloni et al. 2006). Briefly, pShuttle plasmid DNA
was linearized by PmeI digestion and introduced, by electroporation (Gene Pulser II,
Biorad) into the Escherichia coli strain BJ5183 carrying pAdeasy (Zeng, Smith et al.
2001). Recombinants were selected on media containing 50 μg/ml kanamycin, and their
plasmid DNA checked by PacI digestion. HEK-293 cells grown to 90% confluence in
25cm2 flasks were transfected with 3μg of PacI linearized recombinant plasmid DNA
using Lipofectamine 2000 (Invitrogen, USA). Following the appearance of viral
plaques (5 – 10 days) culture lysates were used for viral amplification in HEK-293 cells.
Adenoviral particles were purified and concentrated from cell lysates using the AdenoX kit (BD Biosciences, USA). Viral titers were determined by end-point dilution assay,
as indicated by enhanced green fluorescent protein (GFP) reporter expression.

3.3.5: Hydrogen peroxide treatment

Neuronal cultures were exposed to 3μM H2O2 for 30 minutes, media removed and
replaced with fresh NB2 and further maintained in CO2 incubator at 37oC for 24 hours.
Neuronal lysates were collected after 24 hours and CD147 expression determined by
western blot analysis.
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3.3.6: Western blot analysis

The levels of CD147 and full length APP (FL-APP) were determined by western blot as
described in section 2.5. The EMMPRIN SC-9757 (Santa Cruz) and C1/6.1 (kindly
provided by Collin Masters) primary and anti-goat and anti- mouse secondary
antibodies were used to probe for CD147 and FL-APP respectively from protein
collected culture lysates. Following immunobloting, CD147 and FL-APP protein bands
were quantified using the GS-800 Calibrated Densitometer (BioRad). Cell viability (in
the presence and/or absence of CyPA, 100ηg/ml) were determined by LDH release
assay as described in section 2.2.2.
3.4: Results

3.4.1: Cholesterol treatment increases CD147 expression in primary neuronal
cultures in a dose dependent manner

To determine if cholesterol influences CD147 expression in neurons, rat primary
cortical neuronal cultures at DIV12 were treated with increasing doses of soluble
cholesterol (0, 5, 10, 15, 20, 25, 30ug/ml). At 48 hours post-cholesterol addition, cell
homogenates were collected and subjected to Western blot analysis to determine CD147
(Fig.3.1) and FL-APP protein levels (Fig.3.2). Cholesterol treatment increased CD147
protein expression in a dose dependent manner from 5 μg/ml, reaching a statistically
significant peak at 20μg/ml (p<0.001), then dropping below untreated control levels at
30μg/ml. (Fig.3.1; n=6 independent experiments). Western blot analysis revealed a
steady, dose dependent decline in FL-APP protein levels with increasing cholesterol,
which dropped below untreated control levels at 25μg/ml (p< 0.005) and 30ug/ml
(p<0.001; Fig.3.2).
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Figure 3.1: Cholesterol increases CD147 expression in primary cortical neuronal
cultures
Representative Immunoblots (run in duplicates) from rat primary cortical neuronal
culture lysates following treatment with cholesterol for 48 hours. Membranes were
probed with anti-CD147 and ant-β-actin antibodies (A). CD147 values were normalized
against beta actin and calculated as a percent of the control. Densitometry and statistical
data analysis of CD147 protein levels (B). Values are expressed as mean ±SD (from 6
independent experiments). *p < 0.001 and *p < 0.05). Compared to controls, neuronal
cultures treated with 20μg/ml cholesterol showed significant increase of CD147
expression while those treated with 30μg/ml cholesterol showed significant decrease of
CD147 expression levels.
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Figure 3.2: Cholesterol decreases FL-APP expression in primary cortical neuronal
cultures
Representative Immunoblots (duplicate samples) from rat primary cortical neuronal
culture lysates following treatment with cholesterol for 48 hours. Membranes were
probed with anti- anti-FL-APP and ant- β-actin antibodies (A). FL-APP values were
normalized against beta actin and calculated as a percent of the control. Densitometry
and statistical data analysis of FL-APP (B). Values are expressed as mean ±SD (from 6
independent experiments). *p < 0.005 and ***p < 0.001).
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3.4.2: Cholesterol increases LDH release in rat primary cortical neuronal cultures

In the previous experiment (4.4.1) I observed a dramatic decline in both CD147 and FLAPP, at the two highest cholesterol concentrations, 25ug/ml and 30ug/ml. Why this
occurred is not known but toxic Aβ peptide accumulation (Notkola et al., 1998, Refolo
et al., 2000a, Oksman et al., 2006) and free cholesterol loading is associated with
widespread mitochondrial dysfunction and apoptosis (Yao and Tabas, 2001, Matsuda et
al., 2002). Furthermore, protein translation can be suppressed in cells undergoing
environmental stress (Hara et al., 2011, Nilsson and Sunnerhagen, 2011, Koponen et al.,
2012). Thus I next investigated if cell viability was affected by cholesterol loading. In
these experiments increased cholesterol levels appeared to induce cell stress as indicated
by cell rounding and degeneration (data not shown).

To determine if cholesterol

increases cellular stress, we measured lactate dehydrogenase (LDH) release in the
supernatants from cholesterol treated cultures. I chose LDH because it is a reliable
marker of mitochondrial function, and hence, cellular health (Ying (Salahudeen et al.,
2001, Sawane et al., 2002, Ying and Gervay-Hague, 2005, Aras et al., 2008). I found
that compared to untreated cells, LDH release increased in a dose dependent manner in
response to cholesterol treatment (48 hours post addition), (p=0.001; Fig.3.3).
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Figure 3.3: Cholesterol treatment increases LDH release in primary
neuronal cultures
LDH release in rat primary cortical rat neuronal cultures exposed to cholesterol
at DIV14 for 48 hours. The chart represents data from 6 independent
experiments and values are expressed as mean ±SD, *** p<0.001.
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3.4.3: Oxidative stress induces CD147 expression and affects cell viability in rat
primary cortical neuronal cultures in a dose dependent manner

Oxidative stress is an important contributing factor in a number of neurodegenerative
disorders including AD, and strong evidence links Aβ mediated neurotoxicity and
oxidative stress. Oxidative stress occurs when reactive oxygen species (ROS), which are
by-products of mitochondrial phosphorylation, exceed the cells antioxidant defence
systems (Huang et al., 1999, Zhu et al., 2002, Lustbader et al., 2004b). Reactive oxygen
species such as H2O2 and OH- damage proteins, DNA, and cell organelles leading to
cellular death.

Thus, as oxidative stress is known to induce CD147 expression in cardiac myocytes
(Seko et al., 2004), I wondered if Aβ treatment could similarly increase CD147
expression in neuronal cultures. As part of this study, I first confirmed that hydrogen
peroxide (H2O2), an oxidative stress inducer, induces CD147 protein expression
(Fig.3.4).

Compared to control, results from these experiments have shown that

cultures exposed to 3μM H2O2 showed increased CD147 expression and LDH release
(Fig.3.4).

Next I sought to determine if Aβ42 induces CD147 expression (Fig.3.5), I treated rat
primary cortical neuronal cultures on DIV12 with increasing concentrations of Aβ42
peptide (0, 1, 2.5, 5, 10 and 15µM). I first measured LDH release and as expected,
observed a significant increase in neuronal cultures exposed to higher Aβ42 (p<0.001)
(Fig.3.5). Finally I measured CD147 and FL-APP levels using western blot analysis of
lysates which revealed that CD147 protein levels increased in response to Aβ in a dose
dependent manner, reaching statistical significance at 5 - 15μM compared to controls
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(p<0.001 respectively) (Fig 3.6). By contrast, high Aβ concentrations (≥5μM) caused
FL-APP expression to decline (p<0.001) compared to untreated controls (Fig 3.7).
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Figure 3.4: Hydrogen peroxide (H2O2) treatment of rat primary neuronal cultures
increases CD147 levels and LDH release
Representative immunoblots from rat primary cortical neuronal culture lysates
following treatment with 3μM H2O2 for 24 hours. Membranes were probed with antianti-CD147 and ant- β-actin antibodies (A). Densitometry and statistical data analysis of
CD147 (B). Values are expressed as mean ±SD (from 3 independent experiments) **p
< 0.01).
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Figure 3.5: Aβ42 treatment of rat primary neuronal cultures increases LDH
release
LDH release in rat primary cortical rat neuronal cultures exposed to Aβ42 at
DIV14 for 48 hours. The chart represents data from 6 independent experiments
and values are expressed as mean ±SD, *** p<0.001.
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Figure 3:6: Differential CD147 expression in neuronal cultures following treatment
with Aβ42 peptide.
Western blot analysis of rat primary cortical neuronal culture lysates harvested 48 hours
after Aβ42 treatment; A) representative immunoblot probed with anti-CD147 and antiβ-actin antibodies. B) Densitometry and statistical analysis of CD147 expression. The
chart represents data from 6 independent experiments and values are expressed as mean
±SD, *** p<0.001.
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Figure 3:7: Differential FL-APP expression in neuronal cultures following
treatment with Aβ42 peptide.
Western blot analysis of rat primary cortical neuronal culture lysates harvested 48 hours
after Aβ42 treatment; A) representative immunoblot probed with anti-FL-APP and antiβ-actin antibodies. B) Densitometry and statistical analysis of FL-APP expression. The
chart represents data from 6 independent experiments and values are expressed as mean
±SD, *** p<0.001.
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3.4.4: Adenoviral mediated CD147 over expression does not affect cell viability in
rat primary neuronal cultures.
To determine if elevated CD147 expression can cause cell death, I transduced rat
primary cortical neuronal cultures with a recombinant adenovirus expressing human
CD147 (AdRSV-CD147) and control recombinant adenovirus (AdRSV-Empty) at 100
moi. Approximately 70% of the neurons were transduced as indicated by GFP reporter
expression GFP (Fig.3.8). CD147 levels were determined by western blot analysis using
human EMMPRIN SC-9757 monoclonal antibody. As expected the results clearly show
the absence of human CD147 expression in the AdRSV-Empty transduced neuronal
cultures and expression of human CD147 protein in neuronal cultures transduced with
AdRSV-CD147 (Fig.3.9A). Over expression of CD147 did not alter FL-APP levels
(Fig.3.9A) or decrease cell viability as indicated by LDH release (Fig.3.9B).
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Figure 3.8: Recombinant adenoviral transduction of neuronal cultures
Fluorescent microscopy of rat primary cortical neuronal cultures transduced
with adenoviral constructs AdRSV-Empty and AdRSV-CD147 at 100 moi for
72 hours. GFP reporter expression indicating successful adenoviral transduction
of cortical neuronal cultures.
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Figure 3.9: CD147, FL-APP and LDH release levels in recombinant
adenoviral transduced neuronal cultures
Rat primary cortical neuronal cultures transduced with adenoviral constructs
AdRSV-Empty and AdRSV-CD147 at 100 moi for 72 hours. Immunoblots
probed for human CD147, FL-APP, and β-actin loading control (A) and
corresponding LDH release in culture (B).
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3.4.5: Adenoviral mediated CD147 expression protected rat primary cortical
neuronal cultures against Aβ42 toxicity only in the presence of cyclophilin A
(CypA)
Studies have shown that cyclophillin A (CypA)/CD147 receptor-mediated ERK1/2
signalling protects neurons against oxidative stress and ischemic injury (Boulos et al.,
2007). These findings prompted me to determine if increased CD147 expression, in the
absence and/or presence of CyPA, is responsible for protecting neuronal cultures
against Aβ42 toxicity. Rat primary cortical neuronal cultures were transduced with
AdRSV-Empty and AdRSV-CD147 adenoviruses (Fig.3.10). Prior to Aβ42 (20μM)
exposure, cultures were treated with recombinant CyPA (100ng/ml) or protein vehicle
for 30 minutes. I measured LDH release in culture supernatants to determine the level of
cell viability. Visual inspection of the cultures showed that CyPA provides protection
against Aβ42 injury (Fig.3.10). However, analysis of LDH release in cultures
transduced with AdRSV-CD147 and CyPA showed statistically significant protection
against Aβ42 toxicity (p<0.05) (Fig.3.11B). However AdRSV-Empty transduced
cultures treated with CyPA showed protection trend against Aβ42 toxicity (Fig.3.11A).
This outcome was possibly due to low CD147 expression in AdRSV-Empty transduced
cultures as cells exhibiting low level expression are reportedly unresponsive to CyPA
(Trachtenberg et al., 2011).
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Figure 3.10: Rat primary cortical neuronal cultures transduced with recombinant
adenoviruses and exposed to Aβ42 in the presence and absence of CyPA
Rat primary cortical neuronal cultures transduced with AdRSV-Empty (A, B and C) and
AdRSV-CD147 (D, E and F) at a moi of 100. Cultures exposed to 20μM Aβ42 (B, C, E
and F) without (B and E) and with (C and F) CypA (100ng/ml). Compared to untreated
control cultures (A and D), cultures without CyPA pre-treatment (B and E) showed
induced increased neuronal death compared to those pre-treated with CyPA (C and F).
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Figure 3.11: Aβ42 toxicity in neuronal cultures transduced with recombinant
adenoviruses
LDH release in rat primary cortical neuronal cultures transduced with AdRSV-Empty
(A) and AdRSV-CD147 (B) at moi of 100 and exposed to 20μM Aβ42 with and without
CypA (100ng/ml) pre-treatment. Values are expressed as mean ±SE (n=3) and indicate
that CD147 protected neuronal cultures against Aβ42 toxicity in the presence of CyPA
(p<0.05).

130

3.4.6: Adenoviral mediated CD147 expression protected SH-SY5Y cell cultures
against Aβ42 toxicity only in the presence of cyclophilin A (CypA)
In order to consolidate the findings from rat primary cortical neuronal cultures, I
performed additional experiments in SH -SY5Y human neuroblastoma cell line. I chose
SH-SY5Y cells because they have low CD147 expression and are of human origin, and
unlike mixed neuronal cultures are more of purely neuronal cell type. This eliminates
potentially indirect effects of CyPA protection to demonstrate if CyPA acts through
CD147 to mediate neuroprotection that has not been confirmed in neurons. SH-SY5Y
cultures were transduced with adenoviral constructs (AdRSV-Empty and AdRSVCD147) at moi 40. Compared to controls (Fig.3.12 B and C) positive adenoviral
transduction was confirmed by GFP reporter expression in AdRSV-Empty (Fig.3.12B)
and AdRV-CD147 (Fig.3.12C) cultures. Next cultures were exposed to Aβ42, CyPA
and CyPA+ Aβ42 and LDH release was measured with a cell viability marker. The
results showed that AdRSV-CD147, in the presence of CyPA, protected SH-SY5Y
cultures against Aβ42 toxicity (p<0.001) (Fig.3.13B). These results are similar to those
from rat primary neuronal cultures, providing further confirmation that adenoviral
mediated CD147 protects neurons against Aβ42 induced oxidative stress in the presence
of CyPA. Just as in the rat primary neuronal culture experiments, SH-SY5Y cultures
transduced with AdRSV-Empty showed protection trend against Aβ42 induced toxicity
(Fig.3.13A).
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Figure 3.12: SH-SY5Y cultures transduced with recombinant adenoviruses
Fluorescent microscopy images of SH-SY5Y cultures transduced with AdRSV-Empty
and AdRSV-CD147 at moi of 40. GFP reporter expression indicating over 80% of
neurons transduced with recombinant adenoviruses.
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Fig. 3.13: Aβ42 Toxicity in SH-SY5Y human neuroblastoma cultures transduced
with recombinant adenoviruses
LDH release in SH-SY5Y human neuroblastoma cultures transduced with AdRSVEmpty (A) and AdRSV-CD147 (B) at moi 40 and exposed to 20μM Aβ42 with and
without CypA (100ng/ml) pre-treatment. Values are expressed as mean ±SE (n=3).
Results indicate that CD147 protected SH-Y5Y human neuroblastoma cells against
Aβ42 toxicity in the presence of CyPA (**p<0.001).
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3.5: Summary of results

Overall the in vitro results presented in this chapter have demonstrated for the first time
that cholesterol and Aβ42 can induce CD147 expression. Finally that adenoviral
mediated CD147 expression protects neuronal cultures against Aβ42 induced oxidative
stress only in the presence of CyPA.

3.6: Discussion

3.6.1: Cholesterol loading affects CD147 levels in vitro

In the current study I demonstrated for the first time that cholesterol increases CD147
expression dose dependently in primary neuronal cultures. The sterol carrier protein
(SCP) which is involved in cholesterol uptake (McLean et al., 1989, Moncecchi et al.,
1996, Atshaves et al., 1999, Atshaves et al., 2009), intracellular transport (Kraemer et
al., 1995, Ren et al., 2004), esterification (Murphy and Schroeder, 1997) and oxidation
(Atshaves et al., 2009), reportedly affects CD147 expression by modulating
transcription (Puglielli et al., 1995, Ko and Puglielli, 2007). This link suggests that
cholesterol may influence SCP protein levels, thereby modulating CD147 expression.
To investigate this relationship, I postulated that SCP protein levels change in response
to cholesterol challenge. However, attempts to detect SCP protein in culture lysates by
western blot analysis were unsuccessful, despite trying 4 different commercially
available antibodies. Thus, I was unable to confirm or refute this hypothesis.

As part of this study, I also confirmed that neuronal degeneration increased in response
to cholesterol using LDH release as a marker of mitochondrial function and cellular
health (Nixon, 2004, Feng et al., 2010, Metrailler-Ruchonnet et al., 2010, Zhang et al.,
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2010b). The increase in CD147 expression and LDH release suggested an association
between CD147 regulation and the cells response to injury. Oxidative stress is a major
contributor to neuronal cell loss in a number of neurodegenerative disorders including
AD, and there is strong evidence linking oxidative stress to Aβ. Oxidative stress occurs
when reactive oxygen species (ROS), resulting from mitochondrial oxidative
phosphorylation, exceed the cells naturally occurring antioxidant defence systems, lead
to chemical damage of cellular structures and components. That this process occurs in
AD is supported by the findings of Martins et al (Martins et al., 1986) who reported an
increase in activity of enzymes from the hexose monophosphate pathways in postmortem brain samples compared to age-matched controls. Several reports have also
shown extensive oxidative damage in AD, including lipid peroxidation (Sayre et al.,
1997, Kontush et al., 2001, Butterfield, 2002), oxidized proteins (Carney et al., 1994,
Chan et al., 1999, Wang et al., 2003) nucleic acid damage and advanced glycation end
products (AGE) (Torreggiani et al., 2009). Oxidative damage in AD may be a direct
result of Aβ peptide accumulation which causes neurotoxicity by producing reactive
oxygen species (ROS) (Carney et al., 1994, Devi et al., 2006, Torreggiani et al., 2009)
through interaction with metals, but mainly copper (Huang et al., 1999, Curtain et al.,
2001, Dong et al., 2003, Crouch et al., 2005). Specifically, the combination of Aβ and
Cu ions generates hydrogen peroxide (H2O2) that causes damage to lipids and proteins.
These findings clearly show that Aβ mediated generation of ROS is a potentially import
contributor of neuronal cell death in AD.

Thus, since elevated cholesterol is also associated with increased Aβ production (Refolo
et al., 2000a, Wu et al., 2003, Fitz et al., 2010), I postulated that oxidative
stress/reactive oxygen species (ROS) generation, induced by Aβ (Smith et al., 1998, Lin
et al., 2001, Butterfield et al., 2002), might also account for the observed CD147
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increase, independently of any SCP related mechanism.

Specifically, CD147

expression has been linked to oxidative stress (Boulos et al., 2007). As mentioned
earlier, and in support of this idea, I noted that cultures treated with increasing
cholesterol levels exhibited hallmarks of degeneration, indicating cellular stress. To test
this hypothesis, I also measured Aβ levels in the supernatants of cholesterol treated
cultures. However, despite using a highly sensitive commercial ELISA assay, I found
that Aβ levels were undetectable. Interestingly, Western blot analysis also revealed a
steady, dose dependent decline in FL-APP protein levels with increasing cholesterol.
These results are consistent with another study that previously reported a downward
shift in FL-APP levels with increasing cholesterol levels (Galbete et al., 2000b), due
apparently to a decrease in APP (sAPP) secretion caused by the disruption of the
immature APP glycosylation by cholesterol. The disruption of FL-APP may account for
the lack of detectable Aβ, as reduced FL-APP levels would have limited the amount of
amyloid protein available for cleavage by gamma secretase and hence Aβ generation.

Cholesterol can reportedly increase oxidative stress by directly impacting on
mitochondrial function (Homma et al., 2004, Oliveros et al., 2004, Lu et al., 2011, Mei
et al., 2012), a process that may produce injurious levels of ROS, including hydrogen
peroxide. In testing this possible association I exposed rat primary neuronal cultures to
hydrogen peroxide and observed an increase in CD147 expression alongside increased
LDH release. Subsequently, I tested if the human Aβ42 toxic peptide species could
similarly increase CD147 levels in neuronal cultures, given that it also induces
H2O2/oxidative stress (Butterfield et al., 2002). As postulated and for the first time, I
demonstrated that, Aβ42 increases CD147 expression in a dose dependent manner, a
potentially significant finding in AD, given that CD147 down regulation increases Aβ42
(Zhou et al., 2005, 2006, 2007). Furthermore and importantly, I demonstrated that
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increased CD147 expression is not directly toxic to neurons in vitro.

3.6.2: CD147 protects neuronal cultures form Aβ42 induced toxicity only in the
presence of CYPA

As part of this study I also investigated the behaviour of extracellular CYPA protein
within the context of AD and Aβ toxicity and CD147 expression. Recent reports
indicate that CD147 depletion and/or knock down results in elevated Aβ peptide levels
(Zhou et al., 2005) and that CyPA/CD147 signalling may protect neurons from
oxidative and ischemic injury (Boulos et al., 2007). Furthermore, it is also reported that
CD147 null mice exhibit neurological abnormalities such as spatial learning and
memory deficits and that CD147 depletion affects embryonic development (Igakura et
al., 1998, Muramatsu and Miyauchi, 2003, Chen et al., 2007). Taken together, these
findings suggest that CD147 expression may protect against neuronal damage in vivo.
The question arises, whether the biological effects attributable to CYPA would occur in
vivo and additionally, if CYPA protein occurs within the extracellular compartment.
Importantly, strong evidence indicates that CYPA secretion occurs in response to
oxidative stress, which as alluded to earlier is a feature of the AD brain. Indeed,
endothelial cells and even neurons are known to secret CYPA at least in vitro.

Whilst exogenous addition of recombinant CyPA protein reportedly protects neurons
against oxidative and ischemic injury (Boulos et al., 2007), no studies have conclusively
determined that protection against Aβ is mediated via the CD147 receptor. In the
current study, I showed for the first time that recombinant CYPA protein protects
primary cortical neurons and human SH-SY5Y neuroblastoma cultures against Aβ42,
via a CD147 dependent mechanism. Importantly, although recombinant CYPA protein
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appeared to increase the viability of cultures with basal CD147 expression, the level of
protection only reached significance when CD147 was over expressed. These findings
may be explained by a recent study, demonstrating that CYPA mediated biological
effects require a threshold level of CD147 expression (Yang et al., 2008, Trachtenberg
et al., 2011) cultures.

Nevertheless, these results support the notion that CYPA

mediates its neuroprotective effects through the CD147 receptor, which is presumably
imparted by increasing pro-survival signalling such as ERK1/2 activation (Boulos et al.,
2007), Bcl-2 up regulation (Biswas and Greene, 2002, Perkins et al., 2003, MetraillerRuchonnet et al., 2010) and through Bax and caspase3 inhibition (Abdi et al., 2011).

The impact of extracellular CYPA protein and CD147 signalling on AD may not just be
limited to neuroprotective. CYPA/CD147 receptor signalling can also induce the
production of matrix metalloproteinases (MMPs), including MMP9, which interestingly
is known to be up regulated in AD brain (Backstrom et al., 1996, Lorenzl et al., 2003,
Bruno et al., 2009, Romi et al., 2012). Of particular significance, Vetrivel et al, (2008)
postulated that CD147 may aid Aβ clearance, by somehow promoting its degradation.
My findings linking Aβ, CD147 expression and extracellular CYPA may provide a
potential mechanism by which this could occur.

3.7: Conclusion

Taken together, the findings of the present chapter identify potentially important
relationships between cholesterol loading, CD147 expression, Aβ toxicity and the
putative involvement of CYPA protein in neuroprotection, and possibly in Aβ clearance
in AD.
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CHAPTER 4

A high fat/ high cholesterol diet does not affect CD147 levels in APPswe
transgenic mice

4.1: Introduction

The previous chapter provided evidence that cholesterol levels can modulate CD147
expression in culture as evidenced by elevated cellular CD147 levels under conditions
of high cholesterol in the medium. The aims of the studies of this chapter involve
extending these findings, in particular, determining the effect of increased cholesterol
on CD147 levels in vivo.

Cholesterol, a component of cell and organelle membranes, is essential for normal brain
function. The brain contains the largest single pool of cholesterol that account for 25%
of total body cholesterol and its derivatives (Dietschy and Turley, 2004, Vaya and
Schipper, 2007). Cholesterol levels in the brain are maintained mostly by recycling
brain cholesterol, however some transfer of cholesterol from the brain to the periphery
does occur across the BBB, most likely following conversion to 24-OH cholesterol.
Transfer from the blood to the brain can also occur. Excessive dietary cholesterol may
upset this balance in many ways, both directly and indirectly via effects on general lipid
metabolism, inducing insulin resistance and cardiovascular problems. Defects in
cholesterol metabolism can induce neurological dysfunctions (Tint et al., 1994, Feng et
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al., 2003). Cholesterol accumulation has been shown to be toxic (Li et al., 2011) and
can contribute to the development of age-related diseases (reviewed in Liu et al., 2010).

A number of studies have assessed the impact of high fat/ high cholesterol diets on AD
pathology in transgenic and non-transgenic animal models. Animals fed high
cholesterol diets often suffer from increased Aβ deposition (Sparks et al., 1994b, Refolo
et al., 2000b, Shie et al., 2002). For example, hypercholesterolemic mice (Refolo et al.,
2000b) demonstrate an increase in deposit sizes of Aβ (Refolo et al., 2000b), and in
rabbits, a comparatively longer duration on a high cholesterol diet results in a more
severe accumulation of brain Aβ (Sparks et al., 1994a). In another study, higher levels
of Aβ deposition were observed in 12 month old TgAPPswe mice which had been fed a
high fat/high cholesterol diet (HFHC) for 10 months (Shie et al., 2002), compared to
TgAPPswe mice fed standard rodent chow.

As APP itself and the enzymes involved in its cleavage are associated with membranes,
particularly the trans-membrane γ-secretase enzyme, it is not surprising that much
research has centred around membrane cholesterol levels and their effect on Aβ
production. Cholesterol and sphingolipid-rich membranes microdomains (so called lipid
rafts; (Lee et al., 1998, Wahrle et al., 2002) have been found to contain BACE1 and the
γ-secretase complex, promoting Aβ production at these sites (reviewed in Cheng et al.,
2007). Aβ40 and Aβ42 have been found to accumulate in the lipid rafts of aging
Tg2576 mice (Kawarabayashi et al., 2004), and interestingly, there appears to be a
sequence in the appearance of APOE and phosphorylated tau with the former increasing
progressively from 12 months and the latter from 18 months of age in Tg2576 mice
(Kawarabayashi et al., 2004).

140

Membrane cholesterol content can switch APP processing from the amyloidogenic
pathway to the non-amyloidogenic pathway or vice versa. Although the mechanisms
remain unclear, alterations in membrane cholesterol levels may modulate lipid fluidity.
Depletion of membrane cholesterol has been shown to lead to a reduction in Aβ
production, which is restored when cholesterol is replenished (Simons et al., 1998b,
Wahrle et al., 2002). There is some controversy concerning these results however, as
some researchers claim that the depletion of membrane cholesterol in many experiments
is too severe for the effects to be physiologically relevant. It is thought that
disorganization in the structure of the lipid bilayer could alter the α-secretase processing
of APP by shifting the proximity of the secretase cleavage sites to the intramembrane
domain of APP, and in vitro studies have demonstrated that high levels of cholesterol
affect α-secretase and BACE activity and result in a decrease in soluble APP levels and
an increase in Aβ production. However, it is still unclear how membrane cholesterol
influences γ-secretase activity, thought to be concentrated to lipid rafts (Dickstein et al.,
2010). Some studies have shown that γ-secretase is dependent on lipid rafts but is not
cholesterol-dependent, whereas others have shown that cholesterol can indeed modulate
enzyme activity. Evidence has also been provided proposing that cholesterol plays a
role in the conversion of soluble monomeric Aβ into insoluble aggregates (Schneider et
al., 2006).

Another mechanism that is explored in this chapter involves the regulation of some of
the components of cholesterol metabolism. Many proteins have been linked to both
cholesterol metabolism and AD, and one protein that is involved in both cholesterol
metabolism and in CD147 function is the sterol carrier protein SCP-2. This protein
plays a key role in cholesterol metabolism as it functions in cholesterol uptake (Hirai et
al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al., 1996, Schroeder et al.,
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1998, Atshaves et al., 1999), intracellular transport (Puglielli et al., 1995), esterification
(Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al., 1986, Yamamoto et
al., 1991). In addition it has been shown to remodel lipid composition, structure and
function of lipid rafts (Schroeder et al., 2007). As described in chapter 1 (section 1.7.6)
SCP facilitates CD147 transcription; it is therefore conceivable that changes in
cholesterol homeostasis (i.e. under cholesterol loading) will alter levels of SCP, thereby
impacting on CD147 levels and Aβ metabolism. Indeed cholesterol enrichment in rat
aortic smooth muscle cells has been shown to result in an increase in SCP mRNA
(Kraemer et al., 1995), providing evidence that cholesterol and its derivatives can
regulate SCP expression. Whether this results in changes in CD147 levels, remains to be
determined.

4.2: Aims

The overall aim of the current study was to determine if dietary cholesterol loading
impacts on cerebral CD147 levels in vivo. To assess this, AD model transgenic mice
(APPswe) were fed a normal chow diet or a high fat/high cholesterol diet and the
following were determined.

1) The impact of a high fat/high cholesterol diet on body weight and plasma
cholesterol levels.
2) The impact of a high fat/high cholesterol diet on CD147 levels in the brain and
peripheral organs. Any potential correlations between extent of changes and
circulating cholesterol levels were also assessed.
3) The impact of a high fat/high cholesterol diet on SCP mRNA levels in the brain.
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4) The impact of a high fat/high cholesterol diet on cerebral levels of APP and its
metabolites.

4.3: Materials and methods
4.3.1: Experimental animals and diets

The APPswe mice were divided into 4 different groups, and fed for 10 weeks on either
standard mouse chow (control) or a high fat/high cholesterol diet containing 10% fat,
0.75% cholesterol, 0.3% cholate and additional vitamins (Fig.4.1). Baseline body
weights were recorded, then mice were weighed once a fortnight. The average weight
gain for each animal was calculated at the end of the study to determine the weight gain
over the course of administering the diet. Following 10 weeks, mice were sacrificed and
plasma, liver, brain and kidney tissues were collected; snap frozen and stored at – 80oC.
The brains were divided into right (which were instantly snap frozen) and left (stored in
RNA Later) hemispheres.

4.3.2: Western blot and ELISA analyses

Brain tissue homogenates underwent Western immunoblotting for CD147, FL-APP and
the APP C-terminal fragments C-99 and C-83, whereas liver and kidney homogenates
were immunobloted for CD147 only, as described in section 2.5.

Films of western

immunoblots were scanned and optical density determined through the Bio-rad,
Quantity One Software. Specifically film backgrounds were subtracted from optical
density of individual protein bands. An internal control was run on each gel for inter-gel
normalisation. Levels for the proteins of interest were represented as a ratio of the βactin, to control for inter sample loading differences and presented in scatter plots.
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Western blots for all individual data points are presented in next to their corresponding
scatter plots.
ELISA was used for analysis of brain and plasma Aβ40 and Aβ42 levels as described in
section 2.6.1. Total cholesterol levels were measured in plasma as described in section
2.6.2.

4.3.3: SCP-2 analysis

To assess whether the high fat/high cholesterol diet led to changes in SCP-2 transcript
levels, SCP-2 mRNA was extracted from 100mg of APPswe mice brains fed on a
normal chow or a high fat/high cholesterol diet using RNeasy Lipid Tissue Mini Kit
(50) (Qiagen) according to the manufacturer’s instructions. SCP-2 forward
(TGCGTTGGCTATGTGTATGG) and reverse (TGCCAGTCAGTCCCAAACTA) primers were designed
using the Net Primer program and manufactured by Gene Works (Australia). Successful
generation of the SCP-2 cDNA PCR product was confirmed by acrylamide gel
electrophoresis. The cDNA amplification was performed using a 2-step cycling protocol
(10 min at 95oC activation, 40 cycle of 15 sec at 95oC and 60 sec at 60oC, 60oC-95oC
melt). The qRT-PCR reactions were performed using KAPA SYBR® FAST qPCR Kit
Master Mix (South Africa) using the same primers on the Bio-Rad iCycler RT-PCR
System using a total reaction volume of 20 µl. The optical densities were normalized
against mTB House Keeping Gene. SCP-2 expression was determined by comparing
relative ratio values of mice fed on a normal chow diet against those fed on a high
fat/high cholesterol diet.
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(n=36)

Chow
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Figure.4.1: Experimental groups
APPswe mice (n=36; 17 males, 19 females) were divided into two major groups. The
first group (n=17; 7 males, 10 females) were fed a normal chow diet and the other
(n=19; 10 males, 9 females) a high fat high cholesterol diet.

145

4.4: Results
4.4.1: Impact of a high fat/high cholesterol diet on body weight and plasma
cholesterol levels.

Experimental mice were fed either a normal chow control or a high fat/high cholesterol
diet for 10 weeks and weighed every fortnight. The body weight gain over the 10 week
period is shown in Figure 4.2. As expected, all mice (either on the normal chow or high
fat/ high cholesterol diet) gained weight over the treatment period, indicating that they
were eating the diets provided.

Following 10 weeks of administering the diets, mice were sacrificed and tissues and
plasma collected. Total plasma cholesterol was measured in all mice and levels are
shown in Fig. 4.3 Compared to mice fed on the normal chow control diet, those fed a
high fat, high cholesterol diet had significantly higher plasma cholesterol levels. Female
mice on the high fat/high cholesterol diet exhibited a greater (2 fold) increase in
cholesterol level, than males (compare Fig. 4.3C with Fig.4.3B). Overall, the results
indicate that the high fat, high cholesterol diet consumed by the mice significantly
increased plasma cholesterol levels.

To address the hypothesis that CD147 is altered in the presence of cholesterol in vivo, I
then measured levels of this protein in the brain and peripheral organs of mice fed the
different diets.
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Figure 4.2: Body weights of APPswe mice fed on a normal chow and high fat/high
cholesterol diets.
Graphs represent body weight gain in (A) all mice, n=36, (B) males, n=17 and (C)
females, n=19 during the course of study. Mice were weighed at baseline (0) and every
fortnight for 10 weeks after administering the diet. Data represents average body weight
of mice at each of the measurement stages ± SD. ***, p<0.001, values significantly
increased over baseline weights.
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Figure 4.3: Total plasma cholesterol levels in APPswe mice following 10 weeks
feeding with experimental diets.
Plasma cholesterol levels in (A) all experimental mice on a normal chow (n=17) or a
high fat/high cholesterol diet (n=19), (B) males on a normal chow diet (n=7) or a high
fat/high cholesterol diet (n=10) and (C) females on a normal chow (n=10) or a high
fat/high cholesterol diet (n=9). The data represents mean ± SE. *p<0.05, **p<0.01;
values significantly increased over those obtained from mice fed normal chow diet.
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4.4.2: Cerebral CD147 protein levels are not significantly altered in APPswe mice
fed a high fat/high cholesterol diet

The CD147 protein levels of tissue homogenates were measured by Western
immunoblot analysis using the rodent specific antibody EMMPRINE SC-9753 as
described above. Although expression of CD147 in rodent brain tissue has been widely
reported (Nahalkova et al., 2010, Xie et al., 2010, Agrawal and Yong, 2011), detection
of this protein in the kidneys and liver has yet to be documented. Thus preliminary
analysis was performed where expression in the peripheral organs was compared to that
observed in homogenates of primary rat neuronal lysate, human brain and mouse brain
(Fig 4.4). A protein band similar to that detected in rat primary neuronal lysate, was
also detected at ~58 kDa in mouse brain, liver and kidney homogenates. However this
protein band was absent from the human brain homogenates, indicating EMMPRINE
SC-9753 antibody specificity for rodent CD147.

Having established that CD147 can be detected in mouse brain, liver and kidneys,
immunoblotting with this antibody was then performed on homogenates from all the
experimental mice (Fig.4.5). Semi-quantitative analysis revealed no significant changes
in CD147 level in either the males or the females. However, compared to mice fed on a
normal chow diet, the data indicate an increasing trend in males (p=0.096) and a
decreasing trend in females (p=0.201) fed on the high fat/high cholesterol diet
(Fig.4.5C and D, respectively). Analysis of CD147 protein levels in the peripheral
organs (kidney and liver) revealed a significant reduction in the kidney tissue levels of
CD147 in the males only (p=0.03) (Fig. 4.6). No significant differences in CD147
levels were observed in the liver samples (Fig.4.7) from either the male or the female
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mice on the different diets. However, compared to mice fed the normal chow diet, a
trend towards lower CD147 levels was observed in liver tissues from the male mice fed
on the high fat/high cholesterol diet.

150

Figure 4.4: Immunodetection of CD147 using rodent EMMPRINE SC-9753
antibody.
Immunoblot of rat neuronal lysate (lane 1), human and mouse brain tissues (lanes 2-4)
and mouse peripheral tissues (lanes 5-6). CD147 was detected in rat (lanes 1 and 3) and
mouse (lanes 4-6) but not human (lane 2) tissue samples indicating the EMMPRINE
SC-9753 antibody used is specific for rodent CD147.
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Fig.4.5: Brain CD147 levels in brain tissue from APPswe mice following 10 weeks feeding with experimental diets.
153

Figure 4.5: Brain CD147 levels in brain tissue from APPswe mice following 10 weeks feeding with experimental diets.
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and
females (B, D). Western blots of brain homogenates run in duplicate show the 58 kDa CD147 protein levels and corresponding β-actin levels as a
loading control in males (A) and females (B). Scatter plots of quantitated CD147 levels in males (C) and females (D) on the different diets. Individual
points represent a specific mouse sample value (average of duplicate samples in adjacent lanes) with the group mean represented by a horizontal line.
Compared to those fed on a normal chow diet, data indicate a trend towards higher CD147 levels in males and a trend towards lower levels in females
fed the high fat/high cholesterol diets respectively.
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Figure 4.6: CD147 levels in kidney tissue from APPswe mice following 10 weeks feeding with the experimental diets.
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Figure 4.6: CD147 levels in kidney tissue from APPswe mice following 10 weeks feeding with the experimental diets.
Western blot analysis of kidney tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and
females (B, D). Western blots of kidney homogenates show the ~58 kDa CD147 and corresponding β-actin levels as a loading control in males (A)
and females (B). Scatter plots of quantitated CD147 levels from in males (C) and females (D) on the different diets. Individual points represent a
specific mouse value with the group mean represented by horizontal line. Compared to mice fed the normal chow diet, data indicate a significant
reduction in CD147 levels (*p<0.05) in the male mice fed the high fat/high cholesterol diet, with a trend towards lower levels in the female mice fed
the high fat/high cholesterol diet.
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Figure 4.7: CD147 levels in liver tissue from APPswe mice following 10 weeks feeding with the experimental diets.
157

Figure 4.7: CD147 levels in liver tissue from APPswe mice following 10 weeks feeding with the experimental diets.
Western blot analysis of liver tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and
females (B, D). Western blots of liver homogenates run as single samples show the ~58 kDa CD147 levels and corresponding β-actin levels as a
loading control in males (A) and females (B). Scatter plots of quantitated CD147 levels from males (C) and females (D) on the different diets.
Individual points represent a specific mouse value (as quantitated from adjacent samples) with the group mean represented by a horizontal line.
Compared to mice fed the normal chow diet, data indicate no significant change in CD147 levels. However there is a trend towards lower CD147
levels in the males fed the high fat/high cholesterol diet.
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4.4.3: Transcription of SCP-2 is not altered by a high fat/high cholesterol diet.

The sterol carrier protein (SCP-2) plays a key role in a number of aspects of cholesterol
metabolism (Hirai et al., 1994, Colles et al., 1995, Lipka et al., 1995, Moncecchi et al.,
1996, Schroeder et al., 1998, Atshaves et al., 1999) and is a key regulator of CD147
expression (Ko and Puglielli, 2007). Evidence exists that cholesterol can regulate SCP
mRNA in rat aortic smooth muscle cells (Kraemer et al., 1995). In the section above I
have shown that the CD147 protein levels in the brain are not altered but increasing
trend in males and decreasing trend in females were observed in mice fed on a high fat
high cholesterol diet. To determine if this is associated with changes in SCP
transcription, the brain tissue underwent quantitative RT-PCR analysis as described in
section 4.3. The mRNA was extracted from brain tissue stored in RNA later. Forward
and reverse primers were designed against SCP as well as a housekeeping gene mTB
(see section 4.3) and used to amplify the transcripts for quantitative RT-PCR. PCR
analysis of cDNA using the primers (Fig. 4.8A) shows the presence of a ~173 bp
transcript representing SCP-2 (lanes 3-6, blue arrow) and a ~175 bp transcript
representing mTB (lanes 8-11, red arrow). These bands were absent in the control (lanes
2 and 7), which consisted of master mix without cDNA template and indicates the
absence of contaminating DNA. These results validated the use of the primers for
quantitative RT-PCR analysis for amplification of the mRNA.

Amplification curves show that SCP-2 was successfully amplified starting from cycle
25 peaking at cycle 35 (Fig. 4.8B) with the amplification peak temperature of 80oC
(Fig. 4.8 C and D). The relative amounts of generated SCP-2 transcript, represented as
a ratio of the MTB housekeeping gene is shown in Figure 5.9. The results show that
compared to mice fed normal chow control diet, SCP-2 transcript levels were not altered
in brain tissue from mice fed a high fat/ high cholesterol diet (Fig.4.9).
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Figure 4.8: Amplification of SCP-2 mRNA by RT-PCR in brain tissue from APPswe mice fed the experimental diets
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Figure 4.8: Amplification of SCP-2 mRNA by RT-PCR in brain tissue from APPswe mice fed the experimental diets
Agarose gel of PCR products of cDNA extracted from 4 samples of 100 mg brain tissue (2 from mice fed the normal chow diet and 2 from mice fed
high fat/high cholesterol diet) (A). The 100 bp DNA ladder is shown in lane 1, and the master mix without cDNA (negative control) is shown in lanes
2 and 7. SCP was successfully amplified and detected as a ~173 bp band (lanes 3-6, blue arrow). The mTB housekeeping gene was also successfully
amplified and can be seen as a ~175bp band (lanes 8-11, red arrow). Representative charts of (B) amplification (C), melting curve and (D) melting
peak of amplified SCP-2.
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Figure 4.9: SCP-2 mRNA levels in brain tissue from APPswe mice fed the normal
chow diet or the high fat/high cholesterol diet.
Levels of SCP-2 mRNA were measured in brain tissue from (A) Male and (B) Female
mice fed a normal chow diet or high fat/high cholesterol diets. Data was normalised
against the housekeeping gene mTB and levels are represented as a ratio of that
observed in brain tissue from mice fed the normal chow diet (indicated as a “relative
ratio”). Data are represented as mean ±SD and show no difference in SCP-2 mRNA
levels between mice fed on normal chow and high fat/high cholesterol diets.
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4.4.4: Effects of the high fat/high cholesterol diet on APP and some of its
metabolites.

Studies investigating APP metabolism in transgenic mice fed high fat and/or high
cholesterol diets have shown various effects on Aβ metabolism. Refolo et al. reported
increases (Refolo et al., 2000a), Howland et al. reported a decrease (Howland et al.,
1998) and George et al. reported no change in Aβ levels (George et al., 2004). To
determine if the diet used in this study impacted on levels of APP and its metabolites in
mouse brain tissue, brain homogenate levels of full length APP and its C-terminal
fragments (C83 and C99) were assessed by Western immunoblotting (as described in
section 2.5). The C83 fragment is the C-terminal fragment of APP left in the membrane
after α-secretase cleavage, whereas the C99 fragment is the membrane fragment of APP
that is left after β-secretase cleavage. The results show a significant increase in FL-APP
levels in brain tissue from both the male (p=0.026) and female (p=0.004) mice fed the
high fat high cholesterol diet (Fig. 4.10). Furthermore, the male mice fed the high
fat/high cholesterol diet demonstrated significantly lower levels of the APP C83
fragment (p=0.003) compared to those fed a normal chow diet (Fig. 4.12A and C). A
trend towards lower levels of the APP C99 fragment was also observed in the brain
tissue of male mice that had been fed the high fat/high cholesterol diet (Fig.4.11A and
C), compared to those on the normal chow diet.

164

110

5

FL-APP levels
(relative to β-actin; AU)

C

MW (kDa)
Normal Chow Diet - Males
110
FL-APP 80
β-actin
40
1
2
3
4

7

6

HF/HC Diet - Males

FL-APP 80
β-actin
40

200

FL-APP

2

3

4

5

7

6

8

*

150

100

50

0

Chow
1

HF/HC

10

9

D

B
110
FL-APP
80
β-actin
40

Normal Chow Diet - Females

1

110

2

3

4

5

7

6

10

9

8

HF/HC Diet - Females

FL-APP 80
β-actin
40
1

2

3

4

5

6

7

8

FL-APP levels
(relative to β-actin; AU)

A

250

FL-APP

*

200

150

100

50

9
0

Chow

HF/HC

Figure 4.10: FL-APP levels in brain tissue homogenate from APPswe mice fed the normal chow diet or the high fat high cholesterol diet.
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Figure 4.10: FL-APP levels in brain tissue homogenate from APPswe mice fed the normal chow diet or the high fat high cholesterol diet.
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diet for 10 weeks, males (A, C) and
females (B, D). Western blots of brain homogenates run in duplicate showing the ~95-105 kDa FL-APP protein levels and corresponding β-actin
levels as a loading control in males (A) and females (B). Scatter plots of quantitated FL-APP levels from males (C) and females (D) on the different
diets. Individual points represent a specific mouse sample value (average of duplicates in adjacent lanes) with the group mean represented by a
horizontal line. Compared to those fed the normal chow diet, data indicates significantly higher FL-APP levels (*p<0.05 respectively) in both males
and females fed the high fat/high cholesterol diet.
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Figure 4.11 Brain APP-C99 levels in APPswe mice after 10 weeks on the different diets
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diets for 10 weeks, males (A, C) and
females (B, D). Western blots of brain homogenates showing the ~10 kDa APP-C99 protein levels and the corresponding β-actin levels as a loading
control in males (A) and females (B). Scatter plots of quantitated APP-C99 levels from males (C) and females (D) on the different diets. Individual
points represent a specific mouse sample value (as quantitated from adjacent lanes) with the group mean represented by a horizontal line. Compared to
those fed the normal chow diet, the data indicate no change in APP-C99 levels in either the male or female mice fed the high fat high cholesterol diet.
However a trend towards lower levels of C99 fragments can be seen in the male mice fed the high fat/high cholesterol diet.
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Figure 4.12 Brain APP-C83 levels in APPswe mice after 10 weeks on either the normal chow diet or the high fat/high cholesterol diet.
169

Figure 4.12 Brain APP-C83 levels in APPswe mice after 10 weeks on either the normal chow diet or the high fat/high cholesterol diet.
Western blot analysis of brain tissue from APPswe mice fed the normal chow diet or the high fat/high cholesterol diets for 10 weeks, males (A, C) and
females (B, D). Western blots of brain homogenates showing the ~10 kDa APP-C83 protein levels and corresponding β-actin levels as a loading
control in males (A) and females (B). Scatter plots of quantitated APP-C83 levels from males (C) and females (D) fed the different diets. Individual
points represent a specific mouse sample value (as quantitated from adjacent lanes) with the group mean represented by a horizontal line. Compared to
those fed the normal chow diet, data indicates a significantly lower levels of APP-C83 fragments (*p<0.01) in the males after being fed the high
fat/high cholesterol diet.
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4.4.5: Ratio of Aβ42/Aβ40 peptides in the brain and periphery of APPswe mice
after 10 weeks on a high fat/high cholesterol diet or normal chow diet.

To determine whether the high fat high cholesterol diet impacted on brain Aβ
accumulation, brain levels of Aβ40 and Aβ42 peptides were measured by ELISA as
described in section 2.6.1. As an increase in Aβ42 is indicative of greater pathology, the
data is represented as a ratio of Aβ42/Aβ40 (Fig. 4.13). Although not significant, a
trend towards an increase in brain Aβ42/Aβ40 ratio is observed in mice fed high
cholesterol/ high fat diet (Fig. 4.13 A-C), indicating a shift in Aβ production towards
the longer more amyloidogenic form of Aβ (Aβ42), or perhaps indicating that less Aβ42
was being cleared. It is noted however, that there is a large variation amongst those
mice fed the high fat/high cholesterol diet. In particular a few mice (2 females and 3
males) had ratios of much greater than 2, indicating more than 2-fold greater levels of
Aβ42 compared to Aβ40 levels. Interestingly it should be noted that 3 of these mice had
the highest levels of plasma cholesterol (>200nMol), suggesting plasma cholesterol
levels can influence APP metabolism and/or Aβ42 production.

Peripheral Aβ levels have been evaluated as a potential AD biomarker and have been
used to assess a number of therapeutic agents including γ-secretase inhibitors or agents
to promote amyloid clearance in preclinical studies using transgenic mice models
(Kounnas et al., 2010, Wang et al., 2011, Winkler et al., 2010, Martone et al., 2009).
Clinical studies have shown positive correlations between hypercholesterolaemia or
body fat and peripheral Aβ levels (Balakrishnan et al., 2005, Hoglund et al., 2004,
Smith et al., 2001). To determine if a high fat/ high cholesterol diet can induce changes
in peripheral Aβ levels, plasma Aβ40 and Aβ42 levels were measured. The results are
again shown as a ratio (Fig 4.14), and no overall significant change in plasma Aβ42/40
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ratio was observed in the periphery of mice fed the high fat/ high cholesterol diet,
compared to those fed the normal chow diet.
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Figure 4.13: Brain Aβ42/40 ratios in APPswe mice fed on a high fat/high
cholesterol diet compared to controls after 10 weeks. Representative scatter plots
showing brain Aβ42/40 ratios: (A) all mice, (B) males and (C) females. Individual
points represent a specific sample value with the sample mean represented by horizontal
line. There were no significant differences however results show that there is a trend
towards an increase in the mice brain Aβ42/40 ratios, after being fed the high fat/high
cholesterol diet for 10 weeks.
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Figure 4.14: Plasma Aβ42/40 ratios in APPswe mice fed either a high fat/high
cholesterol diet or a normal chow diet for 10 weeks.
Representative scatter plots showing plasma Aβ42/40 ratios: (A) all mice, (B) males and
(C) females. Individual points represent a specific sample value with the group mean
represented by a horizontal line. Results indicate that plasma Aβ42/40 ratios were not
altered.
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4.5: Summary of results

Overall the results presented in this chapter show associations between increases in
plasma cholesterol with increases in brain FL-APP, and a trend towards a higher
proportion of brain Aβ being the more amyloidogenic Aβ42 peptide. No changes in
cerebral CD147 levels were detected as a result of high fat/high cholesterol diet, though
significantly lower levels were detected in the male mouse kidney samples, and a trend
towards lower CD147 levels was detected in the female mouse kidney samples.
Observed changes do not appear to be mediated by changes in SCP-2 gene expression,
as the high fat/ high cholesterol diet did not alter SCP-2 transcript levels. Although not
significant, a trend towards increases in cerebral Aβ42 levels was observed in those
mice fed the high fat/ high cholesterol diet, and there was also a trend towards lower
levels of C-terminal fragments of APP, though only in male mice.

4.6: Discussion
The expression of CD147 is known to play an important role in a number of
pathological diseases/disorders. Examples include facilitating metastasis of many
cancers (lung, cervical and prostate cancers) through MMP induction (Zeng et al., 2011,
Wu et al., 2011, Han et al., 2011 (Zhu et al.) and facilitating chemokine-mediated
recruitment of inflammatory cells in pathological conditions involving inflammation
(see chapter 1, (Kanyenda et al., 2011)). Roles of CD147 expression in the CNS are less
established, however it appears to be important in neurodevelopment and
neuroprotection (see chapter 1, (Kanyenda et al., 2011)). With respect to AD, CD147
expression has been shown to regulate Aβ levels in vitro and in vivo, for example RNAi
knockdown of this gene results in Aβ accumulation (Zhou et al., 2005) and overexpression results in a reduction in Aβ levels (Vetrivel et al., 2008b).
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Knockdown studies have shown that the sterol carrier protein is a major transcription
factor that controls the expression of CD147. As shown and described in chapter 6, SCP
binds CD147 within the promoter region and influences CD147 transcription. The
sterol carrier protein is a key protein involved in cholesterol metabolism where it has
been shown to promote cholesterol uptake (Hirai et al., 1994, Colles et al., 1995, Lipka
et al., 1995, Moncecchi et al., 1996, Schroeder et al., 1998, Atshaves et al., 1999), and
facilitate cholesterol intracellular transport (Puglielli et al., 1995), esterification
(Murphy and Schroeder, 1997) and oxidation (Chanderbhan et al., 1986, Yamamoto et
al., 1991). In addition it has been shown to remodel lipid composition, structure and
function of lipid rafts (Schroeder et al., 2007). Given the importance of this protein in
cholesterol metabolism, it is conceivable that SCP would respond to changes in
cholesterol levels. Indeed Kraemer and colleagues (Kraemer et al., 1995) showed an upregulation of SCP in muscle cells treated with cholesterol.

4.6.1: High fat/high cholesterol diet influences plasma cholesterol levels

In the previous chapter, evidence was produced which showed that CD147 levels in
primary neuronal cells were altered in a dose dependent manner following exposure to
cholesterol (Chapter 3, section 3.4.2). In the current study, APPswe mice were fed a
high fat/high cholesterol diet to provide an in vivo experimental model to assess the
impact of a high cholesterol diet on CD147 protein expression, and to determine if there
were any changes associated with alterations in SCP and APP metabolism.

To raise peripheral levels of cholesterol, mice were fed a diet containing 10% fat, 0.75%
cholesterol and 0.3% cholate, with controls feed on normal chow diet (SF08-020,
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AIN93M Extra added vitamins) for 10 weeks. This led to a ~2 fold increase in plasma
cholesterol levels (Fig.4.3). Previous studies on AD transgenic models have used
similar high fat/high cholesterol diets however with cholesterol content ranging from
1.25% to 5% ((Refolo et al., 2000b, Shie et al., 2002, Li et al., 2003a, Fitz et al., 2010).

The composition of the diet was the same as that used in a study undertaken by a
previous PhD student in our laboratory (Florence Lim) following changes from the
initial composition of the diet. The student initially used a high fat/ high cholesterol diet
comprising of 10% fat, 1% Cholesterol and 0.5% cholate, which was fed to APOE KI
mice. The mice did not adapt well to the high fat/ high cholesterol diet, they did not find
it palatable, most likely due to the bitter taste of cholate. The problem was rectified
promptly by the addition of 7.5g fructose per 100 g of animal chow to make the food
sweeter and to counteract the bitterness of the cholate. The percentages of cholesterol
and cholate were also reduced (10% fat, 0.75% Cholesterol and 0.3% cholate). It is also
important to note that when fructose was added to this high fat/high cholesterol diet, the
sucrose content was also decreased slightly from 10g/100g feed (as in control rodent
chow) to 7.5g/100g feed. In the presence of cholate, cholesterol can be more readily
absorbed by the animal and therefore needs be included in the diet. Despite the lower
dietary cholesterol content, significant fold increases in plasma cholesterol (2-3 folds)
were observed in these previous experiments, compared to plasma levels of mice on the
control diet. The same diet conditions were used in the current study and resulted in
similar increases in plasma cholesterol.

In previous studies, apart from the diet containing greater cholesterol content, the mice
were maintained on the high fat/high cholesterol diets for a much longer period of time
(4 months to 10 months). This may explain the slightly greater increase in serum
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cholesterol levels (2-4 fold increase) than that observed in the current study. However,
using such diets and treatment periods (7-10 months), some studies have shown similar
increases to those shown in the current study (Shie et al., 2002, Mihovilovic et al., 2007,
Fitz et al., 2010)). Despite the above-mentioned studies not showing dramatic increases
in serum cholesterol, enhanced amyloid deposition was still evident, indicating that
moderate increases in cholesterol can still lead to changes in pathology. As described
below, despite the lower cholesterol content used and shorter duration of treatment in
the current study, changes in Aβ levels were observed.

Interestingly, the increase in plasma cholesterol in female mice was greater than that
observed in male mice. Male and female mice exhibited a similar weight gain,
suggesting that the amount of food ingested by the male and female mice was similar,
thus it is unlikely that the male to female differences in serum cholesterol levels are due
to the females eating significantly more than the males. Previous studies have reported
sex differences in cholesterol metabolism and homeostasis. In a model of severe
hypercholesterolaemia,

where

the

peroxisome

proliferator-activated

receptor

(PPARalpha) important for lipid metabolism and homeostasis was ablated, differences
between female and male mice were observed where female mice showed higher
cholesterol levels and deposited fat earlier than male mice (Costet et al., 1998). Another
study provided evidence for a role for oestrogen, such that in the absence of this
hormone (through ablation of aromatase), serum cholesterol levels were increased only
in female mice. In contrast, under conditions of cholesterol loading, male mice showed
reduced serum but increased hepatic cholesterol and this was associated with changes in
expression of cholesterol transporters (Hewitt et al., 2004). Although differences in the
severity of AD pathology have been reported in male and female AD transgenic mice
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models (Barrier et al., 2010, Carroll et al., 2010, Oikawa et al., 2010, Rosario et al.,
2010), whether differences in cholesterol metabolism contribute to this remains unclear.

4.6.3: Increased cholesterol levels do not alter brain CD147 levels in vivo.

To determine if the increases in serum cholesterol in those mice fed the high fat/high
cholesterol diet were associated with changes in peripheral or cerebral CD147 levels,
CD147 protein levels

were measured

in tissue homogenates

by Western

immunoblotting. The expression of CD147 in brain tissue has been widely reported
(Nahalkova et al., 2010, Xie et al., 2010, Agrawal and Yong, 2011). Expression of
CD147 has also been reported in many peripheral tissues including the lung, cervix,
kidney and liver (Han et al., 2010, Kong et al., 2011, Wu et al., 2011, Zeng et al., 2011)
and a soluble form has been indentified in human serum (Moonsom et al., 2010).

The current study found that cerebral CD147 expression levels did not change
significantly after 10 weeks on the high fat/high cholesterol diet, however, the male
mice showed a trend towards higher CD147 levels and the female mice showed a trend
towards lower CD147 levels in the brain after being on the high fat/ high cholesterol
diet. In kidney tissue however, there were significant reductions in CD147 protein
levels in the male mice and a trend towards lower levels in the female mice fed the high
fat/high cholesterol diet. Whilst no significant changes in CD147 levels were observed
in the liver, there was a trend toward a decrease in males fed the high fat/high
cholesterol diet. Together, these results suggest that systemic increases in cholesterol do
impact on the kidney. High dietary cholesterol may also alter cerebral CD147 levels and
CD147 protein levels in other peripheral tissues, in particular if levels of soluble CD147
are altered in the mice serum/plasma. Soluble CD147 can be detected in conditioned
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media from human tumour cell cultures (Tang et al., 2004, Hanata et al., 2007),
supernatant of human lipid loaded macrophages (Yue et al., 2009). A quantitative
ELISA assay to measure CD147 in human serum, has only recently been reported
(Moonsom et al., 2010). Currently, there is a lack of suitable assays to measure soluble
CD147 in rodent serum, and as is shown in Fig 5.4, specific antibodies and assays are
required to detect CD147 from different species. Within the group of mice fed the high
fat, high cholesterol diet, plasma cholesterol levels were found to be negatively
correlated with brain CD147 levels, strengthening the notion of possible cholesterol
mediated changes in brain CD147 levels. If these experiments were repeated with
greater numbers of mice to increase the statistical strength of the results, or perhaps if
mice were kept on these diets for a much longer period, it is possible that many of the
trends seen here would be significant differences in such expanded or extended studies.

4.6.4: A high fat/high cholesterol diet does not appear to affect SCP-2 transcript
levels

As mentioned above, CD147 transcription can be regulated by SCP-2. In vitro evidence
also indicates that cholesterol can alter SCP-2 transcription (Kraemer et al., 1995).
There is yet no in vivo evidence that cholesterol mediated changes in SCP-2 occurs. To
the best of my knowledge this is the first study to investigate whether dietary
cholesterol can alter SCP-2 transcription. Thus, one aim of the work in this chapter was
to determine whether the high fat/high cholesterol diet would increase SCP
transcription. The results in Fig 5.10 show that the high fat/ high cholesterol diet did not
alter brain SCP transcription. A previous, in vitro study has investigated the effects of
cholesterol on SCP transcription. In this study, smooth muscle cells harvested from rat
thoracic aortas were treated with cholesterol (Kraemer et al., 1995) and it was found that
under these conditions transcription of SCP was increased. Apart from the differences in
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experimental models (in vitro vs in vivo), the study by Kraemer et al. also used
cationised LDL cholesterol, a positively charged LDL cholesterol which promotes a
sterile inflammatory response in muscle and is a method used to measure cholesterol
efflux (Tayler et al.). Under in vitro conditions, concentrations of specific lipoproteins
can be more readily controlled, in contrast to in vivo where increases in LDL and other
lipoproteins occur as a result of increased dietary cholesterol. The use of the type of
LDL (native vs cationised) may also influence transcription (although there is no direct
evidence of this as the Kraemer et al., study did not compare native versus cationised
LDL).

The particular isoform of SCP protein that may be up-regulated may also impact on
CD147 transcription.

The SCP-2 gene is part of a fusion gene that contains two

initiation sites encoding a 15.4 kDa (pro-SCP-2) and a 58.9 kDa (SCP-x) protein (Ohba
et al., 1994, Ohba et al., 1995). The 58.9 kDa SCP-x protein undergoes a posttranslational cleavage process to yield a mature 12.9 kDa SCP-2 which has been shown
to translocates to the nucleus and activate CD147 transcription (Ko and Puglielli, 2007).
In contrast, expression of pro-SCP-2 has been shown to abolish activity of 12.9 kDa
SCP-2 and inhibit CD147 transcription, resulting in an increase in Aβ production. In
their study, Kraemer et al. assessed protein and mRNA levels of both 13 KDa SCP-2
(~12.9 kDa) and 58 KDa SCP-x (58.9 kDa) and showed that expression of SCP-2
mRNA and protein, but not SCP-x, were increased (Kraemer et al., 1995) which would
most likely lead to increased CD147 expression.

It is conceivable that the high/ fat high cholesterol diet could alter CD147 levels,
independent of any effects on SCP-2 expression. In addition to enhancing amyloid
deposition, high fat/ high cholesterol diets fed to wild-type or transgenic mice have also
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been associated with increases in cytokines/mediators and gliosis consistent with
neuroinflammation (Thirumangalakudi et al., 2008) and increases in oxidative stress
(Homma et al., 2004, Oliveros et al., 2004, Torreggiani et al., 2009). Changes in CD147
expression have been reported in many pathological conditions, involving
inflammation, including rheumatoid arthritis (Tomita et al., 2002, Zhu et al., 2006,
Yang et al., 2008, Damsker et al., 2009) and atherosclerosis (Spinale et al., 2000, Choi
et al., 2002, Yoon et al., 2005, Siwik et al., 2008) where it has roles such as the
facilitation of chemokine-mediated recruitment of inflammatory cells or tissue repair
through activation of MMPs (chapter 1, (Kanyenda et al., 2011)). Although a specific
role for CD147 in neuroinflammation has yet to be established, the presence of CD147
mRNA transcripts in microglia (Inoue et al., 1999) and astrocytes (Meeuwsen et al.,
2003), suggest a similar role in the brain. CD147 expression and particularly its
interaction with CypA is known to protect against neuronal oxidative stress (Boulos et
al., 2007). The inflammation and oxidative stress evident in AD model transgenic mice
may be exacerbated by the high fat/ high cholesterol diet, subsequently impacting on
CD147 expression. In this scenario, the observed decreasing trend in levels of CD147
may be suggestive of a consequence of exacerbated AD pathology.

4.6.5: CD147 influences on Aβ production

Considering the roles that CD147 is currently believed to play in APP metabolism, in
which it is thought to be capable of reducing Aβ levels, it was expected that an increase
in CD147 levels would correlate with reduced Aβ load under conditions of the highcholesterol/ high fat diet. To assess this, levels of APP and its metabolites, including Aβ
and the APP- C-terminal fragments C83 and C99 were assessed in brain tissues from
mice fed the control chow diet or the high fat/ high cholesterol diet. As expected in
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APPswe transgenic mice, significant increases in FL-APP levels were observed and
decreases in one of the APP-C terminal fragments (C83) were also detected, although
only in the male mice. With respect to these particular APP-C83 results, the levels were
particularly low in two of the mice, which most likely reduced the average to provide
the overall significantly lower levels. Indeed, overall there was a large animal-to-animal
variation in APP-C99 and C83 levels. All mice used in this study were confirmed to
have the APP-transgene (by PCR, data not shown) and to express human APP protein
(as confirmed by immunoblotting with human APP specific antibodies WO2 and 6E10,
data not shown).

Thus the variation in C-terminal fragments and later in the Aβ

peptide measurements were not due to some mice being non-transgenic.

Variations were also observed in brain Aβ40 and Aβ42 levels as values spanned from
<1 to 20 nmol/g levels in Aβ42 levels and <1 to 60 nmol/g in Aβ40 levels. The APPswe
mice used in these experiments were relatively young mice (4.5 months). At this age,
although Aβ40 and Aβ42 levels would begin to increase, plaque deposition would not
be evident (plaque deposition occurs between 12-14 months of age). As the major aim
of this study was to determine the effects of the high fat/ high cholesterol diet on
CD147, the mouse age was chosen so that plaque/ AD pathology would not yet be
evident. If the mice already had established AD pathology, any effects of the high
fat/high cholesterol diet may have been masked by this pathology. The study was also
aiming to examine changes in the initiating stages of the disease. As a result of the age
of the mice, since AD pathology should not have been present, the variation in Aβ
levels cannot be attributed to variations in Aβ deposition.

To normalise for animal variations in cerebral Aβ40 and Aβ42 levels, the ratio of
Aβ42/40 was calculated for each animal and represented as a scatter plot in (Fig. 4.14).
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This not only accounted for the large variations in the data but also provided a better
indicator of whether the high fat high cholesterol diet increased levels of the more
pathological Aβ42 species. Although not significant, there was a trend towards higher
Aβ42/40 ratios (particularly in female mice). Although to a lesser degree (as explained
above with differences in diets used), these results are consistent with previous reports
in cholesterol fed transgenic APPswe mice, where cerebral amyloid load and Aβ levels
are increased (Refolo et al., 2000b, Refolo et al., 2001, Shie et al., 2002, George et al.,
2004).

A trend towards lower CD147 levels and increases in Aβ42 levels, following a period
on a high fat/high cholesterol diet would be consistent with the notion that CD147
negatively regulates Aβ levels. The results presented in this chapter cannot determine if
this is a consequence of increases in Aβ, a scenario in which progressive increases in
Aβ would down-regulate CD147 levels, thereby allowing further accumulation of Aβ.
This could occur either through a growing inability of CD147 to regulate γ-secretase
activity or less inducement of enzymes that can degrade Aβ such as MMPs (Vetrivel et
al., 2008b). The measurement of CD147 protein, relevant enzyme activities and Aβ
levels in similar cholesterol fed mice at different ages could be performed in future
studies to determine if changes in CD147 expression occur as Aβ accumulates.
However, further studies aimed at deciphering how CD147 may (or may not) be
involved in the early pathogenesis stages of AD would most likely be the most
interesting.
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4.7: Conclusions

The results from this in vivo study have confirmed that a high fat/high cholesterol diet
results in elevated circulating plasma cholesterol levels as evidenced by the elevated
levels in both males and female fed on this diet. Although no significant increase in
Aβ42/40 ratios were observed, a trend towards an increase in all mice fed on the high
fat/high cholesterol diet was observed. The major finding observed in this study was a
significant reduction in kidney CD147 protein levels in males combined with trends
towards decreasing CD147 levels in brain, liver and kidney tissues from females fed the
high fat/high cholesterol diet, compared to the control diet. In addition to changes in
CD147 levels, the current study also identified significant increases in brain FL-APP
levels and a significant reduction in APP-C83 fragments. Although there were no
changes in SCP transcript levels, changes in SCP protein isoforms (pro-SCP and SCP-x)
cannot be ruled out. Whether the onset of AD results in changes in CD147 protein
levels and if there is a correlation with AD pathology is addressed in chapter 5.
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CHAPTER 5

CD147 protein expression and localisation in AD brain tissue.

5.1: Introduction

The findings in chapters 3 and 4 describe the regulation of CD147 expression in vitro
and in vivo. Together with evidence supporting a role for CD147 in regulating Aβ
levels, either through regulating γ-secretase activity (Zhou et al., 2005) or Aβ
degradation (Vetrivel et al., 2008b) warrants investigation of its expression in AD brain.
In this chapter, expression levels of CD147 were assessed in brain tissue from controls,
AD and Non-AD type dementia {dementia with Lewy Bodies (LBD) and frontal
temporal dementia (FTD)} cases.

The CD147 protein is expressed in many tissues including the brain (Seulberger et al.,
1990, Fan et al., 1998). The protein is expressed in a number of brain regions, including
the frontal cortex and thalamus, and is particularly abundant in the hippocampus (Fan et
al., 1998). CD147 expression has been reported in normal brain (in the vascular
endothelium) and has been shown to be highly and widely expressed in gliomas,
consistent with its role in tumour progression (Sameshima et al., 2000, Sameshima et
al., 2003, Gu et al., 2009). Correlations between CD147 expression and BBB function
have also been reported (Sameshima et al., 2000, Sameshima et al., 2003). Despite the
number of studies describing CD147 expression in human brain, only one study has
compared expression in the frontal cortex and thalamus form AD and control brain
tissue (Nahalkova et al., 2010). The findings were inconclusive, as only a small number
of samples were assessed (3 controls and 3 AD brains).
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In this chapter I assessed CD147 protein expression analysis in a larger number of
samples by immunohistochemistry (AD; n=17 and Controls; n=5), western blot (AD;
n=14 and controls; n=4) and extended this analysis to hippocampal tissue. In addition,
CD147 expression analysis was assessed in tissue from non-AD type dementias (LBD
and FTD) to determine if any changes in expression is a result of general
neurodegeneration. Furthermore, given evidence suggesting that CD147 expression
regulates γ-secretase activity (Zhou et al., 2005) and although not a core component,
interacts with the complex (Zhou et al., 2005, Winkler et al., 2009), expression of the γsecretase core components, presenilins (PS1), nicastrin, and pen-2 were assessed and
correlated with CD147 protein levels.

5.2: Aims

1) To determine if CD147 protein levels are altered in the frontal cortex or hippocampus
of AD brain.
Assess tissue expression and localisation of CD147 protein in the frontal cortex
from AD cases and compare with control and non-AD type dementia (LBD and FTD)
cases.

2) To determine if there is a correlation of CD147 protein levels with Aβ and that of the
core components of the γ-secretase complex.
Assess protein levels of Aβ42 and the PS1, NCT, aph1 and pen2 in frontal
cortex and hippocampus from control, AD and non-AD type dementia (LBD and
FTD) cases.
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5.3: Materials and methods
5.3.1: Sourcing and preparation of tissues

Tissue collection and analysis was approved by Hollywood Private Hospital and Edith
Cowan University human ethics committees. Western Australian Brain Bank Network
(WABBN) supplied us with the frozen and formalin fixed frontal cortex and
hippocampal tissues. Paraffin embedded tissue sections from formalin fixed tissues
from ABBN were prepared in our laboratory (Table 5.1). Frozen hippocampal and
frontal cortical tissues from controls (n=4; 4 males, no females), lewy body disease
(LBD) (n=5; 3 males, 2 females =), frontal temporal dementia (FTD) (n=5; 3 males, 2
females) and Alzheimer’s disease (AD) (n=14; 7 males, 10 females) were homogenised
as described in section 2.3.3 prior to total protein estimation and expression analysis as
described in sections 2.4.4 and 2.5 of the methodology chapter (chapter 2).
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Table 5.1: List of IDs, pathology, age and sex of test samples

ID
Pathology
WABBN
R10A 08A
R09A 33E
R09A 13L
R07A 32R
R07A 29L
R07A 27H
R07A 21T
R07A 09T
R07A 06A
R06A 20F
R06A 16K
R06A 06B
R05A 22L
R05A 20H
R05A 02T
R04A 36F
R04A 29P

Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers
Alzheimers

R10A 11F
R09A 19A
R08A 19B
R07A 38F
R06A 18N

Age

Sex

74
86
57
64
60
55
91
92
76
100
93
58
76
80
83
84
73

M
M
M
M
F
F
F
F
F
F
F
F
M
F
M
F
M

Frontotemporal
Frontotemporal
Frontotemporal
Frontotemporal
Frontotemporal

78
58
63
60
63

F
M
M
M
F

R09A 35J
R09A 32N
R09A 02M
R08A 15R
R07A 28X

Lewy Body Disease
Lewy Body Disease
Lewy Body Disease
Lewy Body Disease
Lewy Body Disease

79
82
88
78
77

F
M
F
M
M

R09A 11H
R07A 34X
R07A 33H
R07A 25D

Control
Control
Control
Control

47
67
66
46

M
M
M
M
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5.3.2: Western blot analysis

CD147 protein levels were determined by SDS-PAGE gel electrophoresis in frozen
hippocampal and cortical tissues as described in section 2.5 using anti goat EMMPRIN
SC-9754 primary (Santa Cruz) specific for EMMPRIN of human origin, anti-Nicastrin
(Sigma), anti-Presenilin (Kindly provided by Dr Paul Mathews, NYU), anti- PEN2
(Sigma), β-Actin (AB8229)(Abcam – Australia) and anti goat HRP secondary
antibodies. The CD147 (~55kDa), nicastrin (~78kDa), presenilin (~ 30kDa) and PEN2
(~12kDa) and β-actin (~42kDa) protein bands were quantified using BioRad
densitometry. Analysis of variance (ANOVA) with post-hoc analysis and Pearson’s
correlation analysis were used to determine significant differences in levels of the
proteins of interest among the test groups using SPSS software.

5.3.3: Immunohistochemistry analysis

In addition to western immunoblotting, CD147 protein levels were also determined by
immunohistochemistry in formalin fixed and paraffin embedded tissue sections (4-5μ)
from all cases analysed in this study. Sections were stained by EMMPRIN MAB2623
primary antibody (Chemicon, USA) as described in section 2.18. Stained sections were
examined under light microscope (Olympus BX 51) fitted with Olympus DP71 Digital
Camera. Two sets of pictures of each stained section were taken at the same light
intensity and magnification. The first set was taken at x10 and the second set at x40
magnifications. Image analysis to generate raw data was performed using ImageJ
software (NIH). Images were first changed to HSB type for haematoxylin stained tissue
analysis, then binary pictures generated to discriminate background staining and stained
tissues. Particle analysis was performed and generated raw data values were converted
using the following formula: 1/sample mean OD x 10000.
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5.4: Results

5.4.1: CD147 protein expression levels are not altered in brain tissue from
Alzheimer’s disease (AD) cases.

In mouse brain, CD147 expression has been located in the hippocampus and upper
layers of the cortex (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et
al., 2003) where depletion in AD models results in increased Aβ deposition (Zhou et al.,
2007, Vetrivel et al., 2008b). In human brain, expression of CD147 has been shown in
the frontal cortex and thalamus (Sameshima et al., 2000, Nahalkova et al., 2009). Only
one study has investigated expression of CD147 in control and AD brain, however no
conclusive changes were observed due to the limited number of samples (Nahalkova et
al., 2010). Here, I analyse a larger cohort of cases and also compare expression in AD
brain tissue to that from controls and non-AD type dementias.

CD147 tissue expression and localisation was assessed using immunohistochemistry
with a human specific EMMPRIN MAB2623 primary antibody (Chemicon, USA).
Prior to immunohistochemical analysis, specificity of the CD147 was assessed (Fig
5.1). Analysis was performed on a control and AD case. Melanoma and glioma tissue
samples which are known to express high levels of CD147 (Liang et al., 2009, Han et
al., 2010, Matsudaira et al., 2010, Kong et al., 2011, Wu et al., 2011) were used as
positive controls . As expected, intensive staining was observed in the glioma (Fig 5.1,
Bi) and melanoma (Fig 5. 1, Ci) tissues. Staining was absent in tissue sections that
were exposed to secondary antibody only, in the absence of primary antibody (Fig 5.1,
Ai- ii), indicating that the staining seen in the glioma or melanoma tissues is not
background staining (Fig 5.1, Bi, Ci). Staining was also evident in hippocampal and
frontal cortex tissue of the control (Fig 5.1, Bii, and Cii) and AD (Fig 5.1, Biii, and
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Ciii). Although staining was evident throughout the tissue, it was particularly prominent
in the vascular endo-thelial cells (arrows).

Diffuse cytoplasmic staining with

accentuation along the cell membrane was also observed. Of note is that staining
appeared to be more intense in the AD brain tissue, compared with control (Fig 5.1,
compare Bii and Cii, with Biii and Ciii). Whether this held true in a larger sample size,
was assessed next.

Immunohistochemical analysis for CD147 was assessed in control, AD, FTD and LBD
brain tissue. Representative figures of hippocampus and frontal cortex for each case at
low (x10) and higher magnification (x40) are shown in Figures 5.2 and 5.4,
respectively. As described above staining was evident throughout the tissue, it was
particularly prominent in blood vessels/capillaries (arrows).

Diffuse cytoplasmic

staining with accentuation along the cell membrane was also observed. A similar
staining pattern has been observed in other studies of brain tissue (Sameshima et al.,
2000, Sameshima et al., 2003, Gu et al., 2009). Qualitatively, it appeared that compared
to control tissue, overall staining and in particular the capillaries were more prominent
in the AD, FTD or LBD frontal cortex or hippocampal tissue (Figures 5.2 and 5.4,
compare B-D with A). Overall quantitation of staining using ImageJ software (NIH)
(which measures both cytoplasmic and vascular staining) revealed similar levels of
CD147 expression in control, AD, FTD and DLB tissue samples (Fig. 5.3 and 5.5). No
regional differences were observed when levels were compared in the hippocampus and
frontal cortex (Fig. 5.6).
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Figure 5.1: Immunostaining for CD147 in melanoma, glioma and brain tissue.
Cancer (i), brain tissue from a control (ii), and AD case (iii) underwent immunostaining
with and without primary antibody. No or minimal background staining was observed in
the antibody control tissues (A; i, ii and iii). CD147 staining was observed in frontal
cortex (Bii) and hippocampal (Cii) tissues from the control sample. Intensive CD147
staining was observed in the glioma (Bi), melanoma (Ci) tissues, and frontal cortex (Bii)
and hippocampal (Cii) tissues from the AD sample.
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Figure 5.2: CD147 immunostaining in the hippocampus from control, LBD, FTD
and AD brain tissue. Representative immunostained images at x10 (first column) or
x40 magnification (second column) of hippocampal tissue from controls (A), LBD (B),
FTD (C), and AD (D). Scale bar represents 100 µm at 10x and 25µm at 40x
magnifications respectively. Qualitatively, compared to control tissue (A), staining of
the vascular endo-thelial cells (red arrows) was more prominent in the AD, FTD or
LBD tissue (B-D).
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Figure 5.3: Quantitation of CD147 immunostaning from hippocampus of control,
LBD, FTD and AD cases.
Cytoplasmic and vascular endothelial CD147 expression in the hippocampus tissue was
assessed in all tissues and data is represented as mean ± SD. Groups represent controls
(n=4), LBD (n=5), FTD (n=5), AD (n=17). Compared to controls results indicate no
significant differences in CD147 expression.
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Figure 5.4: CD147 immunostaining in the frontal cortex from control, LBD, FTD
and AD brain tissue.
Representative immunostained images at x10 (first column) or x40

magnification

(second column) of hippocampal tissue from controls (A), LBD (B), FTD (C), and AD
(D). Scale bar represents 100 µm at 10x and 25µm at 40x magnifications respectively.
Qualitatively, compared to control tissue (A), staining of the vascular endo-thelial cells
(red arrows) was more prominent in the AD, FTD or LBD tissue (B-D)
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Figure 5.5: Quantitation of CD147 immunostaining from frontal cortex of control,
LBD, FTD and AD cases.
Cytoplasmic and vascular endothelial CD147 staining in the frontal cortex was
measured in all tissues and data is represented as mean ± SD. Groups represent controls
(n=4), LBD (n=5), FTD (n=5), AD (n=17). Compared to controls results indicate no
significant differences of CD147 expression in LBD, FTD and AD, however there is a
slight trend towards an increase observed in LBD and FTD.
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Figure 5.6: A comparison of CD147 immunostaining in hippocampus and frontal
cortex from control, LBD, FTD and AD cases.
Cytoplasmic and vascular endothelial CD147 expression in hippocampal and frontal
cortex tissue was assessed in all tissues and is represented as mean ± SD. Groups
represent control (n=4), LBD (n=5), FTD (n=5), AD (n=17).
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In order to more accurately quantitate total CD147 levels, brain homogenates from all
cases underwent western blotting with EMMPRIN SC-9754 primary antibody (Santa
Cruz). A ~ 55 kDa band representing CD147 was observed in the hippocampus and
frontal cortex from all brain tissue samples (Fig 5.7A and C). Quantitation of the
protein band, revealed no significant differences in total CD147 levels in hippocampal
tissue from control, AD, LBD or FTD brain samples (Fig 5.7B). However a trend
towards an increase was observed in hippocampus from AD brains. Similarly, no
significant differences were observed in the frontal cortex from control, AD, FTD and
LBD cases (Fig.5.7C and D).
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Figure 5.7: CD147 levels in hippocampus and frontal cortex.
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Figure 5.7: CD147 levels in hippocampus and frontal cortex.
Western immunoblot analysis of CD147 protein levels in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain
homogenates run in singles showing the ~55 kDa CD147 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and
frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing CD147 levels in hippocampus and frontal cortex from controls,
LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean
represented by horizontal line. Compared to controls, data shows no significant differences of CD147 expression in both hippocampus and frontal
cortex in LBD, FTD and AD.

202

5.4.2: Associations of CD147 protein expression with levels of Aβ42 and core
protein components of γ-secretase.

Although there was no overall changes in CD147 expression levels (see section above),
as might be expected, there were large variations between samples, despite similar βactin levels. The close association of CD147 expression with Aβ levels and γ-secretase
activity (Zhou et al., 2005) (Zhou et al., 2005, Winkler et al., 2009), prompted the
investigation of whether there was an association between CD147 levels and levels of
Aβ42, and expression of the γ-secretase core components in the brain tissue. Thus
levels of Aβ42, PS1, NCT and Pen2 were measured in the brain tissue samples.

Levels of Aβ42 were measured in the hippocampus and frontal cortex of control, FTD,
LBD and AD brain tissue using ELISA. The results are shown in Figures 5.8 and 5.9.
As expected compared to control tissue, Aβ42 levels were not altered in FTD brain
tissue whilst levels were significantly increased in AD brain tissue (p<0.001) in
hippocampus and (p=0.02) in the frontal cortex. Although there was large variation,
compared to controls, levels were increased (p=0.004) in brain tissue from LBD
dementia patients. A comparison of Aβ42 levels showed high levels in the frontal cortex
(Fig.5.10).

203

*

Aβ42 Levels (pg/mg Total Protein

1000

***

800

600

400

200

0

Controls

LBD

FTD

AD

Figure 5.8: Aβ42 levels in hippocampus.
Aβ42 levels in brain tissue from the hippocampus of controls, lewy body disease
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Scatter plots
representing Aβ42 levels in hippocampus from controls, LBD, FTD and AD brain
tissue. Individual points represent a specific sample value with the sample mean
represented by horizontal line. Compared to the controls data shows that Aβ42 levels
are significantly increased in hippocampus from LBD and AD (***p<0.001 and
*p<0.05 respectively) with AD showing the highest levels.
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Figure 5.9: Aβ42 levels in frontal cortex.
Aβ42 levels in brain tissue from the frontal cortex of controls, lewy body disease
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Scatter plots
representing Aβ42 levels in frontal cortex from controls, LBD, FTD and AD brain
tissue. Individual points represent a specific sample value with the sample mean
represented by horizontal line. Compared to the controls data shows that Aβ42 levels
are significantly increased in hippocampus from AD (*p<0.05).
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Figure 5.10: Comparison of Aβ42 levels between hippocampus and frontal cortex.
Aβ42 levels in hippocampus and frontal cortex from controls, lewy body disease
(LBD), frontal temporal dementia (FTD) and Alzheimer’s disease (AD). Data is
presented as ±SEM and indicate that frontal cortex has high Aβ42 expression compared
to hippocampus.
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Levels of the core protein components of γ-secretase including nicastrin, PS1 and PEN2 were assessed in the hippocampus and frontal cortex from all brain samples via
western immunoblotting.

Nicastrin, a type 1 transmembrane glycoprotein (Yu et al., 2000), plays a role in the
assembly and intracellular trafficking of the γ-secretase complex (see chapter 1) (Shah
et al., 2005, Zhang et al., 2005). Compared to controls, nicastrin levels were not altered
in hippocampal (Fig.5.11A and B) and frontal cortex (Fig.5.11C and D) tissues from
AD, FTD or LBD. However, though not significant, an increasing trend was observed in
both hippocampus and frontal cortex tissues from AD.

The presenilins are regarded as the core catalytic component of γ-secretase (L'Hernault
and Arduengo, 1992, Levitan and Petersen, 1995, Martins et al., 1995, Xia et al., 1997)
(Herreman et al., 1999)-(Palacino et al., 2000). Levels of PS1 were measured as recent
evidence suggests that PS1 containing γ-secretase complexes are more active than PS2
containing complexes (Stromberg et al., 2005, Hedskog et al., 2011, Yonemura et al.,
2011). Levels of PS1 were not significantly altered in hippocampal tissue from AD,
FTD or LBD compared to controls (Fig.5.12A and B). However a trend towards and
increase was observed in hippocampus tissue. A comparison between AD and LBD,
showed significant difference of PS1 (p=<0.031) in hippocampus tissue. In the frontal
cortex, compared to controls, PS1 levels were not altered in tissue from AD subjects
(Fig.5.12C and D) but an increasing trend was observed in AD and LBD.

The Presenilin Enhancer 2 (PEN-2) is a ~12 kDa protein and has a critical role in the γsecretase complex as described in chapter 1, where it facilitates end proteolysis of the
presenilins (Crystal et al., 2003, Prokop et al., 2004, Steiner et al., 2002, Luo et al.,
2003, Takasugi et al., 2003, Hasegawa et al., 2004). Levels of this protein were
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significantly increased in hippocampal tissue from AD tissue (p=0.014) compared to
controls (Fig.5.13A and B). In the frontal cortex, PEN2 levels showed no significantly
change in FTD, LBD or AD tissue, although a trend towards an increase was observed
(Fig.5.13C and D).

Overall, these results show that compared to control brain tissue Aβ42 levels were
increased in AD tissue. In addition levels of components of the γ-secretase enzyme
including, PS1 and PEN-2 were altered. To determine if there were associations
between CD147 levels and levels of Aβ42 and the γ-secretase components, a bivariate
Pearson’s correlation analysis was performed (Table 5.2).

Strong significant positive correlations between CD147 and PS1 in hippocampus from
controls (p=0.028), AD (p=0.002) and LBD (p=0.003); CD147 and NCT in AD
(p=0.0001) and CD147 and PEN2 in controls (p=0.035) were observed. However, in
the frontal cortex, significant correlations were observed in LBD (PS1, p=0.034; PEN2,
p=0.003 respectively) and FTD (PEN2, p=0.042). Interestingly, there were similar
correlations observed in LBD samples, which may reflect the presence of AD pathology
in this type of dementia (Griffin et al., 2006, Maetzler et al., 2009). However, as there
were only five samples obtained of LBD tissue, the significant correlation may need to
be confirmed in a larger sample. There was no correlation between CD147 and Aβ42 in
AD brains.
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Table 5.2: CD147 correlations with nicastrin, presenilin1 and presenilin enhancer 2 in
hippocampus and frontal cortex from AD, LBD and FTD brains.
HIPPOCAMPUS

CD147

FRONTAL CORTEX

Aβ42

NCT

PS1

PEN2

Aβ42

NCT

PS1

PEN2

-.017

.723

.972

.965

-.167

-.259

.764

-.629

CO

0.983

0.277

0.028*

0.035*

0.833

0.741

0.236

0.371

AD

.405

.824

.760

.207

.211

.468

.386

.443

0.151

0.0001**

0.002**

0.478

0.470

0.091

0.173

0.113

.615

.763

.982

.582

-.402

.025

.906

.983

0.385

0.134

0.003**

0.304

0.598

0.968

0.034*

0.003**

-.091

-.030

-.922

.491

.711

-.729

-.766

.958

0.909

0.970

p.078

0.509

0.178

0.271

0.234

0.042*

LBD

FTD

P-value calculated by bivariate Pearson’s correlation analysis. * Correlation is
significant at the 0.05 level. ** Correlation is significant at the 0.01 level (2-tailed).
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Figure 5.11: Nicastrin levels in hippocampus and frontal cortex.
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Figure 5.11: Nicastrin levels in hippocampus and frontal cortex.
Western blots and data analysis of nicastrin in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain
homogenates run in singles showing the ~75 kDa nicastrin protein levels and corresponding β-actin levels as a loading control in hippocampus
(A) and frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing nicastrin levels in hippocampus and frontal
cortex from controls, LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots)
with the sample mean represented by horizontal line. Compared to the controls, there was no difference in nicastrin levels observed in
hippocampus and frontal cortex from LBD, FTD and AD respectively. However an increasing trend was observed in hippocampus and frontal
cortex tissues from AD.
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Figure 5.12: PS 1 levels in hippocampus and frontal cortex.
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Figure 5.12: PS 1 levels in hippocampus and frontal cortex.
Western blots and data analysis of PS1 levels in hippocampus (A and B) and frontal cortex (C and D). (A and C) Western blots of brain homogenates
run in singles showing the ~38 kDa PS1 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and frontal cortex (C)
in controls, LBD, FTD and AD. (B and D) Scatter plots representing PS1 levels in hippocampus and frontal cortex from controls, LBD, FTD and AD
brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean represented by horizontal
line. Compared to the control group, there is no significant difference in PS1 levels in hippocampus and frontal cortex. However in hippocampus there
was significant difference in PS1 between AD and LBD (*p<0.05) with an increasing trend observed in frontal cortex from LBD.
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Figure 5.13: PEN2 levels in hippocampus and frontal cortex.
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Figure 5.13: PEN2 levels in hippocampus and frontal cortex.
Western blots analysis of PEN2 protein levels in the hippocampus (A and B)) and frontal cortex (C and D). (A and C) Western blots of brain
homogenates run in singles showing the ~12 kDa CD147 protein levels and corresponding β-actin levels as a loading control in hippocampus (A) and
frontal cortex (C) in controls, LBD, FTD and AD. (B and D) Scatter plots representing PEN2 levels in hippocampus and frontal cortex from controls,
LBD, FTD and AD brain tissue. Individual points represent a specific sample value (as quantitated from adjacent blots) with the sample mean
represented by horizontal line. Compared to the controls, PEN2 levels are significantly increased in hippocampus of AD patients (*p<0.05). A trend
towards an increase is seen in the in frontal cortex from AD, FTD and LBD.
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5.5: Summary of results:
This chapter has shown the expression and localisation profile of CD147 in the frontal
cortex and hippocampus of control, AD and non-AD type dementia subjects. The
results have shown cytoplasmic and particularly strong staining pattern surrounding the
vascular endothelial cells which qualitatively appear to increase in intensity in AD brain
tissue. Similar staining intensity was also observed in LBD and FTD brain tissue.
Quantitatively measuring CD147 levels revealed no significant changes, however trends
were observed. Highly significant positive correlations between CD147 and PS1 and
CD147 and NCT were observed in hippocampal tissue from AD samples, suggesting
tight associations between CD147 and core components of the γ-secretase complex.

5.6: Discussion

The expression of CD147 has been shown to impact on neuro-protection and
modulating Aβ levels. Apart from in vitro over-expression and knock-down studies in
proof-of-concept studies, the effects of CD147 transcription/expression on AD
pathology have not been explored. Indeed, whether CD147 transcription or protein
expression is altered in AD has not been fully examined.

Only one study has

investigated CD147 protein expression levels in different regions in a small number of
control and AD brain samples (Nahalkova et al., 2010). The numbers used (3 control
and 3 AD brains) were too small to show significant differences, however qualitative
analysis of immunostained tissue sections revealed that CD147 staining was more
intensive in the neurons and capillaries in both frontal cortex and thalamus of AD brain
compared to control brain. In this chapter a more detailed, qualitative and quantitative
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analysis in a larger number of tissue samples (4 controls and 17 AD brains) was
undertaken to determine if CD147 protein expression is significantly altered in AD. In
addition, CD147 expression analysis was assessed in tissue from non-AD type
dementias (LBD and FTD) to determine if any changes in expression is a result of
general neurodegeneration.

In mouse brain, CD147 expression has been located in the hippocampus and upper
layers of the cortex (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et
al., 2003). In human brain, expression of CD147 has been shown in the frontal cortex
and thalamus (Sameshima et al., 2000, Nahalkova et al., 2009). The results presented in
this thesis also show prominent CD147 expression in the hippocampus (See Fig 5.1 and
5.2). Analysis of brain tissue by immunohistochemistry revealed a similar tissue
localisation as reported by previous studies of human brain (Nahalkova et al., 2010) in
both the hippocampus and frontal cortex. Immunostaining with an antibody specific to
human CD147 showed that staining was evident throughout the tissue with diffuse
cytoplasmic staining with accentuation along the cell membrane was also observed.
Staining was particularly prominent in capillaries and blood vessels (Fig 5.2 and 5.4 at
x40 magnification). This is in line with previous reports that have located CD147
expression to the vascular endothelium and have suggested a role in BBB function
(Sameshima et al., 2000, Sameshima et al., 2003, Gu et al., 2009). Indeed an MRI and
immunohistochemical study of brain tumours has correlated CD147 expression in
vascular endothelial cells with blood-brain barrier function (Sameshima et al., 2003).
BBB function is known to be comprimsed in AD and other neurodegenerative diseases
(Caserta et al., 1998, Clifford et al., 2007, Nagele et al., 2011) whether it correlates with
vascular endothelial expression of CD147 levels in these disease states may provide
insight into a possible marker of BBB dysfunction.
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It was noted that compared to control brain tissue, there was a strong CD147 staining of
the blood vessels or capillaries in AD (Fig 5.2 and 5.4 at x40 magnification). CD147 is
known to play a role in cerebral injury after ischemic stroke by stimulating endothelial
cells to secrete matrix metalloproteases (MMPs) (Liebetrau et al., 2005). The blood
vessels are the structures in the brain that contain ECM proteins known to be substrates
for MMPs and take part in micro vascular damage. Abnormalities in brain vascular
system and brain hypofusion are features of AD and are consistent with the vascular
hypothesis of AD development (de la Torre, 2004) and although not to the extent of
vascular dementia or AD, can also occur in other neurodegenerative diseases
(Grammas, 2011). Indeed, CD147 staining within capillaries and blood vessels appeared
to be increased in FTD and LBD compared to controls in the current study (Fig 5.2, B
and D).

As a more quantitative analysis of CD147 expression, brain homogenates underwent
western immunoblotting. The study by Nahalkova et al., (2010) investigated CD147
expression in the cortex and thalamus of 3 controls and 3 AD brain samples. Overall
there was no significant changes as the number of sample assessed were small and there
were variations in expression levels (increased, unchanged, and decreased). In the
current study, a greater number of control and AD samples were assessed to increase the
statistical power of observing changes in CD147 levels. In addition to the frontal cortex,
the hippocampus, where expression has been reported to be highest in rodent brain (Lee
et al., 2003a, Lee et al., 2003b) was also assessed.

Quantitation by western

immunoblotting of CD147 protein levels in the frontal cortex and hippocampus revealed
no significant changes in mean protein values in AD brain compared to control brain,
however there was an increasing trend observed in the hippocampus from AD.
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Considering the reported roles of CD147 in modulating Aβ levels and interactions with
core components of the γ-secretase complex, and that CD147 has been shown to
partially co-localise with components of the complex, PS1, nicastrin and Pen-2
(Nahalkova et al., 2010), correlations with levels of these proteins in the brain samples
were assessed. Correlations would be indicative of potentially functional involvement of
this protein in the pathological changes happening in AD brain.

As expected Aβ42 levels were increased in the hippocampus and frontal cortex of the
AD brain. Levels were also increased in both regions of brain tissue obtain from
subjects with LBD. In addition to the wide-spread distribution of lewy bodies, subjects
with LBD also show a variable burden of amyloid deposition and neurofibrillary
tangles, a characteristic of AD (Gomperts et al., 2008, Armstrong and Cairns, 2000,
2009). Although not to the extent of AD, Aβ42 is the predominant species deposited
(Mann et al., 1998). In the current study, results have shown that Aβ42 does not
correlate with CD147 which is consistent with the findings of Vetrivel (Vetrivel et al.,
2008b).

5.6.3: PEN2 are increased in Alzheimer’s disease (AD)

Nicastrin is a type 1 transmembrane glycoprotein and a component of the γ-secretase
enzyme complex (Yu et al., 2000). In addition NCT plays a role in the assembly of the
γ-secretase complex within the endoplasmic reticulum and its intracellular trafficking to
the cell surface (Shah et al., 2005, Zhang et al., 2005). NCT also acts as a scaffold for
the assembly of the γ-secretase enzyme complex that binds with APH-1 to form the first
sub-complex (Morais et al., 2003, Periz and Fortini, 2004). Since γ-secretase enzyme is
responsible for the production of Aβ, the current study investigated if NCT is altered in
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hippocampus and frontal cortex tissues from controls, LBD, FTD and AD. Although not
significant, our results have shown an increasing trend in nicastrin levels both in
hippocampus and frontal Cortex from AD (Fig.5.11C and D). In addition to AD,
increasing trends were also observed in hippocampus from FTD. Taken together these
findings are suggestive of an increased γ-secretase enzyme activity during Aβ
generation as NCT plays a role in its assembly. This is consistent with findings from
other studies which reported increased NCT levels in Tg2576 mice (Chu et al., 2012,
Gwon et al., 2012).

The Presenilins (PS1 and PS2) are also transmembrane proteins (Sherrington et al.,
1995, Lehmann et al., 1997) which facilitates APP metabolism and processing and
mutations in PS1 increase the production of the longer more pathological Aβ species
(Martins et al., 1995, Xia et al., 1997). In addition to Nicastrin, the current study also
investigated PS1 expression levels in hippocampus and frontal cortex from controls,
LBD, FTD and AD. Although not significant, increasing trends of PS1 levels in
hippocampus and frontal cortex from FTD and AD were observed (Fig.5.12A and B).
Interestingly though was the finding of a significant difference in PS1 levels between
AD and LBD in hippocampus. This difference may have been influenced by one LBD
sample that showed the lowest PS1 expression hence pulling down the mean of this
group. The increasing trend in PS1 levels observed in AD in the current study are
consistent to those reported in previous studies (Kodam et al., 2010, Chu et al., 2012)
and is an indication of increased APP metabolism through the amyloidogenic pathway.
This may also suggest a possible relationship between CD147 and PS1 expression
levels in hippocampus. Since both CD147 and PS1 are transmembrane proteins, there
may be possible interactions taking place during their biological functions at cellular
levels, since CD147 is a multifunctional protein. There is therefore a need to investigate
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further any possible interactions, not only between CD147 and PS1, but also with other
members of the γ-secretase complex which will help explain further how CD147 and
the γ-secretase complex interact to facilitate APP metabolism.

Interaction of PEN-2 with other proteins results in the stability of the γ-secretase
complex (Crystal et al., 2003, Prokop et al., 2004) and is required for stabilization of the
presenilin N- and C-terminal fragments within the γ-secretase complex in addition to
contributing to NCT maturation. Reports have also shown that knocking down PEN-2
expression results in marked decrease in Aβ production, suggesting that PEN-2 is
essential for γ-secretase activity (Steiner et al., 2002, Luo et al., 2003, Takasugi et al.,
2003). In addition to NCT and PS1 the current study also investigated PEN2 levels in
hippocampus and frontal cortex from controls, LBD, FTD and AD. Our results have
shown a significant increase of PEN2 levels in hippocampus from AD and an increasing
trend in frontal cortex from AD, FTD and LBD (Fig.5.13A and B, and Fig. 5.13C and
D). These findings are also consistent to those reported in other studies where increased
PS1, NCT and PEN2 levels were observed (Kodam et al., 2010, Chu et al., 2012). The
increased PEN2 levels observed in the hippocampus from AD may also be attributed to
increased γ-secretase activity as PEN2 is responsible for its stability. Since PEN2 levels
are increased in AD and we have also observed an increasing trend in CD147 level in
hippocampus from AD, taken together these findings indicate a close relationship
between PEN2 and CD147 that needs to be investigated further.

It was interesting to observe that CD147, NCT, and PS1 levels showed an increasing
profile in hippocampus and decreasing profile in some disease status in the cortex. I
anticipated finding significant levels of these γ-secretase complex components in LBD
and FTD that have similar manifestations as AD but this was not the case. These
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findings are consistent with other studies that have reported mean differences between
AD and age matched controls but with no statistical differences (Schonlein et al., 1993,
Patel et al., 2006, Vetrivel et al., 2008a). In addition, our findings from hippocampal
tissues are correct as it has also been reported that over expression of one member does
not affect the whole complex (Edbauer et al., 2003, Kimberly et al., 2003, Takasugi et
al., 2003) and that elevation of γ-secretase activity can only be achieved by over
expressing all the components (Li et al., De Strooper, 2003). The cited studies support
our findings where NCT, PS1, and currently CD147 showed increasing trends in
addition to a significant increase in PEN2

I have also reported decreasing trends in NCT, PS1 and PEN2 levels in the cortex which
is consistent with TPM 21 findings by Vetrivel and colleagues. These findings confirm
that γ-secretase complex components, including CD147, are reduced in the cortex and
provide additional proof that CD147 is not elevated in cortex from AD brains as
reported by Nahlakova et al (2010). Our data has shown increased PS1 and PEN2 levels
with increasing trends of CD147 and NCT, in addition to a positive correlation between
CD147 and NCT and PS1 levels in the hippocampus. These findings may indicate that a
balance between CD147 and γ-secretase may be responsible for modulating Aβ levels in
brains.

5.7: Conclusion

I report for the first time that CD147 is not altered in AD. However the observed
increasing trends in CD147, PS1, nicastrin and significant increase and PEN2 levels in
hippocampus from AD is an indication of increased γ-secretase activity. I also report for
the first time that CD147 correlates with PS1 and NCT but not Aβ42 in hippocampus
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from AD brains. Finally the findings confirm that CD147 is not part of the γ-secretase
complex but rather that it may influence the γ-secretase complex activity indirectly by
interacting with NCT, PS1, ALPH-1 and PEN 2 as it is a multifunctional protein.
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CHAPTER 6

Polymorphisms in the CD147 promoter region may influence
Alzheimer’s disease (AD) pathology.

6.1: Introduction

The CD147 protein description and classification

(Biswas and Vonderhaar, 1987,

Fossum et al., 1991, Miyauchi et al., 1991, Kasinrerk et al., 1992, Biswas et al., 1995),
its role in MMPs production (Biswas et al., 1995, Guo et al., 1997) and it involvement
in the development of the nervous system, spatial learning and memory, sensory inputs
and retinal functions (Naruhashi et al., 1997, Muramatsu and Miyauchi, 2003, Zhou et
al., 2005) have been reported. In addition its involvement in the development of cancer,
tumour progression and AD pathogenesis (Nabeshima et al., 2006a, Winkler, 2008,
Nahalkova et al., 2010), in particular regulating Aβ levels (Zhou et al., 2005, Vetrivel et
al., 2008b) have also been reported.

CD147 expression is facilitated by Sterol carrier protein 2 (SCP-2). The properties of
SCP-2 have been discussed in Chapter 1 of this thesis, where I have described SCP-2 as
part of a fusion gene with two initiation sites coding for a 15.4 kDa (pro-SCP-2) and a
58.9 kDa (SCP-x) proteins (Ohba et al., 1994, Ohba et al., 1995). In addition to its
involvement in cholesterol trafficking and metabolism, SCP-x undergoes a posttranslational process yielding a mature 12.9 kDa DNA binding fragment in the nucleus
where it regulates CD147 transcription (Ko and Puglielli, 2007). This fragment is
controlled by pro-SCP-2 which acts as a competitive regulator for CD147 transcription
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(Ko and Puglielli, 2007). SCP-2 was initially identified as a sterol carrier and a nonspecific lipid-binding protein. However, subsequent studies have shown that SCP-2
binds fatty acid and cholesterol and facilitates their translocation between membrane
systems both in vitro and in vivo. It has been established that SCP-2 is responsible for a
rapid protein-mediated translocation of cholesterol in cells and tissues and that it alters
cholesterol metabolism in the liver and plasma (Baum et al., 1997, Zanlungo et al.,
2000).

The expression of pro-SCP-2 abolishes the transcriptional activity of 12.9kDa SCP-2
which thereby shuts down CD147 transcription. The loss of CD147 expression (Ko and
Puglielli, 2007) and deletion of CD147 in female knock- out mice (Zhou et al., 2006)
lead to the increased production of Aβ. In addition findings in chapter 3 of this thesis
have shown that cholesterol loading affects CD147 expression in rat primary cortical
neuronal cultures. Taken together these findings suggest that both cholesterol and SCP2 play a role in CD147 expression, which in turn has an impact on Aβ peptide levels.
The findings in chapters 3 and 4 describe the regulation of CD147 expression in vitro
and in vivo. In addition findings in chapter 5 reveal CD147 expression in brain tissue
from controls, AD and Non-AD type dementia (dementia with Lewy Bodies (LBD) and
frontal temporal dementia (FTD)) cases and its association with the γ-secretase complex
components. Taken together the in vitro and in vivo evidence supporting a role for
CD147 in regulating Aβ levels, (either through regulating γ-secretase activity (Zhou et
al., 2005) or Aβ degradation (Vetrivel et al., 2008b) warrants further investigation of its
genotypic association with AD. It is not known if any polymorphisms in the CD147
promoter region (where SCP-2 binds to initiate its transcription) influence AD
development and pathology. Thus in this chapter I investigated the presence of single
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nucleotide polymorphisms (SNPs) within the CD147 promoter region, where SCP-2
binds to initiate its transcription, that may be involved in AD pathology.

6.2: Aims

a) To confirm SCP-2 binding of CD147 DNA.
b) To identify novel SNPs within the SCP-2 binding site on the CD147 promoter in
addition to the already characterised SNPs reported in NCBI
c) To determine an association between the identified SNPs and AD pathology.

6.3: Material and methods

The generation and purification of SCP-2 protein was performed as described in
sections 2.4.2 and 2.4.3 of the methodology chapter. SCP-2 protein was generated using
chemically competent KRX E.coli cell line transformed with pro-SCP and SCP-x DNA
(1μl) and subcultured on Kanamycin agar plates over night. Following several steps of
the transformation procedure protein expression was induced by the addition of 1mM
IPTG and 0.1% Rhamnose. After approximately 18 hours of incubation the cell
suspension was subjected to three passages of homogenization using a French press,
followed by centrifugation at 10000g for 10 minutes. Inclusion bodies containing the
desired protein were recovered from the homogenate as a pellet. The lysate was retained
and further processed to recover recombinant proteins localized to the cytoplasm.

The purification of pro-SCP and SCP-x cytoplasmic protein was achieved through
immobilized metal ion affinity chromatography (IMAC) as described in section 2.4.3 of
the methodology chapter. In brief the lysate was treated with 1ml of Ni-NTA agarose
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beads (Qiagen) and gently mixed at 4°C for 1 hour, centrifuged at 2000g for 5 minutes,
and the supernatant removed. Four millilitres of wash solution was then mixed with the
remaining beads, followed by centrifugation at 2000g for 5 minutes repeated 4 times.
Protein was eluted by addition of 1ml of elution buffer to the beads, centrifuged for 5
minutes at 2000g and the supernatant collected. The protein solution was transferred to
dialysis tubing and dialysed against three 2 litre volumes of dialysis buffer solution at
4°C, over a 24 hour period. The protein solution was then removed from the cellulose
tubing, combined with glycerol (10%), filter sterilised (0.2µM) and stored at -80oC.
Protein recovery was confirmed by western blot whereas SCP-2 binding of the CD147
DNA was confirmed by electrophoretic mobility shift assay (EMSA) following the
manufacturer’s instruction.

The DNA binding properties of mature SCP-2 on an electrophoretic mobility shift assay
(EMSA) following incubation of affinity-purified 12.9-kDa SCP-2 with PCR products
corresponding to the CD147 promoter region has been described (Ko and Puglielli,
2007) (Fig. 6.1). KO and Puglielli generated probes corresponding to nucleotides -492
to -392, -392 to -242, -245 to -95 and -94 to 10 and used them to determine their
binding capacity for the CD147 promoter DNA. They reported no binding observed
with PCR products corresponding to nucleotides -492 to -392 and -94 to 10. However
there was a strong mobility shift with the probe corresponding nucleotides to -245 to 95 with a weak shift with the probe corresponding to nucleotides -392 to -242 when
incubated with the transcriptionally active fragment of SCP-2 suggesting the existence
affinity binding sites for SCP-2 on the CD147 promoter as shown in Figure 6.1. The
471 bp EMMPRIN DNA used for EMSA as described by Liang et al. (Liang et al.,
2002) was kindly provided by Dr. Sherif Boulos of Australia Neuromuscular Research
Institute (ANRI – Australia).
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CD147 promoter region

CD147
SCP-2 binding site
Fig.6.1: The schematic view of the 5’-Untranslated region of CD147
CD147 promoter region showing SCP-2 binding site between nucleotides -392 and -95
(adapted from (Ko and Puglielli, 2007))
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Human genomic DNA samples (health controls; n=100 and AD cases, n=100) were
sourced from the Australian Imaging Biomarker and Lifestyle (AIBL) study (Perth and
Melbourne – Australia). A larger 709 bp fragment that covers the whole region
sequenced by KO and Puglielli (Ko and Puglielli, 2007) as well as regions up and down
stream of this region (Fig.6.3). To generate the 709bp fragment a slowdown PCR was
performed as described by Frey et al. (Frey et al., 2008). Approximately 30-50ng of
genomic DNA was amplified by PCR in a reaction containing 400nM each primer
(forward

5’

AGGCTCTGGGAGTACAGACG

and

reverse

5’

CCGGGAGGAACCTCTAGTC), 1.6μl MgCl2, 0.2 μl Taq polymerase, 4 μl 10x PCR
buffer (Phusion), 1.5 μl 7-Deaza-dGTP, 2 μl dNTPS and 9.7 μl dH2O. The thermal
cycle conditions are as follows:

•

1 cycle of 95oC for 5min., setting heating ramp to 2.5oC-1 and the cooling ramp
rate for reaching annealing temperature to 1.5oCs-1

•

48 cycles of 95oC x 30sec denaturation.
o 30sec annealing with a progressively lowered temperature from 70-53oC
at a rate of 1oC every third cycle and a primer extension of 40 sec at
72oC.

•

15 cycles of 58oC, 4oC hold.

The 709bp product, which covers up- and down-stream of the putative SCP binding
region (-392 to -95 nucleotides; (Ko and Puglielli, 2007), was verified by agarose
electrophoresis and viewed under UV on a Biorad Gel doc prior to sequencing.

Sequencing of the amplified region of the CD147 promoter was undertaken at Applied
Genetic Diagnostics (APG), Department of Pathology-University of Melbourne. The
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provided 709bp product was verified by agarose electrophoresis before pre-sequencing
cleanup using EXOSAP-IT (GE Healthcare) and a sequencing reaction with 5μM
forward primer and Big Dye V3.1 terminators (Applied Biosystems). The Qiagen
DyeEx kit was used to clean up the product before capillary electrophoresis on an
ABI3130xl Genetic Analyser with POP7 polymer. The product was amplified by PCR
and sequenced by capillary electrophoresis on an ABI 3130xl Genetic Analyser and
compared to the reference sequence NG_007468.1 using Mutation Surveyor Software®
(Soft Genetics). Results were confirmed by repeat sequencing.

Linkage Dysequilibrium was estimated by D’ and r2 as implemented in Haploview V4.2
software (Barrett et al., 2005). Allelic and haplotypic associations with clinical
classification were undertaken using chi-squared (χ2) tests as implemented in
Haploview. Corrections for multiple testing were considered if mandatory, 1000
permutations as implemented in Haploview. Genotype associations were then analyzed
using IBM SPSS® Statistics version 19.

Analysis of association with categorical

variables (i.e. clinical classification) was undertaken using χ2 analysis, whilst continuous
variables were analyzed using either the Student’s T-test or One Way ANOVA, where
appropriate.

6.4: Results.

6.4.1: SCP-x and pro-SCP bind CD147 DNA in vitro

The two isoforms of SCP-2 protein (pro-SCP and SCP-x) were generated and purified
as described in the methodology. In order to confirm its purity and production the
protein was run on western blot and stained with His antibody. A positive 15kDa band
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(Fig.6.2A) was identified and provided proof that the protein had been successfully
produced and purified. For SCP to initiate transcription it has to bind to the CD147
promoter region. Just like in the study by Ko and Puglielli (Ko and Puglielli, 2007) I
also used the electrophoretic mobility shift assay (EMSA) to determine the SCP-2
binding of the CD147 DNA and to confirm that the generated SCP isoforms were also
binding CD147 DNA. I used yeast extract protein (lane 2), SCP-x and pro-SCP (lanes 3
and 4 respectively), CD147 protein (lane 5) and yeast extract protein plus CD147 (lane
6) as my controls. Compared to yeast extract protein (lanes 2 and 5), SCP protein minus
CD147 DNA (lanes 3 and 4) and CD147 protein (lane 5), results showed positive
CD147 DNA binding as evidenced by reduced mobility of SCP protein isoforms (lanes
7 and 8) on the gel (Fig.6.2B).
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Figure 6.2: Purified SCP-2 protein and elctrophoretic mobility shift assay of SCP
protein.
Purified SCP protein separated by SDS-PAGE gel eletrophoretic method (A).
Electrophoretic mobility shift assay (EMSA) (B) showing SCP isoforms binding CD147
DNA. Compared to yeast extract protein (lanes 2 and 5), SCP protein minus CD147
DNA (lanes 3 and 4) and CD147 protein (lane 5), results show positive SCP protein
binding (lanes 7 and 8) of CD147 DNA as evidenced by reduced mobility of the SCP
protein bands with SCP-x showing strong binding (red arrow).
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6.4.2: CD147 promoter is a GC-rich region requiring special PCR technique to
amplify.

CD147 promoter region was amplified in human genomic DNA by polymerase chain
reaction (PCR) as described above. Although PCR amplification of DNA has previously
been reported (Mullis and Faloona, 1987, Saiki et al., 1988, Huh et al., 2011, Kang et
al., 2011, Ramana et al., 2011), amplification of the GC-rich sequences have not been
easy because they are refractory to amplification due to the formation of secondary
intermolecular structures reported (Varadaraj and Skinner, 1994, Schwientek et al.,
2011). CD147 promoter region, as a regulatory domain, is a GC-rich region (Fig.6.3)
requiring a special PCR method to amplify (Jung et al., 2002, Deng et al., 2010, Jensen
et al., 2010, Wei et al., 2010). Thus preliminary amplification of the region was
performed using the slowdown PCR as described in (Frey et al., 2008) in order to
ascertain that the GC-rich region was successfully amplified (Fig 6.4). Results have
shown that compared to negative control (master mix minus DNA, lane 1) the promoter
region was successfully amplified in the PCR products from 6 human brain test samples
(lanes 2 – 7). Having established that CD147 promoter can be successfully amplified in
human genomic DNA, the region was amplified in 200 DNA samples (n=100, controls
and AD cases respectively) from the AIBL study cohort with the resultant product sent
to Melbourne for sequencing as described above.
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(Chr19:571680)
CAGCGAGACCACTTTACTTGTACGGAAGGGGGCTGCCTGCGTGGGATGCAA
TCTCCAGAGCACACGGGACAAAGGAAGGGAGCTTCTGTTCCTCTGTCCTTTC
CCTGTTGGCTGGGGTTGGACGCCCACAATCTAAGCTGATCCCGGTTGGCTAA
AACTTAAAACTTTTTTAAAATAGGGTAAACGCGCCACCTGCGAGGAAAGAA
GAAGGGGGTAAGGTTGATTGACAACTTTAGACCTGGAAGTTGAGTTTCTGA
AGAGGAACTTACTTGTCCCAACCAAATGGTGCACAGGACGTTTATACTAAG
AAATTATTCATTTTCTGAGATCCAGATTCAAGTGCCCTTTAAGTATTTTTATT
TGGGCGGAGGAGGTCACTTCCTCCCACCTAATTTATTAATACGTTCATATAT
ATATATATATATGTACATTTTTAAAGGCAGAGATGTGCGTCTCGCCATGTTG
CCGCGTCTGGTCTCGAGCTCCCGGGCTCAAGCGATCTTCCCGCCTCGACCTC
CCAAGGCTCTGGGAGTACAGACGTGAGCCACAGCGGCCGGCCCGTGTTTAA
CTCAGATAAAATCTGGGTAACACACTTTCAACGCTTCAACCCCCTCGGGCGC
ACCGCTCTGCGCTCATTGCAACTTTGAAAGCAGGAAGGAAGAAATGCGCAG
GCTCCAGCCGCGTCCCCGCAGGCCCCACTCCCGTTTCCTAGCAACGCCGGGT
CACGTGCGCCGCCGCCCGGATTCCGTAGCGTGAGCCTGCCGGAGCCGGCGC
GTACATGCGAGCGTGTGCGCGCGTGCGCAGGCGGGGCGACCGGCGTCCCCG
GCGCTCGCCCCGCCCCCGAGATGACGCCGTGCGTGCGCGCGCCCGGTCCGC
GCCTCCGCCGCTNTTTTATAGCGGCCGCGNGGCGGCGGCGGCAGCGGTTGG
AGGTTGTAGGACCGGCGAGGAATAGGAATCATGGCGGCTGCGCTGTTCGTG
CTGCTGGGATTCGCGCTGCTGGGCACCCACGGAGCCTCCGGGGCTGGTGAG
GAGCGGGTAGGGGGCGGGGGTGCGGTCCTGCAGGGGCCGGGAATGGAGGC
CGCGGTGCCGACCCGAAGCCGACGGGAGCCTGGGGCCTCGGCGCGGGGCG
GCCTGGGGTGCGAAAGGCCGGCCCCGGGGGCTTCCCGCGCCAGCATGGAGC
TTGGGGGTGAAGTCCCAGGGTTTGAGGGGGGACTAGAGGTTCCTCCCGGCG
CGGCCTGCCGGGCTCCCCCGGGCGCT (Chr19:572934)

Figure 6.3: Sequence of the CD147 promoter region
Promoter region showing the GC-rich cis-elements, NCBI annotated SNPs (in red), and
the region where SCP binds to initiate CD147 transcription (underlined). In this thesis a
total of 709bp was sequenced using primers (blue italics) to determine known SNPs and
ascertain the presence of novel SNPs.
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Figure 6.4: Slowdown PCR amplification of the CD147 promoter region
Amplification of 709bp PCR product from the CD147 promoter region. Compared to
negative control (master mix minus DNA, lane 1), results indicate successful
amplification of the CD147 GC-rich promoter in human genomic DNA PCR products
from 6 human brain test samples (lanes 2 - 7) by slowdown PCR method.
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6.4.3: CD147 promoter contains two novel SNPs not previously reported.

The CD147 promoter region sequenced in this thesis contains 16 SNPs that have been
previously reported in NCBI with varying minor allele frequencies. Analysis of
sequencing data failed to observe any sequence variation at 9 of these sites (potentially
monomorphic in the cohort studied), whilst the remaining 7 SNPs already reported in
NCBI were successfully identified, these being: rs4919859, rs145461969, rs11551906,
rs28915407, rs142683396, rs28915408, and rs2072307. In addition to the previously
reported SNPs results from the current study have identified two new novel SNPs that
have not been previously reported. A comparison of minor allele frequencies in the
current study is made to those reported in European populations from NCBI in Table
6.1.
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Table 6.1: Comparison of minor allele frequencies reported in European
populations from NCBI and in the current study
SNP

Position

MAF – NCBI*

MAF – Current Study

rs4919859

chr19:572317

0.333, 0.350

0.385

rs145461969

chr19:572550

NA, NA

0.0025

rs000001(c.-61A>G)**

chr19:572574

Not reported

0.0025

rs000002 (37C>G)**

chr19:572672

Not reported

0.0025

rs11551906

chr19:572680

NA, NA

0.02

rs28915407

chr19:572811

0.087, NA

0.02

rs142683396

chr19:572823

NA, NA

0.002

rs28915408

chr19:572860

0.022, NA

0.032

rs2072307

chr19:572878

0.022, NA

0.102

*European population (PGA_CEPH-PANEL, HapMap-CEU): NA, not available in
given population. Not reported, SNP has not been previously reported in NCBI
database.
**Novel SNP
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The first of these, an A to G transition located 61 base pairs upstream (-61A>G) of the
transcription initiation site, was identified in a single heterozygous healthy control
individual and is subsequently referred to in this thesis as rs0000001. A second novel
SNP, a C to G transversion located 37 base pairs downstream (37C>G) of the
transcription initiation site, was identified in a single heterozygous AD individual and is
subsequently referred to in this thesis as rs0000002.

These SNPs need to be

investigated further to determine if they have any influence on the development and
pathology of AD or other neurodegenerative diseases. The 9 SNPs identified with minor
allele frequency (MAF) greater than 0 were determined via Haploview and are
presented with a plot of the relative D’ levels between each marker below (Fig.6.5).
After identifying the SNPs, I then wanted to know if any of them is associated with AD.
Results of this analysis are presented in the sections below.
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Figure 6.5: Linkage disequilibrium for CD147 Single Nucleotide Polymorphisms in
the AIBL cohort sample.
Each of the 9 SNPs identified with MAF greater than 0 are presented with a plot of the
relative D’ levels between each marker below, as determined via Haploview.
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6.4.4: CD147 promoter SNPs are not associated with AD.

SCP-2 binding to CD147 promoter has been reported (Ko and Puglielli, 2007) .
However genetic variations within this region may alter SCP-2 binding which in turn
may lead to alteration in CD147 expression leading to increased AD risk and pathology.
As such, ascertaining the frequency of known genetic variations as well as the discovery
of novel genetic variations within this region would be of interest. In the current study a
sample of 100 AD and 100 healthy controls from the AIBL cohort were utilised. Allelic
and haplotypic associations were analysed using Haploview V4.2 software (Barrett et
al., 2005) and genotype associations were analyzed using IBM SPSS® Statistics version
19 as described in section 6.3 of this chapter. Results from these experiments have
shown no allelic (Table 6.2), genotypic (Table 6.3) and haplotypic (Tables 6.4)
association with AD.
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Table 6.2: Allelic Frequencies
SNP
Risk
CTRL
(major/minor)
Allele
MAF
rs4919859
(G/C)
rs145461969
rs0000001
(A/G)
rs0000002
(C/G)
rs11551906
(A/G)
rs28915407
rs142683396
(G/A)
rs28915408
(G/A)
rs2072307

(G/T)

(G/T)

(T/C)

AD
MAF

chisq

p-value

-

0.385

0.385

0.0

1.0

G

0.005

0.000

1.003

0.3167

A

0.005

0.000

1.003

0.3167

G

0.000

0.005

1.003

0.3167

G

0.015

0.025

0.51

0.4751

G

0.03

0.01

2.041

0.1531

A

0.000

0.005

1.003

0.3167

G

0.04

0.025

0.716

0.3976

T

0.11

0.095

0.245

0.6209

SNPs and minor (MAF) allele frequencies in controls and AD patients. P-values (
range: 0.3167 – 1.0) for the 9 SNPs were calculated using chi-squared (χ2) tests as
implemented in Haploview and indicating no association with AD
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Table 6.3: Genotype association
SNP
Genotype
Controls

rs4919859

AD

GG

39

38

GC

45

47

CC

16

15

GG

99

100

GT

1

0

AA

99

100

AG

1

0

CC

100

99

CG

0

1

AA

98

95

AG

1

5

GC

1

0

GG

94

98

GT

6

2

GG

100

99

GA

0

1

GG

92

95

GA

8

5

TT

80

82

TC

18

17

CC

2

1

rs145461969

rs0000001

rs0000002

rs11551906

rs28915407

rs142683396

rs28915408

rs2072307

Chiq

p-value*

.089

.957

.316

1.00

.316

1.0

.316

1.0

3.713

.156

2.083

.149

1.005

.316

.740

.390

.387

.824

Genotype associations of the 9 SNPs in controls and AD cases were analyzed using
IBM SPSS® Statistics version 19. P-values (range: 0.149 – 1.0) were calculated using
chi-squared (χ2) tests as implemented in Haploview and indicating no association with
AD
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Table 6.4: Manual Haplotype Associations
Haplotype
Freq
AD Freq Ctrl
Freq

chisq

p-value

GGACAGGGT

0.438

0.461,

0.416

0.819

0.3654

CGACAGGGT

0.378

0.375,

0.380

0.01

0.922

GGACAGGGC

0.102

0.094,

0.109

0.245

0.6204

Haplotypic frequencies in health controls and AD patients and p-values (range: 0.3654 –
0.922) calculated using chi-squared (χ2) tests as implemented in Haploview and
indicating no association with AD.
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6.4.5: CD147 promoter SNPs are not associated with Aβ, cholesterol and ApoE
levels.

Many potential risk factors for AD have been described which include, low levels of sex
steroids (Pericak-Vance et al., 1991, Poirier et al., 1993, Strittmatter et al., 1993,
Haskell et al., 1997, Lambert et al., 1998, Short et al., 2001), increased levels of
gonadotropins (Smith et al., 1998, Bowen et al., 2000, Short et al., 2001), head injury,
physical inactivity, stroke, diabetes, hypertension, and hypercholesterolemia. In addition
age and possession of the ε4 allele of the Apolipoprotein E gene (APOE ε4) are some of
the major risk factors for most of the population (Martins et al., 2006). Thus the current
study investigated associations between the CD147 promoter SNPs and plasma Aβ40,
Aβ42, cholesterol and ApoE levels. No association analysis of the new identified SNPs
was done as they appear in only 1 health control and AD case respectively. However an
association analysis of the other SNPs showed that these SNPs are not associated with
Aβ40, Aβ42, cholesterol and ApoE levels (Table 6.5).
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Table 6.5: SNPs association with Aβ, cholesterol and ApoE Levels
SNP

Genotype

n

Mean

Std. Dev

GG
GC
CC
AA
AG
GG
GT
GG
GA
TT
TC
CC

77
92
31
193
6
192
8
187
13
162
35
3

114.3451
112.3340
111.8019
114.0789
91.2300
113.2423
107.8288
109.4164
164.9454
109.4405
126.8474
145.3800

79.03767
70.09841
77.30048
78.27700
29.46459
78.37106
47.42792
71.81514
126.60262
73.89005
90.85050
77.30048

GG
GC
CC
AA
AG
GG
GT
GG
GA
TT
TC
CC

77
92
31
193
6
192
8
187
13
162
35
3

38.4395
37.9095
34.0903
37.7050
33.4433
37.4291
39.7400
37.0856
43.7931
36.3743
42.2791
43.9700

18.64391
17.18257
22.06179
18.80707
6.20001
18.84739
7.93448
17.76225
27.53798
17.55477
22.26998
18.99478

GG
GC
CC
AA
AG
GG
GT
GG
GA
TT
TC
CC

77
91
31
192
6
191
8
186
13
161
35
3

5.3727
5.4967
5.2258
5.4156
4.8167
5.4230
5.0125
5.3995
5.5077
5.4379
5.2686
5.3333

1.05539
1.02604
1.12041
1.05531
0.41673
1.06252
0.66641
1.06418
0.87793
1.04319
1.08784
1.36137

GG
GC
CC
AA
AG
GG
GT
GG
GA
TT
TC
CC

77
87
30
187
6
186
8
181
13
156
35
3

14.5928
15.1154
15.4358
14.9600
14.8298
14.9972
14.0350
14.9955
14.4298
14.8645
15.2719
14.9576

2.92177
2.52136
2.20916
2.64031
3.44908
2.65860
2.43816
2.68765
2.08612
2.56049
3.11273
0.93808

p-value

Aβ40
rs4919859
rs11551906
rs28915407
rs28915408
rs2072307
Aβ42
rs4919859
rs11551906
rs28915407
rs28915408
rs2072307

.982
.477
.847
.143
.371

.526
.581
.731
.208
.193

Cholesterol
rs4919859
rs11551906
rs28915407
rs28915408
rs2072307

.437
.168
.280
.721
.686

ApoE
rs4919859
rs11551906
rs28915407
rs28915408
rs2072307

.255
.906
.316
.459
.532

Association analysis CD147 SNPs (n>1 in ≥2 genotypes) with Aβ40, Aβ42, cholesterol
and ApoE levels were undertaken using χ2 analysis, whilst continuous variables were
analyzed using IBM SPSS® Statistics version 19 with either the Student’s T-test or One
Way ANOVA, where appropriate. P-values (range: 0.143 – 0.982) showing no
association of the SNPs with Aβ40, Aβ42, cholesterol and ApoE levels
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6.4.5: CD147 promoter SNP rs11551906 is associated with AD pathology.

Imaging techniques using radio labelled positron emission tomography (PET) tracers
that bind to Aβ peptides in amyloid plaques are currently being used to assess relative
brain amyloid plaque pathology in AD (Lee et al., 2003a, Mistur et al., 2009, Mosconi
et al., 2009, Jagust et al., 2010, Kadir et al., 2011). The AIBL study performed PET
scans on a subset of the study participants and the current study did a genotype
association analysis of the CD147 promoter SNPs with the standard uptake value ratios
(SUVR) of the radio labelled tracer (Pittsburgh Compound B, PiB) used in the AIBL
study. Results have shown a positive association with rs11551906 SNP (*p<0.05)
(Table 6.6) indicating that presence of the minor allele of this SNP is associated with
increase cerebral amyloid burden.
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Table 6.6: Genotype association with SUVR
SNP

rs11551906

rs28915407

rs28915408

GENOTYPE

n

MEAN

SD

AA

40

1.7850

.56186

AG

2

2.1300

.08485

GG

39

1.8364

.55135

GT

3

1.3467

.40377

GG

39

1.7936

.54587

GA

3

1.9033

.77106

p-value
.010*

.141

.745

Genotypic association of the 3 SNPs with SUVR in AD patients were analyzed using
IBM SPSS® Statistics version 19. P-values (range: 0.010 – 0.745) p-values indicating a
significant association of rs11551906 with SUVR (*p<0.05)
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6.5: Summary of results

Overall the results presented in this chapter show that SCP-2 binds CD147 DNA and
based on previous studies this is likely to be within the promoter region, specifically in
the region -392 to -95 as identified by Ko and Puglielli (Ko and Puglielli, 2007).
Sequencing of a 709bp fragment covering this region identified 2 novel SNPs within the
CD147 promoter that have not been reported before in NCBI. There was neither an
association between the 9 identified polymorphic SNPs and AD risk or with changes in
plasma cholesterol, Aβ40, Aβ42 and ApoE levels. However, a significant association
between the rs11551906 minor allele and elevated cerebral amyloid burden, as
determined by PiB-PET SUVR, (*p<0.05) was observed.

6.6: Discussion
6.6.1: SNPs association with AD

Genetic mutations or polymorphisms linked to AD development and severity (Prince et
al., 2003, Greeve et al., 2004, Frey et al., 2008, Ringman et al., 2010) and AD risk
factors such as sex steroids (Pericak-Vance et al., 1991, Poirier et al., 1993, Strittmatter
et al., 1993, Haskell et al., 1997, Lambert et al., 1998, Short et al., 2001)),
gonadotrophins (Smith et al., 1998, Bowen et al., 2000, Short et al., 2001) and
possession of the APOE ε4 allele (Martins et al., 2006) have been reported. The current
study investigated SNPs in the CD147 promoter region, where SCP-2 binds to stimulate
CD147 transcription and determined their association with AD. Allelic (Table 6.2),
genotypic (Tables 6.3) and Haplotypic (Table 6.4), association analysis were
undertaken and showed no association with AD. These findings cannot completely rule
out the possible association of the identified SNPs with AD as only a small subset of
samples were utilised for sequencing experiments. Due to the small sample size the
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possibility remains that there was not sufficient power to identify any associations.
Further, as the focus of this study was on the promoter region of CD147 it cannot be
ruled out that an untyped variant downstream from the sequenced region, within the
coding region of the gene, may impart risk for AD. Previous studies have associated
differences in CD147 expression with Aβ levels (Zhou et al., 2005, Vetrivel et al.,
2008b) and deficits in memory and behaviour functions (Naruhashi et al., 1997) where a
number of behavioural tasks were carried out in mice lacking CD147. Compared to
wild-type and heterogeneous (Basigin +/-) mice, the CD147 null mice (Basigin -/-)
performed worse in memory and learning tasks (e.g. Y-maze and water finding tasks).
In addition CD147 null mice were less sensitive to light, pain, and induced electric
shock, reflecting the importance of CD147 in sensory functions. As such, genetic
variation within the CD147 promoter may likewise be associated with AD biomarkers
and abnormal limbic system function.

To address the above question the current study investigated any associations between
these SNPs and plasma Aβ40, Aβ42, cholesterol and ApoE levels. Due to previous
links between CD147 expression and the aforementioned biomarkers it was anticipated
that some association with these parameters linked to AD pathology would be observed.
However, there were no associations revealed for the identified SNPs with levels of
Aβ40, Aβ42, cholesterol and ApoE in plasma (Table 6.4) despite these being amongst
the most potent reported AD risk factors (Martins et al., 2006) (Jarvik et al., 1995,
Igbavboa et al., 1996). The findings may suggest that genetic variations in the CD147
promoter do not play a role in AD pathology as seen in those in the APP and ApoE
genes. However, it may also be hypothesised that CD147 promoter mutations play a
role in AD pathology only when SCP-2 binds the promoter region that may result in
increased Aβ generation as reported by Ko and Puglielli (Ko and Puglielli, 2007).
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Further, this study did not investigate any proximal or distal regulatory elements, which
may also impact on CD147 expression levels and in turn impact upon regulation of Aβ
generation. However these hypothesises need to be proved further in future studies.

6.6.2: SUVR is associated with rs11551906

The uses of PET scans that utilise tracers that bind to Aβ peptides in amyloid plaques to
assess relative brain amyloid plaque pathology in AD have been reported (Lee et al.,
2003a, Mistur et al., 2009, Mosconi et al., 2009, Jagust et al., 2010, Kadir et al., 2011).
The AIBL study also used a similar technique on the study subjects as reported in the
previous studies. A subset of 42 individuals from the 200 AIBL subjects sequenced in
this thesis underwent PiB-PET scans and genotype association analysis of SNPs within
the sequenced CD147 promoter region with PiB-PET derived SUVR. Only 3 SNPs
from those identified could be analysed due to the frequency of identified genotypes.
Out of the 3 SNPs only 1 (rs11551906) is associated with SUVR (Table 6.5) indicating
its association with increase cerebral amyloid burden.

CD147 knock down studies reported increased Aβ levels (Zhou et al., 2005, Vetrivel et
al., 2008b) and that SCP-2 binding of CD147 promoter facilitates CD147 transcription
(Ko and Puglielli, 2007). Expression of pro-SCP-2 has been shown to abolish activity of
12.9 kDa SCP-2 and inhibit CD147 transcription, resulting in an increase in Aβ
production (Ko and Puglielli, 2007). Furthermore the current study has shown that
rs11551906 is associated with SUVR. Taken together these findings may suggest that
this SNP interferes with SCP-2 binding to the CD147 promoter or facilitates pro-SCP-2
expression which in turn shuts down CD147 transcription resulting in increased Aβ
generation. This may explain why this SNP is associated with SUVR. It is not known if
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the other SNPs would also show an association if a larger cohort is used, thus a followup study is required to better answer this question.

6.6.3: Novel SNPs within the CD147 promoter

In addition to the already NCBI reported SNPs (Table 6.1), the main aim for
sequencing the CD147 promoter region described in this thesis was to identify novel
SNPs that may be associated with AD development and pathology. At the time of
writing the NCBI database identifies 16 SNPs within the region sequenced and only one
of these (rs28915404 an -/G deletion-insertion variation) located within the putative
SCP binding region. However, no additional SNPs were identified in the region where
SCP-2 binds to initiate CD147 transcription that later influences Aβ levels in vivo.
Interestingly though was the discovery of the 2 novel SNPs within the promoter region
but outside the region where SCP-2 binds. These were an A to G transition located 61
base pairs upstream (-61A>G) of the transcription initiation site and a C to G
transversion located 37 base pairs downstream (37C>G) of the transcription initiation
site. These novel genetic variations were identified in a single heterozygous healthy
control individual and a single heterozygous AD individual, respectively. It is not
known if -61A>G SNP may provide some protection whereas 37C>G SNP may be a
risk factor for AD, however a comprehensive study using a larger and well
characterized sample cohort has to be undertaken to prove this hypothesis.

Taken together that GC-rich sequences are difficult to amplify (Varadaraj and Skinner,
1994, Schwientek et al., 2011) and that CD147 promoter is a GC-rich region (Fig.6.3)
requiring special PCR method to amplify (Jung et al., 2002, Deng et al., 2010, Jensen et
al., 2010, Wei et al., 2010), warrants a robust sequencing of the entire CD147 promoter
252

to identify other novel SNPs that have not been identified yet. This will also further help
in the investigation of the roles such SNPs may play in disease pathology including the
2 currently reported in this thesis despite being identified in one health control and AD
patient only.

6.7: Conclusion

I report for the first time that the CD147 promoter region sequenced in this study
contains 2 novel SNPs that have not been reported before in NCBI. I also report for the
first time that out of the 9 SNPs identified in this region only one (rs11551906) is
associated with AD biomarker SUVR.
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CHAPTER 7

General discussion

7.1: The link between CD147 protein and AD pathology.

There are several theories regarding AD development and pathogenesis with the
amyloid cascade hypothesis being the most widely accepted and studied one. The
amyloid cascade hypothesis proposes that the aggregation and deposition of β-amyloid
(Aβ) is the initial pathological event in AD, which leads to the formation of amyloid
plaques and then to NFT, neuronal cell death, and ultimately dementia. However, the
reasons for Aβ aggregation and additional factor(s) involved in the amyloid cascade are
not properly understood and need to be established. Oxidative stress, inflammatory
processes, reduced Aβ clearance, dys-regulated lipid metabolism, reduced oxygen levels
and hormonal changes have all been suggested, either directly or indirectly, to initiate or
to promote the initial stages of Aβ aggregation. For example, age-related losses of
oestrogen in women and testosterone in men are risk factors for AD, possibly due to
hormone influences on Aβ production and degradation, neuron viability, and oestrogen
signalling mechanisms (Li et al., 2000b, Pike et al., 2009).

Possibly the majority of studies on factors that may influence risk of AD have emanated
from the early genetic studies which found links between AD and possession of
apolipoprotein E4 alleles (Holtzman et al., 2012). This was soon followed by studies
that found links between cardiovascular diseases and AD (Sahathevan et al., 2012).
There is now also substantial evidence that conditions such as stroke, hypertension,
diabetes and lipid disorders are independently associated with an increased risk of AD
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and vascular cognitive impairment. As part of these studies, cholesterol and diet have
been extensively studied. Due to this research, elevated cholesterol levels and high fat
diets have now been associated with increased Aβ production and have been classified
as AD risk factors.

The brain represents only about 2 percent of your body weight, but actually has about
20 percent of your body's cholesterol. Cholesterol is important for normal brain function
- it is important for synaptic function and is also an essential component of cell
membranes in the brain. Defects in cholesterol metabolism are associated with serious
neurological and mental dysfunctions (Tint et al., 1994). Alterations in general
cholesterol metabolism have been implicated in AD pathogenesis (Jarvik et al., 1995,
Igbavboa et al., 1996) as evidenced by reported higher plasma cholesterol levels in
people who subsequently develop AD compared to people who don’t (Notkola et al.,
1998). Some early longitudinal studies of cholesterol-reducing drugs (statins) found that
statins such as lovastatin or simvastatin could reduce the risk of developing AD (Miida
et al., 2005).

By competitive inhibition of hydroxymethyl co-enzyme A-reductase, statins reduce the
production of cholesterol and isoprenoid intermediates including geranyl and farnesyl
pyrophosphate. In vitro studies also found that statin-induced depletion of cellular
cholesterol reduces Aβ production and secretion (Simons et al., 1998a), whereas
cholesterol supplementation results in increased production of Aβ40/42, suggesting that
intracellular cholesterol levels can influence APP processing. The reason for this may
be that membrane cholesterol content influences the activity of γ-secretase, the APP
cleavage enzyme found in cholesterol rich microdomains of the cell membrane, and that
is unusual due to its intra-membrane cleavage site. More recent reviews of the clinical
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statin data, however, have found that statins have no effect on incidence of AD
(McGuinness et al., 2009), or alternatively that the results are just too variable to make
any conclusions (Shepardson et al., 2011a, b). The variability in the results of statin
studies has been put down to differences in the blood-brain barrier permeability among
statins, the stage of AD at which statins were administered, and/or drug pleiotropic
metabolic effects. Nevertheless, the interest in cholesterol metabolism and the effect of
cholesterol on Aβ production has prompted much research into lipids and AD. From
this research, a high fat diet has now also been implicated in the aetiology and
development of AD as evidenced by the findings that AD incidence is higher in
countries with high-fat/high-calorie diets (Kalmijn et al., 1997), and that the risks for
cardiovascular diseases such as elevated blood cholesterol and triacylglycerol
(triglyceride) levels, obesity, diabetes, lack of exercise and hypertension are also risks
for developing AD (Fillit et al., 2008).

Other interesting studies have reported changes in Aβ peptide generation due to cellular
CD147 alterations, an indication of a possible link between CD147 and Aβ. CD147 is a
member of the immunoglobulin superfamily, it was first identified as a tumour surface
protein capable of inducing matrix metalloproteinase (MMP) expression in fibroblasts,
and thus it is also known as EMMPRIN (extracellular matrix metalloproteinase
inducer). CD147 is a transmembrane glycoprotein, and increased expression of CD147
occurs in many tumours, however the protein is also critical in foetal development and
retinal function and it has been shown to play a role in thymic T cell development, as
well as many neurological processes ranging from the development of the nervous
system to involvement in spatial learning (Iacono et al., 2007).
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Cancer studies of CD147-null animals found that a lack of CD147 leads to a dramatic
reduction in accumulation of the monocarboxylate (lactate) transporters (MCT)-1 and -4
proteins, which indicated a role for CD147 in targeting these transporters to the plasma
membrane. Continued association of these proteins is required for function, and high
levels of these proteins are found on aggressive tumour cells, both of these
characteristics are potentially necessary to meet the high glycolytic needs of
transformed (cancer) cells (Iacono et al., 2007). Other studies more relevant to AD
have reported that CD147 expression levels influence Aβ generation and that a lack of
CD147 can cause cognition defects similar to those seen in AD (Zhu et al., 2006, Zhou
et al., 2007). CD147 has been shown to be a regulatory co-factor for the γ-secretase
complex and that depletion of CD147 from the γ-secretase complex through RNA
interference in cell lines results in an increase in Aβ production (Zhou et al., 2005).

These results suggested that CD147 levels could modulate Aβ generation. However,
other studies have found that the levels and localization of CD147 in fibroblasts, as well
as the postnatal expression and distribution of CD147 in the brain, are distinct from
those of integral γ-secretase subunits. It has also been found that membranes isolated
from CD147-depleted cells fail to elevate Aβ production in in vitro γ-secretase assays
(Vetrivel et al., 2008). Instead, Vetrivel et al. found that CD147’s influence on Aβ
levels was more likely due to extracellular degradation by matrix metalloproteinases
(MMPs), the levels of which have been previously reported to be stimulated by CD147
(Vetrivel et al., 2008b). From other studies of γ-secretase, it appears only a small
fraction of the cellular pool of CD147 or p23 (also known as TMP21, involved in
vesicular trafficking between the ER and Golgi) remains complexed with γ-secretase at
steady state, and the precise mechanisms by which these proteins modulate γ-secretase
activity remain obscure.
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A major role for CD147 in the brain is supported by studies that have demonstrated
neurological abnormalities such as spatial learning and memory deficits in CD147 null
mice (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et al., 2003).
However, there is still little literature on CD147 effects on neuronal health and Aβ
production and/or clearance, whereas many studies have been carried out to establish its
involvement in cancer metastasis.

The recent CD147 studies that have attracted the attention of researchers in the AD field
are those which have looked into the regulation of CD147 as a potential strategy to
reduce the risk of AD via the modulation of γ-secretase activity, or via the modulation
of extracellular enzymes (possibly MMPs) that can degrade extracellular Aβ (Zhou et
al., 2007, Vetrivel et al., 2008b). In addition to the siRNA CD147 knock down studies
in transgenic mice which have shown CD147 reduction causes a dose-dependent
increase in Aβ production (Zhou et al., 2005), CD147’s involvement in AD pathology is
also supported by studies which have shown increased levels of the protein in the
frontal cortex of AD affected individuals (Nahalkova et al., 2009, 2010).

The current study has attempted to characterise further the ways in which CD147 may
contribute to AD development and pathogenesis, and the results of these studies are
outlined in chapters 3 – 6 of this thesis. In summary CD147 protein levels were
measured in rat primary neuronal cultures in the presence and/or absence of endogenous
cholesterol and Aβ42 peptide, whilst CD147 neuronal protection against oxidative stress
and Aβ toxicity was also investigated, as reported in chapter 3. In addition to these in
vitro experiments, the current study has also measured CD147 levels in brain tissues
from APPswe transgenic mice fed on normal chow or a high fat/high cholesterol diet to
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investigate the impact of diet on CD147 protein expression. The findings of these
studies are reported in chapter 4. CD147 levels in human brains from control, frontal
temporal dementia, Lewy body disease, and Alzheimer’s disease cases were measured
to characterise any differences in CD147 levels between aged control brains and brains
with the various neurodegenerative disorders. The findings of these experiments are
reported in chapter 5. In chapter 6, sequencing studies were carried out to investigate
known and any novel polymorphisms in the CD147 gene promoter region, which may
also contribute to the development and/or pathology of AD. The findings from all these
experiments listed are discussed in detail below.

7.2: Cholesterol and Aβ42 loading increases CD147 protein expression in vitro

Brain cholesterol can be produced by glial cells, although in adult brains, most brain
cholesterol is believed to be recycled. Neurons, which are especially enriched with
cholesterol, are believed to obtain their cholesterol by uptake of apoE/cholesterol
complexes via receptors of the LDLR family. Neurological and mental dysfunctions
due to defects in cholesterol metabolism have been reported (Tint et al., 1994). There is
now significant in vitro evidence to indicate a role of cholesterol in AD pathology and
recent clinical findings also support the notion that progressive deterioration of
cholesterol homeostasis is a central player in AD pathophysiology. Firstly,
polymorphisms in several proteins and enzymes involved in cholesterol or lipoprotein
transport and metabolism have been linked to the risk of AD. Secondly, enzymatic
production of Aβ is affected by membrane cholesterol levels, thought to be due to
effects on γ-secretase. However, studies that have led to this conclusion have often been
studies of statin effects, and more recent studies have suggested that due to the high
number of pleiotropic effects of statins, novel molecular mechanisms that account for
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the beneficial effect of statins on AD might be discovered in the future. Thirdly,
cholesterol has been shown to affect APP maturation (Galbete et al., 2000a), and
alterations to cholesterol metabolism are likely to affect this step in APP metabolism.

To maintain cholesterol homeostasis in the brain, some excretion occurs following
enzymatic conversion of cholesterol to the oxysterol 24-OH cholesterol. Another
oxysterol found in the brain is 27-OH cholesterol, although this is believed to derive
mostly from the circulation. The brain levels of these oxysterols influence expression of
many enzymes involved in lipid homeostasis in the brain such as the sterol regulatory
element binding proteins (SERBP), apoE (via the liver X receptor) and ABCA1 and
ABCG1 (ATP binding cassette transporters, cholesterol efflux transporters) (Martins et
al., 2009). CSF 24-OH cholesterol has been found to be higher in AD individuals, and
cholesterol efflux appears to be elevated and related to the increased risk for AD
(Papassotiropoulos et al., 2002, Koldamova et al., 2003).

In chapter 3 of this thesis the studies demonstrate that cholesterol and Aβ42 loading in
rat primary cortical neuronal cultures altered CD147 and FL-APP expression levels. In
primary cultures of rat neurons, cholesterol loading increased CD147 protein levels
(Fig.3.1) and reduced FL-APP protein levels (Fig. 3.2). These findings suggest that
CD147 protein expression can increase under conditions of hypercholesterolemia. It is
possible that a similar scenario happens in human brains in relation to AD
development/pathogenesis. Further investigations are required to establish the detailed
mechanism(s) through which cholesterol exerts its influence on CD147 protein
expression levels at the cellular level.
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In order to determine the cause of the higher CD147 expression, cell viability was
investigated by measuring LDH release into the culture supernatants. A significant
increase in LDH release (Fig. 3.3) was found, indicating that the cholesterol loading
caused stress to the neuronal cultures. It is therefore likely that cellular stress was
responsible for the observed increased CD147 expression. Our findings are consistent
with findings from previous studies that have reported that protein production can be
affected in cells undergoing environmental stress (Yao and Tabas, 2001, Matsuda et al.,
2002, Nilsson and Sunnerhagen, 2011).
The results in this chapter have also shown a reduction in FL-APP levels in response to
cholesterol loading, at high concentrations of cholesterol. In a study by Galbete and
colleagues (Galbete et al., 2000b), it was shown that increased cholesterol levels cause a
decrease in the secretion of the α-secretase-cleaved form of soluble APP by interfering
with glycosylation in the protein maturation pathway. It was concluded that although
APP was probably being inserted in the membrane, a proportion was not being
glycosylated, and was not being cleaved by α-secretase (Galbete et al., 2000b). At much
higher concentrations of cholesterol, cellular toxicity is likely to have reduced APP
production in the cells, which is what we have observed. The findings suggest that
increased cholesterol levels can affect APP production and maturation, and the other
results of this section of chapter 3 shows that cholesterol loading can induce cell
oxidative stress in rat primary cortical neuronal cultures as evidenced by the elevated
LDH release, and result in the over-expression of CD147 protein. The observed
increased CD147 protein levels in the presence of increased cholesterol loading are
most likely due to cell stress induced by exogenous cholesterol. These findings support
the notion that CD147 is a marker of inflammation. In this case it could be hypothesized
that increased cholesterol levels, which in turn activated the apoptotic pathway,
triggered the inflammatory process.
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7.3: Aβ42 induced oxidative stress increases CD147 protein expression in vitro

As mentioned previously, CD147 levels have been shown to influence levels of Aβ,
either by modulating γ-secretase activity, or by stimulating the production of the MMPs,
which have been shown to degrade Aβ. CD147 has also been shown to protect neuronal
cells against oxidative stress and injury (Boulos et al., 2007), and the Aβ42 addition
experiments in chapter 3 were designed to provide further evidence that oxidative stress
leads to increased CD147 protein production. As can be seen from the results, there
was a significant increase in CD147 expression (Fig.3.6, chapter 3) and significantly
reduced FL-APP (Fig.3.7 chapter 3) levels in the neuronal cells following exposure to
high extracellular levels of Aβ42 peptide. LDH release (Fig.3.5, chapter 3) also
increased in the neuronal cultures treated with Aβ42, indicating cellular oxidative stress
was being induced by the peptides. These experiments involved the addition of high
concentrations of Aβ42, and the LDH release results indicate that cellular toxicity
occurs at even the lowest Aβ42 level used (1 µM, Fig. 3.5). The FL-APP bands on the
Western blot suggest that APP maturation is affected at the lower Aβ42 concentrations,
and that FL-APP production is significantly reduced at higher levels of Aβ42. The
effects at the higher levels of Aβ42 (~ 5 – 15 µM) are most likely due to cytotoxicity
(Fig. 3.7), as LDH levels were 4 - 5 fold above control (untreated) levels at these Aβ42
concentrations. The levels of CD147 did not show any significant change till higher
concentrations were utilised, at which point the increase in CD147 protein levels was
highly significant. Other studies have provided evidence that CD147 is a regulatory
component of the γ-secretase complex (Zhou et al. 2005, 2007), by showing that
depletion of CD147 from the γ-secretase complex through RNA interference in cell
lines results in an increase in Aβ production without affecting expression levels of the
other γ-secretase components. However, as follow-up studies have indicated, instead of
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regulating Aβ production, CD147 may play a role in its degradation and clearance
(Vetrivel et al., 2008b), it may be that the high Aβ concentrations have induced an
increase in CD147 production, in an effort to remove the Aβ and reduce the oxidative
stress. Nevertheless, the Aβ42 concentrations that appear to be required to induce the
increase in CD147 (5-15 µM) are not physiologically relevant, thus the increase in
CD147 may be simply due to cytotoxicity. It also needs to be remembered that the
CD147 neuronal protection may require the presence of cyclophilin A (CyPA) as
reported by Boulous et al (2007).

The discovery that CD147 is a signalling receptor for CyPA has provided a novel
function for CD147 (Yurchenko et al., 2002). Activation of the CD147 receptor by
CyPA has been shown to stimulate the phosphorylation of ERK1/2, which activates the
anti-apoptotic proteins Bcl-2 (Riccio et al., 1999) and Bag-1 (Perkins et al., 2003) and
phosphorylation-mediated inactivation of pro-apoptotic proteins such as Bim (Biswas
and Greene, 2002) and Bad (Bonni et al., 1999, Zhu et al., 2002). These downstream
pro-survival signalling events may be one mechanism through which CyPA/CD147
interaction protects neurons from toxic insults. To investigate the involvement of CyPA
in protection against Aβ42, a different in vitro assay system was devised, as discussed
in the next section.

7.4: Adenoviral mediated CD147 over expression protects neuronal cell against
Aβ42 induced oxidative stress only in the presence of CyPA in vitro

Researchers have studied the effect of reducing CD147 levels – for example the RNAi
in vitro studies mentioned in the previous section and in vivo studies which have
reported neurological abnormalities such as spatial learning deficits and memory
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deficits in CD147 null mice (neurological problems that also occur in mouse models of
AD) (Naruhashi et al., 1997, Higgins and Jacobsen, 2003, Richardson et al., 2003).
Other in vitro studies have shown that CD147 is a component of the γ-secretase
complex and that depletion of CD147 results in elevated Aβ levels (Zhou et al., 2005,
2007), possibly due to effects on the γ-secretase complex. However other studies which
have also shown that depletion of CD147 increases extracellular Aβ levels, found that
the levels and localisation of CD147 in fibroblasts, as well as the postnatal expression
and distribution of CD147 in the brain, are distinct from those of integral γ-secretase
subunits (Vetrivel et al., 2008b).

In other experiments, CyPA-CD147 protein interaction has been reported to protect
neurons in vitro from oxidative stress (induced by cumene hydroperoxide) and ischemia
(induced by oxygen glucose deprivation) through the ERK1/2 pathways (Boulos et al.,
2007). Oxidative stress can be induced by elevated Aβ levels and is thought to play a
role in AD pathogenesis. It may be that CyPA-CD147 protein interaction may reduce
Aβ-induced oxidative stress, thus protecting cells. This provides another reason for low
levels of CD147 being detrimental to neuronal health, and suggests that inducing higher
levels of CD147 may protect against AD-related neuropathology. Other studies which
suggest higher levels of CD147 may be advantageous are those which have shown that
CD147 is capable of inducing matrix metalloproteases (MMPs), enzymes capable of
degrading Aβ peptides.

In order to characterise further the possible protective effect of CD147 against oxidative
stress, CD147 protein was over-expressed using recombinant adenoviruses in vitro. Rat
primary neuronal cultures and SH-SY5Y human neuroblastoma cultures were
transduced with recombinant adenoviruses (AdRSV-Empty as a control and AdRSV264

CD147) to over-express CD147 protein. Cells were exposed to Aβ42, with or without
prior exposure to CyPA. The purpose of these studies was to examine the effect of
increased levels of CD147, as well as the possible involvement of CyPA, on neuronal
protection against Aβ42-induced oxidative stress.

In the first stage of this work, it was shown that CD147 protein was successfully overexpressed in rat primary (Fig.3.9) and SH-SY5Y neuronal (Fig.3.12) cultures. The
results of the next stage of the experiments suggest that neuronal cultures exposed to
CyPA prior to Aβ42 exposure are protected from Aβ42-induced oxidative stress
(Fig.3.10 and Fig.3.11). The results also show that adenoviral mediated CD147 overexpression alone does not achieve the protective effect seen when the protein is used in
combination with CypA (Fig.3.11 and Fig.3.13). These results are consistent with those
reported by Boulos et al. (Boulos et al., 2007) where it was shown that the
CyPA/CD147 combination can protect neurons against oxidative stress and ischemia.
Our results are also consistent with the notion that CD147 protein requires interaction
with other proteins to achieve its cellular role. This is supported by a study which has
reported that the functional effect of CD147 at the cellular level is integrin-dependent
and requires the physical association of integrins with CD147 (Berditchevski et al.,
1997). It is interesting to note that CD147- associated α6β1 integrins bind Aβ peptides
and initiate a signal transduction cascade in microglial cells (Bamberger et al., 2003).
This is yet another association that may explain how CD147 protein may be involved in
Aβ metabolism (Vetrivel et al., 2008b).

In summary, the results presented in chapter 3 show that exposure to high cholesterol or
high Aβ42 loading may induce CD147 protein expression and support the theory that
these agents cause oxidative stress and can be neurotoxic, as evidenced by elevated
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LDH release. The studies also support the hypothesis that the CD147/CyPA
combination may be of major significance in the protection against oxidative stress.
CD147 protein is quite abundant in regions of the brain affected early in AD, such as
the CA1 region of the hippocampus. It could therefore be argued that CD147 is wellplaced to play a role in reducing AD pathology indirectly by reducing oxidative stress
when in combination with CyPA protein.

In order to characterise further the influence of cholesterol on CD147 protein expression
reported above, the current study also investigated its levels in the AD model APPswe
transgenic mice fed on either a normal chow or a high fat/ high cholesterol diet. Results
from these in vivo experiments are discussed below.

7.5: CD147 levels are not altered by high fat/high cholesterol diet in vivo

Transgenic and non-transgenic animal models of AD fed high fat/ high cholesterol diets
exhibit increased AD pathology – in particular increased Aβ deposition (Sparks et al.,
1994b, Refolo et al., 2000b, Shie et al., 2002). A comparatively longer duration on a
high cholesterol diet leads to more severe accumulation of Aβ in rabbit brains (Sparks et
al., 1994a). Furthermore, TgAPPswe mice fed a high fat/high cholesterol diet for 10
months have increased Aβ deposition compared to standard chow-fed control mice, and
the Aβ deposition levels correlate inversely with HDL levels (Shie et al., 2002). Aβ40
and Aβ42 appear to accumulate initially in the lipid rafts of aging AD model Tg2576
mice brains (Kawarabayashi et al., 2004). Interestingly, after dimeric Aβ accumulates in
the lipid rafts of the Tg2576 brain, apolipoprotein E (ApoE) and then phosphorylated
tau accumulate, suggesting Aβ aggregation and accumulation is the initial pathology to
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develop, and emphasizing the importance of trying to prevent Aβ accumulation
(Kawarabayashi et al., 2004).

In chapter 4, studies were carried out to assess the impact of a high cholesterol/high fat
diet on CD147 expression in AD-model transgenic mice. Results presented in this
chapter have first confirmed that a high fat/high cholesterol diet affects body weight. All
experimental mice gained weight by the end of the study; however this was more
evident in the APPswe mice fed a high fat/high cholesterol diet (Fig.4.2, chapter 4). It
was also noted that males gained more body weight than females suggesting that the
males were eating more than the females. Secondly, compared to controls, results also
confirmed that a high cholesterol diet affects circulating plasma cholesterol in vivo as
evidenced by a significant increase in circulating cholesterol levels in the mice fed the
high cholesterol diet (Fig.4.3, chapter 4). Interestingly, female mice exhibited a 2-fold
cholesterol increase compared to the males indicating a gender-based difference in
cholesterol metabolism. These results are consistent with the findings from previous
studies that have also reported sex differences in cholesterol metabolism and
homeostasis, where female mice have tended to show higher cholesterol levels and to
deposit fat earlier than male mice (Costet et al., 1998). Other studies have reported that,
following high cholesterol diets, male mice show reduced serum but increased hepatic
cholesterol and that these changes are associated with changes in expression of
cholesterol transporters (Hewitt et al., 2004). Similarly, sex based differences have also
been reported in the severity of AD pathology in male and female AD transgenic mice
models (Barrier et al., 2010, Carroll et al., 2010, Oikawa et al., 2010, Rosario et al.,
2010).
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Lastly the results from this chapter have shown that mice fed on high fat/high
cholesterol diet showed an increasing trend in brain CD147 protein levels in males with
females expressing the reduced levels (Fig. 4.5, chapter 4) and that CD147 correlates
with plasma cholesterol. Furthermore, although not significant, Aβ42/40 ratios showed
increasing trends in mice on a high fat/high cholesterol diet. These findings are also
consistent with other studies that have reported increased Aβ levels in conditions of
high cholesterol (Sparks et al., 1994b, Refolo et al., 2000b, Shie et al., 2002) and
depleted CD147 protein (Zhou et al., 2007) levels. Taken together these findings
suggest that the increasing trend of CD147 in males may be due to higher intake of the
diet as they also showed a higher weight gain. The females may have shown reduced
levels due to not eating the diet more as evidenced by their body weight as compared to
males on the same diet. It can therefore be concluded that high cholesterol diet has some
influence on CD147 expression in vivo. To further understand the mechanism through
which CD147 may be influenced by a high cholesterol diet, the current study also
investigated the influence of this diet on SCP, a protein which stimulates CD147
transcription. The outcomes of these in vivo experiments are discussed below.

7.6: High fat/high cholesterol diet did not affect SCP-2 levels in vivo

The importance of cholesterol homeostasis in brain function and its devastating effects
when its metabolism and circulating levels are altered have been reported before, as
discussed earlier in this thesis (Tint et al., 1994, Jarvik et al., 1995, Igbavboa et al.,
1996, Notkola et al., 1998). Most studies have investigated the association between a
high fat/high cholesterol diet and AD in relation to Aβ generation and cognitive
function. However there has been very little research done on the influence of diet on
SCP-2 protein expression levels. Recently a study by Ko and Puglielli reported that
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SCP-2 influences CD147 transcription (Ko and Puglielli, 2007). Since SCP-2 regulates
cholesterol transport to the cell membrane and that increased cholesterol loading results
in increased CD147 protein levels in vitro, the current study investigated the effects of a
high fat/high cholesterol diet on SCP-2 protein levels in APPswe transgenic mice.

SCP-2 levels were measured in APPswe mice fed a normal chow and a high fat/high
cholesterol diet by RT-PCR. Results are presented in chapter 4 of this thesis (Fig. 4.8,
chapter 4) and show that SCP-2 was successfully amplified and that a high fat/high
cholesterol diet did not alter SCP-2 mRNA levels (Fig. 4.9, chapter 4). These results are
different from those reported by Kraemer et al., who showed that expression of SCP-2,
but not SCP-x, was increased in conditions of increased cholesterol loading in muscle
cells (Kraemer et al., 1995). The difference may be attributed to the type of cholesterol
used, the tissue in which SCP-2 was measured and the type of experiment under which
SCP-2 protein was determined. In the next stage of these studies, the effect of a high
cholesterol/high fat on SCP-2 mRNA levels in the brain were examined in vivo, using
the AD model APPswe mice. Our results showed that a high cholesterol/high fat diet
did not alter SCP-2 levels. In the in vitro studies by Kraemer et al., (1995) cationized
cholesterol was used. This could not be used in vivo as it influences cholesterol efflux
from muscle tissues. These differences in the experimental design and methodology
may explain the differences between the SCP-2 levels reported here and those reported
by Kraemer et al. In addition, it is likely that SCP-2 mRNA/protein levels in different
tissues are not the same, and due to the systemic changes to lipid metabolism that a high
cholesterol diet is likely to bring about, a more comprehensive study of SCP-2 levels in
several tissues including the brain will be needed to determine whether such differences
exist. There is therefore a need for further study to establish conclusively whether
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CD147 expression alters in muscle, brain, liver, or any other tissue in the presence of
increasing cholesterol levels in the diet.

In the next stage of this thesis, CD147 levels in the hippocampus and frontal cortex of
health controls, Lewy Body dementia (LB), fronto-temporal dementia (FTD) and AD
were investigated. In addition, possible associations of single nucleotide polymorphisms
(SNPs) within the CD147 promoter region (where SCP-2 binds to initiate CD147
transcription) and AD pathology were also investigated. Results from these experiments
are discussed below.

7.7: CD147 protein levels are not altered in Alzheimer’s disease (AD)

Some evidence has been reported to indicate a role for CD147 in the pathogenesis of
AD and that CD147 may have neuroprotective actions (Boulos et al., 2007). CD147
protein has been detected in the hippocampus, especially in the CA1 region, a brain
region that plays a key role in memory and learning and that is most vulnerable in AD
(Hrabovszky et al., 2000, Rao, 2001). Recently, elevated CD147 levels have been
reported in AD/dementia (Nahalkova et al., 2009, 2010). This is in addition to its
possible influence on Aβ production via the γ-secretase enzyme (Zhou et al., 2005,
2006, 2007) and the potential influence on extracellular Aβ degradation through MMP
induction (Vetrivel et al., 2008b). Taken together these reports indicate that CD147 may
play an important role in APP processing and/or Aβ clearance. However there is little
information concerning CD147 distribution in the various cells of the brain, thus the
current study measured CD147 expression levels in hippocampal and frontal cortex
tissue from lewy body disease, frontal temporal dementia and Alzheimer’s disease cases
and compared to age-matched control brain tissue.
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The immunohistochemistry and Western blot analysis results presented in chapter 5 of
this thesis show that CD147 protein is not elevated in AD (Fig.5.2 and 5.7). However,
although not significant, there were trends towards higher CD147 levels observed in the
hippocampus and frontal cortex of AD, FTD and LBD brains (Fig.5.2, 5.5.4 and 5.7).
Increased Aβ peptide accumulation that leads to senile plaque deposition in Lewy body
disease pathology and dementia (Gomperts et al., 2008, Armstrong and Cairns, 2009,
Foster et al., 2010) has been reported before. The current study has also shown
significant Aβ levels in AD and LBD which is consistent with findings from the
previous studies mentioned above. The observed positive correlation between CD147
and NCT and PS1 levels in hippocampus from AD brains and PS1 from LBD (Table
5.1) is suggestive that CD147 interacts with the γ-secretase complex components.
Although not significant, the trend towards higher levels of CD147, nicastrin and PS1
levels and the significant increase of PEN2 levels observed in hippocampus from AD
cases, with a trend towards an increase in CD147 levels in the frontal cortex of AD
cases, is an indication of increased γ-secretase activity in dementia that is likely to lead
to increased Aβ production and accumulation and provides further evidence that CD147
is involved to some extent in AD pathogenesis.

As discussed in chapter 5, findings of the current study agree with Nahalkova and
colleagues who reported elevated CD147 levels in AD patients (Nahalkova et al., 2009,
2010). However Nahalkova reported increased CD147 levels in the cortex while our
findings have shown only trends towards an increase in CD147 levels in the
hippocampus and frontal cortex. These differences may be due to the different sample
sizes used. Nahalkova’s findings may have been compromised due to a small sample
size (n=3) which did not give his study a required statistical power. The current findings
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of CD147 expression in the AD are possibly more reliable due to the bigger sample size
(AD, n=14) for Western blot and (n=17) for immunohistochemistry. For statistical
analysis to be applied, this was a big enough sample size to give the study the required
power. As a recent study has provided evidence that CD147 may not influence Aβ
production by being an integral part of the γ-secretase complex (Vetrivel et al., 2008b),
an increase in expression of CD147 in the hippocampus and frontal cortex in AD may
be more the result of increased Aβ accumulation which initiates oxidative stress. Thus
higher levels of CD147 may be a reaction to this oxidative stress, either in an attempt to
reduce stress by inducing production of degradative enzymes (MMPs), or possibly as a
result of cellular toxicity and death (apoptosis). Members of the monocarboxylate
transporter (MCT) family of proteins, MCT1 and MCT4, require CD147 as a chaperone
for their expression at the plasma membrane, CD147 has also been associated with
integrin, γ-secretase, caveolin-1, and cyclophilins, as mentioned earlier in this thesis
(Iacono et al., 2007). This variety of potential functional roles for CD147 makes it very
difficult to come to simple conclusions concerning its likely role in AD. Many more
studies will be required to understand the functions of CD147, the roles this protein has
in lipid and cholesterol metabolism, and the involvement of any of these roles in AD.

7.8: Incidence of known CD147 SNPs and discovery of 2 novel CD147 SNPs

In order to examine other potential aspects of CD147 involvement in AD pathology, the
current study also investigated the incidence of known SNPs and the possibility of novel
SNPs in the promoter region of CD147. This was carried out on human genomic DNA
samples obtained from both control and AD-affected cases. Results presented in chapter
6 of this thesis have shown no association between SNPs in the sequenced region and
AD. This further supports the notion that CD147 is not directly associated with AD
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pathology but rather interacts with several proteins whose outcomes may be linked to
factors associated to AD development and pathology. There does appear to be some
association between possession of the rs11551906 minor allele with elevated cerebral
amyloid burden, warranting further investigation in future studies. Interestingly though
was the discovery of the 2 novel SNPs within the promoter region, outside the region
where SCP-2 binds. These were an A to G transition located 61 base pairs upstream (61A>G) of the transcription initiation site and a C to G transversion located 37 base
pairs downstream (37C>G) of the transcription initiation site. These novel genetic
variations were identified in a single heterozygous healthy control individual and a
single heterozygous AD individual, respectively. It is not known if -61A>G SNP may
provide some protection whereas 37C>G SNP may be a risk factor for AD. However, a
comprehensive study using a larger and well characterized sample cohort has to be
undertaken to investigate this hypothesis.

7.9: Future directions

The work presented in this thesis has provided further evidence that CD147 is a
multifunctional protein whose roles and expression may be influenced by other factors
including cholesterol, oxidative stress and SCP-2. The relationships between CD147
and these factors, as well as others such as MMPs, γ-secretase and MCT proteins, all
require further investigation. As many of the proposed functions of this protein have
been linked to AD pathogenesis, further research into this protein may yield important
information concerning the development and potential prevention of AD pathology.
Some of the proposed future studies include, but are not limited to the following:



A larger sample size of AD cases with similar disease severity as classified by
the Braack Staging method, together with age-matched control cases, should be
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assembled in order to compare more effectively CD147 expression levels in AD
and age-matched control brains.


It may be beneficial to sequence a larger portion of CD147 promoter region in a
well characterized cohort in order to identify other possible CD147 promoterrelated SNPs that may be associated with AD pathology.



The effects of the newly discovered -61A>G and 37C>G CD147 SNPs on AD
pathology and on the transcription/translation of CD147 protein should be
investigated, to help characterise further the role(s) of CD147.

7.10: Conclusions

This study has reported that (a) increasing cholesterol and Aβ42 loading affect cell
viability, induce CD147 expression and that adenoviral mediated CD147 expression
protects neuronal cultures against Aβ42 induced oxidative stress and injury only in the
presence of CyPA. (b) that there is an association between high fat / high cholesterol
diet and plasma cholesterol with a trend towards increasing cerebral CD147 levels and a
positive correlation between CD147 and plasma cholesterol levels. (c) that CD147
protein levels are not significantly elevated in AD. In addition, we report that (d) SNPs
within the CD147 promoter region are not associated with AD and finally (e) that two
novel SNPs (-61A>G and 37C>G) within the CD147 promoter region (not listed in the
NCBI) have been identified.
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